-
1
-
-
2442689092
-
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies
-
Haigwood N.L., Montefiori D.C., Sutton W.F., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004, 78:5983-5995.
-
(2004)
J Virol
, vol.78
, pp. 5983-5995
-
-
Haigwood, N.L.1
Montefiori, D.C.2
Sutton, W.F.3
-
2
-
-
84902046259
-
The Thai VaxGen Trial: What have we learned?
-
Horizon Press, Norkfolk, UK, W. Koff, P. Kahn, I. Gust (Eds.)
-
Beyrer C. The Thai VaxGen Trial: What have we learned?. AIDS Vaccine Development: Challenges and Opportunities 2007, 111-116. Horizon Press, Norkfolk, UK. W. Koff, P. Kahn, I. Gust (Eds.).
-
(2007)
AIDS Vaccine Development: Challenges and Opportunities
, pp. 111-116
-
-
Beyrer, C.1
-
3
-
-
79952445068
-
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial
-
Rolland M., Tovanabutra S., Decamp A.C., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011, 17:366-371.
-
(2011)
Nat Med
, vol.17
, pp. 366-371
-
-
Rolland, M.1
Tovanabutra, S.2
Decamp, A.C.3
-
5
-
-
79953019952
-
Statistical interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: a case study for statistical issues in efficacy trials
-
Gilbert P.B., Berger J.O., Stablein D., et al. Statistical interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011, 203:969-975.
-
(2011)
J Infect Dis
, vol.203
, pp. 969-975
-
-
Gilbert, P.B.1
Berger, J.O.2
Stablein, D.3
-
6
-
-
77949263061
-
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
-
Barouch D.H., O'Brien K.L., Simmons N.L., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323.
-
(2010)
Nat Med
, vol.16
, pp. 319-323
-
-
Barouch, D.H.1
O'Brien, K.L.2
Simmons, N.L.3
-
7
-
-
67649338409
-
Recombinant modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
-
Gudmundsdotter L., Nilsson C., Brave A., et al. Recombinant modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27:4468-4474.
-
(2009)
Vaccine
, vol.27
, pp. 4468-4474
-
-
Gudmundsdotter, L.1
Nilsson, C.2
Brave, A.3
-
8
-
-
44749088148
-
EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone
-
McCormack S., Stohr W., Barber T., et al. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26:3162-3174.
-
(2008)
Vaccine
, vol.26
, pp. 3162-3174
-
-
McCormack, S.1
Stohr, W.2
Barber, T.3
-
9
-
-
78650311033
-
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine
-
Papagno L., Alter G., Assoumou L., et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011, 25:27-36.
-
(2011)
AIDS
, vol.25
, pp. 27-36
-
-
Papagno, L.1
Alter, G.2
Assoumou, L.3
-
10
-
-
77955067596
-
The renaissance in HIV vaccine development: future directions
-
Koff W.C., Berkley S.F. The renaissance in HIV vaccine development: future directions. N Engl J Med 2010, 363:e7.
-
(2010)
N Engl J Med
, vol.363
-
-
Koff, W.C.1
Berkley, S.F.2
-
11
-
-
0019782357
-
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency
-
Gottlieb M.S., Schroff R., Schanker H.M., et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305:1425-1431.
-
(1981)
N Engl J Med
, vol.305
, pp. 1425-1431
-
-
Gottlieb, M.S.1
Schroff, R.2
Schanker, H.M.3
-
12
-
-
0019774135
-
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction
-
Masur H., Michelis M.A., Greene J.B., et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305:1431-1438.
-
(1981)
N Engl J Med
, vol.305
, pp. 1431-1438
-
-
Masur, H.1
Michelis, M.A.2
Greene, J.B.3
-
13
-
-
0032546969
-
The science of AIDS: a tale of two worlds
-
Piot P. The science of AIDS: a tale of two worlds. Science 1998, 280:1844-1845.
-
(1998)
Science
, vol.280
, pp. 1844-1845
-
-
Piot, P.1
-
14
-
-
78349233841
-
Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission
-
Weber J., Tatoud R., Fidler S. Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS 2010, 24(suppl. 4):S27-S39.
-
(2010)
AIDS
, vol.24
, Issue.SUPPL.. 4
-
-
Weber, J.1
Tatoud, R.2
Fidler, S.3
-
15
-
-
28444460441
-
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial
-
Auvert B., Taljaard D., Lagarde E., et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005, 2:e298.
-
(2005)
PLoS Med
, vol.2
-
-
Auvert, B.1
Taljaard, D.2
Lagarde, E.3
-
16
-
-
58749101526
-
Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics
-
Warner L., Ghanem K.G., Newman D.R., et al. Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics. J Infect Dis 2009, 199:59-65.
-
(2009)
J Infect Dis
, vol.199
, pp. 59-65
-
-
Warner, L.1
Ghanem, K.G.2
Newman, D.R.3
-
17
-
-
77955930318
-
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
-
Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
-
(2010)
Science
, vol.329
, pp. 1168-1174
-
-
Abdool Karim, Q.1
Abdool Karim, S.S.2
Frohlich, J.A.3
-
18
-
-
34249792153
-
Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure
-
CD002835
-
Young T.N., Arens F.J., Kennedy G.E., et al. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev 2007, 1. CD002835.
-
(2007)
Cochrane Database Syst Rev
, vol.1
-
-
Young, T.N.1
Arens, F.J.2
Kennedy, G.E.3
-
19
-
-
77956403366
-
Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination
-
Sellier P., Mannioui A., Bourry O., et al. Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS One 2010, 5:e10570.
-
(2010)
PLoS One
, vol.5
-
-
Sellier, P.1
Mannioui, A.2
Bourry, O.3
-
20
-
-
77953293984
-
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
-
Donnell D., Baeten J.M., Kiarie J., et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010, 375:2092-2098.
-
(2010)
Lancet
, vol.375
, pp. 2092-2098
-
-
Donnell, D.1
Baeten, J.M.2
Kiarie, J.3
-
21
-
-
78650549662
-
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
-
Grant R.M., Lama J.R., Anderson P.L., et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599.
-
(2010)
N Engl J Med
, vol.363
, pp. 2587-2599
-
-
Grant, R.M.1
Lama, J.R.2
Anderson, P.L.3
-
22
-
-
41849117498
-
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection
-
CD003510
-
Volmink J., Siegfried N.L., van der Merwe L., et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007, 1. CD003510.
-
(2007)
Cochrane Database Syst Rev
, vol.1
-
-
Volmink, J.1
Siegfried, N.L.2
van der Merwe, L.3
-
23
-
-
34247872923
-
Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection
-
Suksomboon N., Poolsup N., Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther 2007, 32:293-311.
-
(2007)
J Clin Pharm Ther
, vol.32
, pp. 293-311
-
-
Suksomboon, N.1
Poolsup, N.2
Ket-Aim, S.3
-
24
-
-
34548398653
-
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach
-
Tonwe-Gold B., Ekouevi D.K., Viho I., et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 2007, 4:e257.
-
(2007)
PLoS Med
, vol.4
-
-
Tonwe-Gold, B.1
Ekouevi, D.K.2
Viho, I.3
-
25
-
-
77953723667
-
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission
-
Chasela C.S., Hudgens M.G., Jamieson D.J., et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010, 362:2271-2281.
-
(2010)
N Engl J Med
, vol.362
, pp. 2271-2281
-
-
Chasela, C.S.1
Hudgens, M.G.2
Jamieson, D.J.3
-
26
-
-
0035834497
-
HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda
-
Ahmed S., Lutalo T., Wawer M., et al. HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda. AIDS 2001, 15:2171-2179.
-
(2001)
AIDS
, vol.15
, pp. 2171-2179
-
-
Ahmed, S.1
Lutalo, T.2
Wawer, M.3
-
27
-
-
27644524761
-
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir
-
Chun T.W., Nickle D.C., Justement J.S., et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005, 115:3250-3255.
-
(2005)
J Clin Invest
, vol.115
, pp. 3250-3255
-
-
Chun, T.W.1
Nickle, D.C.2
Justement, J.S.3
-
28
-
-
28044456980
-
The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years
-
Gallo R.C. The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. Lancet 2005, 366:1894-1898.
-
(2005)
Lancet
, vol.366
, pp. 1894-1898
-
-
Gallo, R.C.1
-
29
-
-
33644822414
-
Pathogenesis of HIV infection: what the virus spares is as important as what it destroys
-
Grossman Z., Meier-Schellersheim M., Paul W.E., et al. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006, 12:289-295.
-
(2006)
Nat Med
, vol.12
, pp. 289-295
-
-
Grossman, Z.1
Meier-Schellersheim, M.2
Paul, W.E.3
-
30
-
-
0034699512
-
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
-
Allen T.M., O'Connor D.H., Jing P., et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000, 407:386-390.
-
(2000)
Nature
, vol.407
, pp. 386-390
-
-
Allen, T.M.1
O'Connor, D.H.2
Jing, P.3
-
31
-
-
0036181249
-
Viral persistence: HIV's strategies of immune system evasion
-
Johnson W.E., Desrosiers R.C. Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med 2002, 53:499-518.
-
(2002)
Annu Rev Med
, vol.53
, pp. 499-518
-
-
Johnson, W.E.1
Desrosiers, R.C.2
-
32
-
-
0037389643
-
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
-
Richman D.D., Wrin T., Little S.J., et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003, 100:4144-4149.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 4144-4149
-
-
Richman, D.D.1
Wrin, T.2
Little, S.J.3
-
33
-
-
2342540480
-
HIV escape: there and back again
-
Altman J.D., Feinberg M.B. HIV escape: there and back again. Nat Med 2004, 10:229-230.
-
(2004)
Nat Med
, vol.10
, pp. 229-230
-
-
Altman, J.D.1
Feinberg, M.B.2
-
34
-
-
3543078012
-
HIV and SIV CTL escape: implications for vaccine design
-
Goulder P.J., Watkins D.I. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004, 4:630-640.
-
(2004)
Nat Rev Immunol
, vol.4
, pp. 630-640
-
-
Goulder, P.J.1
Watkins, D.I.2
-
35
-
-
67449147145
-
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
-
Goonetilleke N., Liu M.K., Salazar-Gonzalez J.F., et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009, 206:1253-1272.
-
(2009)
J Exp Med
, vol.206
, pp. 1253-1272
-
-
Goonetilleke, N.1
Liu, M.K.2
Salazar-Gonzalez, J.F.3
-
36
-
-
0029875421
-
Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
-
Schwartz O., Marechal V., Le Gall S., et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996, 2:338-342.
-
(1996)
Nat Med
, vol.2
, pp. 338-342
-
-
Schwartz, O.1
Marechal, V.2
Le Gall, S.3
-
37
-
-
0032556872
-
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
-
Collins K.L., Chen B.K., Kalams S.A., et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998, 391:397-401.
-
(1998)
Nature
, vol.391
, pp. 397-401
-
-
Collins, K.L.1
Chen, B.K.2
Kalams, S.A.3
-
38
-
-
0035885920
-
Dressed to kill? a review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection
-
Lieberman J., Shankar P., Manjunath N., et al. Dressed to kill? a review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001, 98:1667-1677.
-
(2001)
Blood
, vol.98
, pp. 1667-1677
-
-
Lieberman, J.1
Shankar, P.2
Manjunath, N.3
-
39
-
-
0034600786
-
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
-
Appay V., Nixon D.F., Donahoe S.M., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000, 192:63-75.
-
(2000)
J Exp Med
, vol.192
, pp. 63-75
-
-
Appay, V.1
Nixon, D.F.2
Donahoe, S.M.3
-
40
-
-
0035130059
-
Functional impairment of simian immunodeficiency virus-specific CD8 + T cells during the chronic phase of infection
-
Vogel T.U., Allen T.M., Altman J.D., et al. Functional impairment of simian immunodeficiency virus-specific CD8 + T cells during the chronic phase of infection. J Virol 2001, 75:2458-2461.
-
(2001)
J Virol
, vol.75
, pp. 2458-2461
-
-
Vogel, T.U.1
Allen, T.M.2
Altman, J.D.3
-
41
-
-
33646163652
-
A review of vaccine research and development: the human immunodeficiency virus (HIV)
-
Girard M.P., Osmanov S.K., Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006, 24:4062-4081.
-
(2006)
Vaccine
, vol.24
, pp. 4062-4081
-
-
Girard, M.P.1
Osmanov, S.K.2
Kieny, M.P.3
-
42
-
-
36148973173
-
HIV/AIDS vaccines: 2007
-
Robinson H.L. HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 2007, 82:686-893.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 686-893
-
-
Robinson, H.L.1
-
43
-
-
57449098504
-
HIV/AIDS vaccines: a need for new concepts?
-
Girard M.P., Bansal G.P. HIV/AIDS vaccines: a need for new concepts?. Int Rev Immunol 2008, 27:447-471.
-
(2008)
Int Rev Immunol
, vol.27
, pp. 447-471
-
-
Girard, M.P.1
Bansal, G.P.2
-
45
-
-
79952787740
-
Human immunodeficiency virus-1 vaccine design: where do we go now?
-
Wijesundara D.K., Jackson R.J., Ramshaw I.A., et al. Human immunodeficiency virus-1 vaccine design: where do we go now?. Immunol Cell Biol 2011, 89:367-374.
-
(2011)
Immunol Cell Biol
, vol.89
, pp. 367-374
-
-
Wijesundara, D.K.1
Jackson, R.J.2
Ramshaw, I.A.3
-
46
-
-
77952311370
-
The role of antibodies in HIV vaccines
-
Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010, 28:413-444.
-
(2010)
Annu Rev Immunol
, vol.28
, pp. 413-444
-
-
Mascola, J.R.1
Montefiori, D.C.2
-
47
-
-
77951918976
-
Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference
-
Ross A.L., Brave A., Scarlatti G., et al. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis 2010, 10:305-316.
-
(2010)
Lancet Infect Dis
, vol.10
, pp. 305-316
-
-
Ross, A.L.1
Brave, A.2
Scarlatti, G.3
-
48
-
-
77958490167
-
Induction of immunity to human immunodeficiency virus type-1 by vaccination
-
McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33:542-554.
-
(2010)
Immunity
, vol.33
, pp. 542-554
-
-
McElrath, M.J.1
Haynes, B.F.2
-
49
-
-
80051564046
-
Vaccine. Human immunodeficiency virus (HIV) vaccine development: a review
-
Girard M., Osmanov S., Assossou O., et al. Vaccine. Human immunodeficiency virus (HIV) vaccine development: a review. Vaccine 2011, 29:6191-6218.
-
(2011)
Vaccine
, vol.29
, pp. 6191-6218
-
-
Girard, M.1
Osmanov, S.2
Assossou, O.3
-
50
-
-
73349094086
-
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
-
Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
-
(2009)
N Engl J Med
, vol.361
, pp. 2209-2220
-
-
Rerks-Ngarm, S.1
Pitisuttithum, P.2
Nitayaphan, S.3
-
51
-
-
76749132657
-
Future paths for HIV vaccine research: exploiting results from recent clinical trials and current scientific advances
-
Bansal G.P., Malaspina A., Flores J. Future paths for HIV vaccine research: exploiting results from recent clinical trials and current scientific advances. Curr Opin Mol Ther 2010, 12:39-46.
-
(2010)
Curr Opin Mol Ther
, vol.12
, pp. 39-46
-
-
Bansal, G.P.1
Malaspina, A.2
Flores, J.3
-
52
-
-
0020596551
-
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
-
Barre-Sinoussi F., Chermann J.C., Rey F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
-
(1983)
Science
, vol.220
, pp. 868-871
-
-
Barre-Sinoussi, F.1
Chermann, J.C.2
Rey, F.3
-
53
-
-
0021237243
-
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
-
Popovic M., Sarngadharan M.G., Read E., et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224:497-500.
-
(1984)
Science
, vol.224
, pp. 497-500
-
-
Popovic, M.1
Sarngadharan, M.G.2
Read, E.3
-
54
-
-
0021150629
-
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS
-
Levy J.A., Hoffman A.D., Kramer S.M., et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984, 225:840-842.
-
(1984)
Science
, vol.225
, pp. 840-842
-
-
Levy, J.A.1
Hoffman, A.D.2
Kramer, S.M.3
-
55
-
-
0023272187
-
Human immunodeficiency virus type 2 infection associated with AIDS in West Africa
-
Clavel F., Mansinho K., Chamaret S., et al. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med 1987, 316:1180-1185.
-
(1987)
N Engl J Med
, vol.316
, pp. 1180-1185
-
-
Clavel, F.1
Mansinho, K.2
Chamaret, S.3
-
56
-
-
84881194271
-
Cryo-electron microscopy reveals conserved and divergent features of gag packing in immature particles of Rous sarcoma virus and human immunodeficiency virus
-
Briggs J.A., Johnson M.C., Simon M.N., et al. Cryo-electron microscopy reveals conserved and divergent features of gag packing in immature particles of Rous sarcoma virus and human immunodeficiency virus. J Mol Biol 2006, 355:157-168.
-
(2006)
J Mol Biol
, vol.355
, pp. 157-168
-
-
Briggs, J.A.1
Johnson, M.C.2
Simon, M.N.3
-
57
-
-
0036133058
-
Directed egress of animal viruses promotes cell-to-cell spread
-
Johnson D.C., Huber M.T. Directed egress of animal viruses promotes cell-to-cell spread. J Virol 2002, 76:1-8.
-
(2002)
J Virol
, vol.76
, pp. 1-8
-
-
Johnson, D.C.1
Huber, M.T.2
-
58
-
-
0038025223
-
Recruitment of HIV and its receptors to dendritic cell-T cell junctions
-
McDonald D., Wu L., Bohks S.M., et al. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300:1295-1297.
-
(2003)
Science
, vol.300
, pp. 1295-1297
-
-
McDonald, D.1
Wu, L.2
Bohks, S.M.3
-
59
-
-
1642540589
-
HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse
-
Jolly C., Kashefi K., Hollinshead M., et al. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 2004, 199:283-293.
-
(2004)
J Exp Med
, vol.199
, pp. 283-293
-
-
Jolly, C.1
Kashefi, K.2
Hollinshead, M.3
-
60
-
-
77955781209
-
3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells
-
Felts R.L., Narayan K., Estes J.D., et al. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A 2010, 107:13336-13341.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 13336-13341
-
-
Felts, R.L.1
Narayan, K.2
Estes, J.D.3
-
61
-
-
36049037370
-
Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses
-
Chen P., Hubner W., Spinelli M.A., et al. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol 2007, 81:12582-12595.
-
(2007)
J Virol
, vol.81
, pp. 12582-12595
-
-
Chen, P.1
Hubner, W.2
Spinelli, M.A.3
-
62
-
-
77950845174
-
SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse
-
Gonzalez N., Bermejo M., Calonge E., et al. SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse. J Virol 2010, 84:4341-4351.
-
(2010)
J Virol
, vol.84
, pp. 4341-4351
-
-
Gonzalez, N.1
Bermejo, M.2
Calonge, E.3
-
64
-
-
51349162563
-
Molecular architecture of native HIV-1 gp120 trimers
-
Liu J., Bartesaghi A., Borgnia M.J., et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
-
(2008)
Nature
, vol.455
, pp. 109-113
-
-
Liu, J.1
Bartesaghi, A.2
Borgnia, M.J.3
-
65
-
-
33745203490
-
Distribution and three-dimensional structure of AIDS virus envelope spikes
-
Zhu P., Liu J., Bess J., et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847-852.
-
(2006)
Nature
, vol.441
, pp. 847-852
-
-
Zhu, P.1
Liu, J.2
Bess, J.3
-
66
-
-
0242268511
-
+ T lymphocytes by favoring cytosolic delivery of viral material
-
+ T lymphocytes by favoring cytosolic delivery of viral material. J Virol 2003, 77:12299-12309.
-
(2003)
J Virol
, vol.77
, pp. 12299-12309
-
-
Tardif, M.R.1
Tremblay, M.J.2
-
67
-
-
0030962180
-
Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization
-
Rizzuto C.D., Sodroski J.G. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997, 71:4847-4851.
-
(1997)
J Virol
, vol.71
, pp. 4847-4851
-
-
Rizzuto, C.D.1
Sodroski, J.G.2
-
68
-
-
0029836852
-
Cytoskeletal proteins inside human immunodeficiency virus type 1 virions
-
Ott D.E., Coren L.V., Kane B.P., et al. Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. J Virol 1996, 70:7734-7743.
-
(1996)
J Virol
, vol.70
, pp. 7734-7743
-
-
Ott, D.E.1
Coren, L.V.2
Kane, B.P.3
-
69
-
-
33646457944
-
Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity
-
Keckesova Z., Ylinen L.M., Towers G.J. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol 2006, 80:4683-4690.
-
(2006)
J Virol
, vol.80
, pp. 4683-4690
-
-
Keckesova, Z.1
Ylinen, L.M.2
Towers, G.J.3
-
70
-
-
54949126675
-
TRIM family proteins and their emerging roles in innate immunity
-
Ozato K., Shin D.M., Chang T.H. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 2008, 8:849-860.
-
(2008)
Nat Rev Immunol
, vol.8
, pp. 849-860
-
-
Ozato, K.1
Shin, D.M.2
Chang, T.H.3
-
71
-
-
77956832938
-
TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species
-
Kirmaier A., Wu F., Newman R.M., et al. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 2010, 8.
-
(2010)
PLoS Biol
, vol.8
-
-
Kirmaier, A.1
Wu, F.2
Newman, R.M.3
-
72
-
-
79951669703
-
Tripartite-motif proteins and innate immune regulation
-
McNab F.W., Rajsbaum R., Stoye J.P., et al. Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol 2011, 23:46-56.
-
(2011)
Curr Opin Immunol
, vol.23
, pp. 46-56
-
-
McNab, F.W.1
Rajsbaum, R.2
Stoye, J.P.3
-
73
-
-
77954165325
-
Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys
-
Lim S.Y., Chan T., Gelman R.S., et al. Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS Genet 2010, 6:e1000997.
-
(2010)
PLoS Genet
, vol.6
-
-
Lim, S.Y.1
Chan, T.2
Gelman, R.S.3
-
74
-
-
0030005423
-
Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates
-
Otteken A., Earl P.L., Moss B. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J Virol 1996, 70:3407-3415.
-
(1996)
J Virol
, vol.70
, pp. 3407-3415
-
-
Otteken, A.1
Earl, P.L.2
Moss, B.3
-
75
-
-
0032546844
-
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens
-
Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
-
(1998)
Science
, vol.280
, pp. 1884-1888
-
-
Wyatt, R.1
Sodroski, J.2
-
76
-
-
40849136223
-
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
-
Montero M., van Houten N.E., Wang X., et al. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008, 72:54-84.
-
(2008)
Microbiol Mol Biol Rev
, vol.72
, pp. 54-84
-
-
Montero, M.1
van Houten, N.E.2
Wang, X.3
-
77
-
-
39449098115
-
HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells
-
Arthos J., Cicala C., Martinelli E., et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008, 9:301-309.
-
(2008)
Nat Immunol
, vol.9
, pp. 301-309
-
-
Arthos, J.1
Cicala, C.2
Martinelli, E.3
-
78
-
-
69249153068
-
Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection
-
Kader M., Wang X., Piatak M., et al. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2009, 2:439-449.
-
(2009)
Mucosal Immunol
, vol.2
, pp. 439-449
-
-
Kader, M.1
Wang, X.2
Piatak, M.3
-
79
-
-
73949112038
-
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1
-
Cicala C., Martinelli E., McNally J.P., et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 2009, 106:20877-20882.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 20877-20882
-
-
Cicala, C.1
Martinelli, E.2
McNally, J.P.3
-
80
-
-
56849129238
-
Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection
-
Yu H., Tudor D., Alfsen A., et al. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection. Retrovirology 2008, 5:93.
-
(2008)
Retrovirology
, vol.5
, pp. 93
-
-
Yu, H.1
Tudor, D.2
Alfsen, A.3
-
81
-
-
38049031709
-
The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent
-
Yu H., Alfsen A., Tudor D., et al. The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent. Cell Calcium 2008, 43:73-82.
-
(2008)
Cell Calcium
, vol.43
, pp. 73-82
-
-
Yu, H.1
Alfsen, A.2
Tudor, D.3
-
82
-
-
23244434512
-
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
-
Li M., Gao F., Mascola J.R., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79:10108-10125.
-
(2005)
J Virol
, vol.79
, pp. 10108-10125
-
-
Li, M.1
Gao, F.2
Mascola, J.R.3
-
83
-
-
0037456827
-
Antibody neutralization and escape by HIV-1
-
Wei X., Decker J.M., Wang S., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
-
(2003)
Nature
, vol.422
, pp. 307-312
-
-
Wei, X.1
Decker, J.M.2
Wang, S.3
-
84
-
-
0031761965
-
Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine
-
Arthur L.O., Bess J.W., Chertova E.N., et al. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res Hum Retroviruses 1998, 14(suppl. 3):S311-S319.
-
(1998)
AIDS Res Hum Retroviruses
, vol.14
, Issue.SUPPL.. 3
-
-
Arthur, L.O.1
Bess, J.W.2
Chertova, E.N.3
-
85
-
-
20144387029
-
Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins
-
Morcock D.R., Thomas J.A., Gagliardi T.D., et al. Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins. J Virol 2005, 79:1533-1542.
-
(2005)
J Virol
, vol.79
, pp. 1533-1542
-
-
Morcock, D.R.1
Thomas, J.A.2
Gagliardi, T.D.3
-
86
-
-
0032546817
-
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology
-
Emerman M., Malim M.H. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998, 280:1880-1884.
-
(1998)
Science
, vol.280
, pp. 1880-1884
-
-
Emerman, M.1
Malim, M.H.2
-
87
-
-
0033587718
-
Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine
-
Gallo R.C. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A 1999, 96:8324-8326.
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, pp. 8324-8326
-
-
Gallo, R.C.1
-
88
-
-
20144389726
-
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters
-
Rezza G., Fiorelli V., Dorrucci M., et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005, 191:1321-1324.
-
(2005)
J Infect Dis
, vol.191
, pp. 1321-1324
-
-
Rezza, G.1
Fiorelli, V.2
Dorrucci, M.3
-
89
-
-
2342595835
-
Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis
-
Wadia J.S., Stan R.V., Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004, 10:310-315.
-
(2004)
Nat Med
, vol.10
, pp. 310-315
-
-
Wadia, J.S.1
Stan, R.V.2
Dowdy, S.F.3
-
90
-
-
0026561508
-
Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency
-
Pomerantz R.J., Seshamma T., Trono D. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol 1992, 66:1809-1813.
-
(1992)
J Virol
, vol.66
, pp. 1809-1813
-
-
Pomerantz, R.J.1
Seshamma, T.2
Trono, D.3
-
91
-
-
0035128420
-
Human immunodeficiency virus type 1 Nef selectively associates with a catalytically active subpopulation of p21-activated kinase 2 (PAK2) independently of PAK2 binding to Nck or beta-PIX
-
Renkema G.H., Manninen A., Saksela K. Human immunodeficiency virus type 1 Nef selectively associates with a catalytically active subpopulation of p21-activated kinase 2 (PAK2) independently of PAK2 binding to Nck or beta-PIX. J Virol 2001, 75:2154-2160.
-
(2001)
J Virol
, vol.75
, pp. 2154-2160
-
-
Renkema, G.H.1
Manninen, A.2
Saksela, K.3
-
92
-
-
0037089651
-
HIV-1 Nef interacts with inositol trisphosphate receptor to activate calcium signaling in T cells
-
Manninen A., Saksela K. HIV-1 Nef interacts with inositol trisphosphate receptor to activate calcium signaling in T cells. J Exp Med 2002, 195:1023-1032.
-
(2002)
J Exp Med
, vol.195
, pp. 1023-1032
-
-
Manninen, A.1
Saksela, K.2
-
93
-
-
0038342442
-
HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection
-
Swingler S., Brichacek B., Jacque J.M., et al. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003, 424:213-219.
-
(2003)
Nature
, vol.424
, pp. 213-219
-
-
Swingler, S.1
Brichacek, B.2
Jacque, J.M.3
-
94
-
-
0043198081
-
Nefarious abuse
-
Pope M. Nefarious abuse. Nat Immunol 2003, 4:729-730.
-
(2003)
Nat Immunol
, vol.4
, pp. 729-730
-
-
Pope, M.1
-
95
-
-
1542317632
-
+ T cells for apoptosis by interacting with CXCR4 surface receptors
-
+ T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 2004, 78:3099-3109.
-
(2004)
J Virol
, vol.78
, pp. 3099-3109
-
-
James, C.O.1
Huang, M.B.2
Khan, M.3
-
97
-
-
0142060865
-
CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 Nef protein in pediatric AIDS progression
-
Casartelli N., Di Matteo G., Potesta M., et al. CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 Nef protein in pediatric AIDS progression. J Virol 2003, 77:11536-11545.
-
(2003)
J Virol
, vol.77
, pp. 11536-11545
-
-
Casartelli, N.1
Di Matteo, G.2
Potesta, M.3
-
98
-
-
0842347716
-
Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity
-
Alexander M., Bor Y.C., Ravichandran K.S., et al. Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity. J Virol 2004, 78:1685-1696.
-
(2004)
J Virol
, vol.78
, pp. 1685-1696
-
-
Alexander, M.1
Bor, Y.C.2
Ravichandran, K.S.3
-
99
-
-
0036201092
-
Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease
-
Simard M.C., Chrobak P., Kay D.G., et al. Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease. J Virol 2002, 76:3981-3995.
-
(2002)
J Virol
, vol.76
, pp. 3981-3995
-
-
Simard, M.C.1
Chrobak, P.2
Kay, D.G.3
-
100
-
-
70349272209
-
Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes
-
Hanna Z., Priceputu E., Chrobak P., et al. Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes. J Virol 2009, 83:9743-9758.
-
(2009)
J Virol
, vol.83
, pp. 9743-9758
-
-
Hanna, Z.1
Priceputu, E.2
Chrobak, P.3
-
101
-
-
0027043276
-
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
-
Daniel M.D., Kirchhoff F., Czajak S.C., et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941.
-
(1992)
Science
, vol.258
, pp. 1938-1941
-
-
Daniel, M.D.1
Kirchhoff, F.2
Czajak, S.C.3
-
102
-
-
0031550781
-
Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa
-
Cranage M.P., Whatmore A.M., Sharpe S.A., et al. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997, 229:143-154.
-
(1997)
Virology
, vol.229
, pp. 143-154
-
-
Cranage, M.P.1
Whatmore, A.M.2
Sharpe, S.A.3
-
103
-
-
0032849066
-
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
-
Wyand M.S., Manson K., Montefiori D.C., et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999, 73:8356-8363.
-
(1999)
J Virol
, vol.73
, pp. 8356-8363
-
-
Wyand, M.S.1
Manson, K.2
Montefiori, D.C.3
-
104
-
-
0037227694
-
A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication
-
Chakrabarti L.A., Metzner K.J., Ivanovic T., et al. A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication. J Virol 2003, 77:1245-1256.
-
(2003)
J Virol
, vol.77
, pp. 1245-1256
-
-
Chakrabarti, L.A.1
Metzner, K.J.2
Ivanovic, T.3
-
105
-
-
29244474887
-
HIV vaccine design: insights from live attenuated SIV vaccines
-
Koff W.C., Johnson P.R., Watkins D.I., et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006, 7:19-23.
-
(2006)
Nat Immunol
, vol.7
, pp. 19-23
-
-
Koff, W.C.1
Johnson, P.R.2
Watkins, D.I.3
-
106
-
-
33645767939
-
Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr
-
Ardon O., Zimmerman E.S., Andersen J.L., et al. Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr. J Virol 2006, 80:3694-3700.
-
(2006)
J Virol
, vol.80
, pp. 3694-3700
-
-
Ardon, O.1
Zimmerman, E.S.2
Andersen, J.L.3
-
107
-
-
33644764832
-
The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest
-
Sakai K., Dimas J., Lenardo M.J. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci U S A 2006, 103:3369-3374.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 3369-3374
-
-
Sakai, K.1
Dimas, J.2
Lenardo, M.J.3
-
108
-
-
38549095979
-
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
-
Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
-
(2008)
Nature
, vol.451
, pp. 425-430
-
-
Neil, S.J.1
Zang, T.2
Bieniasz, P.D.3
-
109
-
-
61449243774
-
Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants
-
McNatt M.W., Zang T., Hatziioannou T., et al. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 2009, 5:e1000300.
-
(2009)
PLoS Pathog
, vol.5
-
-
McNatt, M.W.1
Zang, T.2
Hatziioannou, T.3
-
110
-
-
67249114758
-
Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2
-
Jia B., Serra-Moreno R., Neidermyer W., et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009, 5:e1000429.
-
(2009)
PLoS Pathog
, vol.5
-
-
Jia, B.1
Serra-Moreno, R.2
Neidermyer, W.3
-
111
-
-
78650646751
-
The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses
-
Schmokel J., Sauter D., Schindler M., et al. The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses. J Virol 2011, 85:742-752.
-
(2011)
J Virol
, vol.85
, pp. 742-752
-
-
Schmokel, J.1
Sauter, D.2
Schindler, M.3
-
112
-
-
71749105713
-
Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains
-
Sauter D., Schindler M., Specht A., et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6(5):409-421.
-
(2009)
Cell Host Microbe
, vol.6
, Issue.5
, pp. 409-421
-
-
Sauter, D.1
Schindler, M.2
Specht, A.3
-
113
-
-
80053375827
-
Lack of adaptation to human tetherin in HIV-1 group O and P
-
Yang S.J., Lopez L.A., Exline C.M., et al. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 2011, 8:78.
-
(2011)
Retrovirology
, vol.8
, pp. 78
-
-
Yang, S.J.1
Lopez, L.A.2
Exline, C.M.3
-
114
-
-
0025029028
-
Origin of vpx in lentiviruses
-
Tristem M., Marshall C., Karpas A., et al. Origin of vpx in lentiviruses. Nature 1990, 347:341-342.
-
(1990)
Nature
, vol.347
, pp. 341-342
-
-
Tristem, M.1
Marshall, C.2
Karpas, A.3
-
115
-
-
0038681023
-
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
-
Mangeat B., Turelli P., Caron G., et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103.
-
(2003)
Nature
, vol.424
, pp. 99-103
-
-
Mangeat, B.1
Turelli, P.2
Caron, G.3
-
116
-
-
13844309367
-
Editing at the crossroad of innate and adaptive immunity
-
Turelli P., Trono D. Editing at the crossroad of innate and adaptive immunity. Science 2005, 307:1061-1065.
-
(2005)
Science
, vol.307
, pp. 1061-1065
-
-
Turelli, P.1
Trono, D.2
-
117
-
-
31944438580
-
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity
-
Peng G., Lei K.J., Jin W., et al. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006, 203:41-46.
-
(2006)
J Exp Med
, vol.203
, pp. 41-46
-
-
Peng, G.1
Lei, K.J.2
Jin, W.3
-
118
-
-
0242578406
-
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex
-
Yu X., Yu Y., Liu B., et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
-
(2003)
Science
, vol.302
, pp. 1056-1060
-
-
Yu, X.1
Yu, Y.2
Liu, B.3
-
119
-
-
3442876111
-
APOBEC-mediated editing of viral RNA
-
Bishop K.N., Holmes R.K., Sheehy A.M., et al. APOBEC-mediated editing of viral RNA. Science 2004, 305:645.
-
(2004)
Science
, vol.305
, pp. 645
-
-
Bishop, K.N.1
Holmes, R.K.2
Sheehy, A.M.3
-
120
-
-
33646443637
-
Monomeric APOBEC3G is catalytically active and has antiviral activity
-
Opi S., Takeuchi H., Kao S., et al. Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol 2006, 80:4673-4682.
-
(2006)
J Virol
, vol.80
, pp. 4673-4682
-
-
Opi, S.1
Takeuchi, H.2
Kao, S.3
-
121
-
-
37349006127
-
Mucosal innate immunity as a determinant of HIV susceptibility
-
Iqbal S.M., Kaul R. Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 2008, 59:44-54.
-
(2008)
Am J Reprod Immunol
, vol.59
, pp. 44-54
-
-
Iqbal, S.M.1
Kaul, R.2
-
122
-
-
58249095268
-
Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells
-
Wang Y., Bergmeier L.A., Stebbings R., et al. Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine 2009, 27:870-881.
-
(2009)
Vaccine
, vol.27
, pp. 870-881
-
-
Wang, Y.1
Bergmeier, L.A.2
Stebbings, R.3
-
123
-
-
58149502601
-
Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G
-
Trapp S., Derby N.R., Singer R., et al. Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol 2009, 83:884-895.
-
(2009)
J Virol
, vol.83
, pp. 884-895
-
-
Trapp, S.1
Derby, N.R.2
Singer, R.3
-
124
-
-
77957673112
-
Innate immunity against HIV: a priority target for HIV prevention research
-
Borrow P., Shattock R.J., Vyakarnam A. Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology 2010, 7:84.
-
(2010)
Retrovirology
, vol.7
, pp. 84
-
-
Borrow, P.1
Shattock, R.J.2
Vyakarnam, A.3
-
125
-
-
78049433762
-
Innate immunity in resistance to HIV infection
-
Biasin M., Clerici M., Piacentini L. Innate immunity in resistance to HIV infection. J Infect Dis 2010, 202(suppl. 3):S361-S365.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 3
-
-
Biasin, M.1
Clerici, M.2
Piacentini, L.3
-
126
-
-
77953118149
-
Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques
-
Sui Y., Zhu Q., Gagnon S., et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A 2010, 107:9843-9848.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 9843-9848
-
-
Sui, Y.1
Zhu, Q.2
Gagnon, S.3
-
127
-
-
0037237790
-
Syndecan captures, protects, and transmits HIV to T lymphocytes
-
Bobardt M.D., Saphire A.C., Hung H.C., et al. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 2003, 18:27-39.
-
(2003)
Immunity
, vol.18
, pp. 27-39
-
-
Bobardt, M.D.1
Saphire, A.C.2
Hung, H.C.3
-
128
-
-
0034598905
-
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
-
Geijtenbeek T.B., Kwon D.S., Torensma R., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
-
(2000)
Cell
, vol.100
, pp. 587-597
-
-
Geijtenbeek, T.B.1
Kwon, D.S.2
Torensma, R.3
-
129
-
-
31444453892
-
Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection
-
Wiley R.D., Gummuluru S. Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci U S A 2006, 103:738-743.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 738-743
-
-
Wiley, R.D.1
Gummuluru, S.2
-
130
-
-
0021720872
-
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
-
Klatzmann D., Champagne E., Chamaret S., et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768.
-
(1984)
Nature
, vol.312
, pp. 767-768
-
-
Klatzmann, D.1
Champagne, E.2
Chamaret, S.3
-
131
-
-
0037007670
-
HIV preferentially infects HIV-specific CD4+ T cells
-
Douek D.C., Brenchley J.M., Betts M.R., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-98.
-
(2002)
Nature
, vol.417
, pp. 95-98
-
-
Douek, D.C.1
Brenchley, J.M.2
Betts, M.R.3
-
132
-
-
0027411206
-
Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor
-
Fantini J., Cook D.G., Nathanson N., et al. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc Natl Acad Sci U S A 1993, 90:2700-2704.
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, pp. 2700-2704
-
-
Fantini, J.1
Cook, D.G.2
Nathanson, N.3
-
133
-
-
0034482696
-
Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
-
Kwong P.D., Wyatt R., Majeed S., et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000, 8:1329-1339.
-
(2000)
Structure
, vol.8
, pp. 1329-1339
-
-
Kwong, P.D.1
Wyatt, R.2
Majeed, S.3
-
134
-
-
0032543307
-
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
-
Kwong P.D., Wyatt R., Robinson J., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
-
(1998)
Nature
, vol.393
, pp. 648-659
-
-
Kwong, P.D.1
Wyatt, R.2
Robinson, J.3
-
135
-
-
0037069682
-
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
-
Kwong P.D., Doyle M.L., Casper D.J., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682.
-
(2002)
Nature
, vol.420
, pp. 678-682
-
-
Kwong, P.D.1
Doyle, M.L.2
Casper, D.J.3
-
136
-
-
13844302894
-
Structure of an unliganded simian immunodeficiency virus gp120 core
-
Chen B., Vogan E.M., Gong H., et al. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433:834-841.
-
(2005)
Nature
, vol.433
, pp. 834-841
-
-
Chen, B.1
Vogan, E.M.2
Gong, H.3
-
137
-
-
0141521564
-
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1
-
Labrijn A.F., Poignard P., Raja A., et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003, 77:10557-10565.
-
(2003)
J Virol
, vol.77
, pp. 10557-10565
-
-
Labrijn, A.F.1
Poignard, P.2
Raja, A.3
-
138
-
-
0035884899
-
Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks
-
Resch W., Hoffman N., Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001, 288:51-62.
-
(2001)
Virology
, vol.288
, pp. 51-62
-
-
Resch, W.1
Hoffman, N.2
Swanstrom, R.3
-
139
-
-
27744597054
-
Structure of a V3-containing HIV-1 gp120 core
-
Huang C.C., Tang M., Zhang M.Y., et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028.
-
(2005)
Science
, vol.310
, pp. 1025-1028
-
-
Huang, C.C.1
Tang, M.2
Zhang, M.Y.3
-
141
-
-
0026785547
-
Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein
-
Freed E.O., Myers D.J. Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 1992, 66:5472-5478.
-
(1992)
J Virol
, vol.66
, pp. 5472-5478
-
-
Freed, E.O.1
Myers, D.J.2
-
143
-
-
26944466459
-
Mechanism of membrane fusion by viral envelope proteins
-
Harrison S.C. Mechanism of membrane fusion by viral envelope proteins. Adv Virus Res 2005, 64:231-261.
-
(2005)
Adv Virus Res
, vol.64
, pp. 231-261
-
-
Harrison, S.C.1
-
144
-
-
0030970693
-
Core structure of gp41 from the HIV envelope glycoprotein
-
Chan D.C., Fass D., Berger J.M., et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
-
(1997)
Cell
, vol.89
, pp. 263-273
-
-
Chan, D.C.1
Fass, D.2
Berger, J.M.3
-
145
-
-
0030962291
-
Atomic structure of the ectodomain from HIV-1 gp41
-
Weissenhorn W., Dessen A., Harrison S.C., et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430.
-
(1997)
Nature
, vol.387
, pp. 426-430
-
-
Weissenhorn, W.1
Dessen, A.2
Harrison, S.C.3
-
146
-
-
0033563698
-
The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution
-
Yang Z.N., Mueser T.C., Kaufman J., et al. The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution. J Struct Biol 1999, 126:131-144.
-
(1999)
J Struct Biol
, vol.126
, pp. 131-144
-
-
Yang, Z.N.1
Mueser, T.C.2
Kaufman, J.3
-
147
-
-
0032577550
-
HIV entry and its inhibition
-
Chan D.C., Kim P.S. HIV entry and its inhibition. Cell 1998, 93:681-684.
-
(1998)
Cell
, vol.93
, pp. 681-684
-
-
Chan, D.C.1
Kim, P.S.2
-
148
-
-
46449100666
-
Viral membrane fusion
-
Harrison S.C. Viral membrane fusion. Nat Struct Mol Biol 2008, 15:690-698.
-
(2008)
Nat Struct Mol Biol
, vol.15
, pp. 690-698
-
-
Harrison, S.C.1
-
149
-
-
2442629758
-
Full-length influenza hemagglutinin HA2 refolds into the trimeric low-pH-induced conformation
-
Swalley S.E., Baker B.M., Calder L.J., et al. Full-length influenza hemagglutinin HA2 refolds into the trimeric low-pH-induced conformation. Biochemistry 2004, 43:5902-5911.
-
(2004)
Biochemistry
, vol.43
, pp. 5902-5911
-
-
Swalley, S.E.1
Baker, B.M.2
Calder, L.J.3
-
150
-
-
0032431055
-
Coiled coils in both intracellular vesicle and viral membrane fusion
-
Skehel J.J., Wiley D.C. Coiled coils in both intracellular vesicle and viral membrane fusion. Cell 1998, 95:871-874.
-
(1998)
Cell
, vol.95
, pp. 871-874
-
-
Skehel, J.J.1
Wiley, D.C.2
-
151
-
-
33646185493
-
Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells
-
Yang X., Kurteva S., Ren X., et al. Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J Virol 2006, 80:4388-4395.
-
(2006)
J Virol
, vol.80
, pp. 4388-4395
-
-
Yang, X.1
Kurteva, S.2
Ren, X.3
-
152
-
-
78649861760
-
Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies
-
Frey G., Chen J., Rits-Volloch S., et al. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol 2010, 17:1486-1491.
-
(2010)
Nat Struct Mol Biol
, vol.17
, pp. 1486-1491
-
-
Frey, G.1
Chen, J.2
Rits-Volloch, S.3
-
153
-
-
0742325043
-
The CCR5 and CXCR4 coreceptors: central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection
-
Moore J.P., Kitchen S.G., Pugach P., et al. The CCR5 and CXCR4 coreceptors: central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004, 20:111-126.
-
(2004)
AIDS Res Hum Retroviruses
, vol.20
, pp. 111-126
-
-
Moore, J.P.1
Kitchen, S.G.2
Pugach, P.3
-
154
-
-
0026600926
-
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population
-
Schuitemaker H., Koot M., Kootstra N.A., et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992, 66:1354-1360.
-
(1992)
J Virol
, vol.66
, pp. 1354-1360
-
-
Schuitemaker, H.1
Koot, M.2
Kootstra, N.A.3
-
155
-
-
0031058480
-
Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239
-
Marcon L., Choe H., Martin K.A., et al. Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J Virol 1997, 71:2522-2527.
-
(1997)
J Virol
, vol.71
, pp. 2522-2527
-
-
Marcon, L.1
Choe, H.2
Martin, K.A.3
-
156
-
-
0029909461
-
Participants in HIV Study: correction
-
Dean M., Carrington M., Goedert J., et al. Participants in HIV Study: correction. Science 1996, 274:1069a.
-
(1996)
Science
, vol.274
-
-
Dean, M.1
Carrington, M.2
Goedert, J.3
-
157
-
-
15844388931
-
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
-
Liu R., Paxton W.A., Choe S., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
-
(1996)
Cell
, vol.86
, pp. 367-377
-
-
Liu, R.1
Paxton, W.A.2
Choe, S.3
-
158
-
-
16044367526
-
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
-
Huang Y., Paxton W.A., Wolinsky S.M., et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243.
-
(1996)
Nat Med
, vol.2
, pp. 1240-1243
-
-
Huang, Y.1
Paxton, W.A.2
Wolinsky, S.M.3
-
159
-
-
0031455968
-
Novel alleles of the chemokine-receptor gene CCR5
-
Carrington M., Kissner T., Gerrard B., et al. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997, 61:1261-1267.
-
(1997)
Am J Hum Genet
, vol.61
, pp. 1261-1267
-
-
Carrington, M.1
Kissner, T.2
Gerrard, B.3
-
160
-
-
0036139926
-
Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression
-
Tang J., Shelton B., Makhatadze N.J., et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002, 76:662-672.
-
(2002)
J Virol
, vol.76
, pp. 662-672
-
-
Tang, J.1
Shelton, B.2
Makhatadze, N.J.3
-
161
-
-
2642563503
-
Human genes that limit AIDS
-
O'Brien S.J., Nelson G.W. Human genes that limit AIDS. Nat Genet 2004, 36:565-574.
-
(2004)
Nat Genet
, vol.36
, pp. 565-574
-
-
O'Brien, S.J.1
Nelson, G.W.2
-
162
-
-
16044373004
-
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
-
Samson M., Libert F., Doranz B.J., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
-
(1996)
Nature
, vol.382
, pp. 722-725
-
-
Samson, M.1
Libert, F.2
Doranz, B.J.3
-
163
-
-
21344467949
-
Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons
-
Hummel S., Schmidt D., Kremeyer B., et al. Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons. Genes Immun 2005, 6:371-374.
-
(2005)
Genes Immun
, vol.6
, pp. 371-374
-
-
Hummel, S.1
Schmidt, D.2
Kremeyer, B.3
-
164
-
-
78049445213
-
Genomic approaches to the study of HIV-1 acquisition
-
Telenti A., McLaren P. Genomic approaches to the study of HIV-1 acquisition. J Infect Dis 2010, 202(suppl. 3):S382-S386.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 3
-
-
Telenti, A.1
McLaren, P.2
-
165
-
-
0031051739
-
HIV-1 infection in an individual homozygous for the CCR5 deletion allele
-
Biti R., Ffrench R., Young J., et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997, 3:252-253.
-
(1997)
Nat Med
, vol.3
, pp. 252-253
-
-
Biti, R.1
Ffrench, R.2
Young, J.3
-
166
-
-
33746610538
-
Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics
-
Suresh P., Wanchu A. Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics. J Postgrad Med 2006, 52:210-217.
-
(2006)
J Postgrad Med
, vol.52
, pp. 210-217
-
-
Suresh, P.1
Wanchu, A.2
-
167
-
-
34248578768
-
Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1)
-
Reiche E.M., Bonametti A.M., Voltarelli J.C., et al. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 2007, 14:1325-1334.
-
(2007)
Curr Med Chem
, vol.14
, pp. 1325-1334
-
-
Reiche, E.M.1
Bonametti, A.M.2
Voltarelli, J.C.3
-
169
-
-
18244361800
-
HIV pathogenesis: the first cut is the deepest
-
Picker L.J., Watkins D.I. HIV pathogenesis: the first cut is the deepest. Nat Immunol 2005, 6:430-432.
-
(2005)
Nat Immunol
, vol.6
, pp. 430-432
-
-
Picker, L.J.1
Watkins, D.I.2
-
170
-
-
0033986873
-
Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo
-
Veazey R.S., Tham I.C., Mansfield K.G., et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J l 2000, 74:57-64.
-
(2000)
J l
, vol.74
, pp. 57-64
-
-
Veazey, R.S.1
Tham, I.C.2
Mansfield, K.G.3
-
171
-
-
79251555316
-
Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques
-
Ansari A.A., Reimann K.A., Mayne A.E., et al. Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 2011, 186:1044-1059.
-
(2011)
J Immunol
, vol.186
, pp. 1044-1059
-
-
Ansari, A.A.1
Reimann, K.A.2
Mayne, A.E.3
-
172
-
-
40549092339
-
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy
-
Chun T.W., Nickle D.C., Justement J.S., et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008, 197:714-720.
-
(2008)
J Infect Dis
, vol.197
, pp. 714-720
-
-
Chun, T.W.1
Nickle, D.C.2
Justement, J.S.3
-
173
-
-
78149417719
-
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy
-
Yukl S.A., Gianella S., Sinclair E., et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010, 202:1553-1561.
-
(2010)
J Infect Dis
, vol.202
, pp. 1553-1561
-
-
Yukl, S.A.1
Gianella, S.2
Sinclair, E.3
-
174
-
-
77949409948
-
Targeting early infection to prevent HIV-1 mucosal transmission
-
Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464:217-223.
-
(2010)
Nature
, vol.464
, pp. 217-223
-
-
Haase, A.T.1
-
175
-
-
44649102135
-
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
-
Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008, 105:7552-7557.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 7552-7557
-
-
Keele, B.F.1
Giorgi, E.E.2
Salazar-Gonzalez, J.F.3
-
176
-
-
66049139947
-
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
-
Salazar-Gonzalez J.F., Salazar M.G., Keele B.F., et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009, 206:1273-1289.
-
(2009)
J Exp Med
, vol.206
, pp. 1273-1289
-
-
Salazar-Gonzalez, J.F.1
Salazar, M.G.2
Keele, B.F.3
-
177
-
-
59249096215
-
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1
-
Haaland R.E., Hawkins P.A., Salazar-Gonzalez J., et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009, 5:e1000274.
-
(2009)
PLoS Pathog
, vol.5
-
-
Haaland, R.E.1
Hawkins, P.A.2
Salazar-Gonzalez, J.3
-
178
-
-
77953784170
-
A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251
-
Stone M., Keele B.F., Ma Z.M., et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010, 84:7083-7095.
-
(2010)
J Virol
, vol.84
, pp. 7083-7095
-
-
Stone, M.1
Keele, B.F.2
Ma, Z.M.3
-
179
-
-
77957569793
-
HIV-1 transmission biology: selection and characteristics of infecting viruses
-
Sagar M. HIV-1 transmission biology: selection and characteristics of infecting viruses. J Infect Dis 2010, 202(suppl. 2):S289-S296.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 2
-
-
Sagar, M.1
-
180
-
-
0030162644
-
On the nature of virus quasispecies
-
Eigen M. On the nature of virus quasispecies. Trends Microbiol 1996, 4:216-218.
-
(1996)
Trends Microbiol
, vol.4
, pp. 216-218
-
-
Eigen, M.1
-
181
-
-
77957901912
-
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing
-
Fischer W., Ganusov V.V., Giorgi E.E., et al. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS ONE 2010, 5:e12303.
-
(2010)
PLoS ONE
, vol.5
-
-
Fischer, W.1
Ganusov, V.V.2
Giorgi, E.E.3
-
182
-
-
77952678708
-
Wide variation in the multiplicity of HIV-1 infection among injection drug users
-
Bar K.J., Li H., Chamberland A., et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010, 84:6241-6247.
-
(2010)
J Virol
, vol.84
, pp. 6241-6247
-
-
Bar, K.J.1
Li, H.2
Chamberland, A.3
-
183
-
-
33845532053
-
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
-
Brenchley J.M., Price D.A., Schacker T.W., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
-
(2006)
Nat Med
, vol.12
, pp. 1365-1371
-
-
Brenchley, J.M.1
Price, D.A.2
Schacker, T.W.3
-
184
-
-
39349104176
-
Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection
-
Li Q., Estes J.D., Duan L., et al. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J Infect Dis 2008, 197:420-429.
-
(2008)
J Infect Dis
, vol.197
, pp. 420-429
-
-
Li, Q.1
Estes, J.D.2
Duan, L.3
-
185
-
-
38949134533
-
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis
-
Gori A., Tincati C., Rizzardini G., et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol 2008, 46:757-758.
-
(2008)
J Clin Microbiol
, vol.46
, pp. 757-758
-
-
Gori, A.1
Tincati, C.2
Rizzardini, G.3
-
186
-
-
77950267769
-
Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections
-
Nowroozalizadeh S., Mansson F., da Silva Z., et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis 2010, 201:1150-1154.
-
(2010)
J Infect Dis
, vol.201
, pp. 1150-1154
-
-
Nowroozalizadeh, S.1
Mansson, F.2
da Silva, Z.3
-
187
-
-
33749338938
-
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
-
Petrovas C., Casazza J.P., Brenchley J.M., et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006, 203:2281-2292.
-
(2006)
J Exp Med
, vol.203
, pp. 2281-2292
-
-
Petrovas, C.1
Casazza, J.P.2
Brenchley, J.M.3
-
188
-
-
33748947326
-
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
-
Day C.L., Kaufmann D.E., Kiepiela P., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
-
(2006)
Nature
, vol.443
, pp. 350-354
-
-
Day, C.L.1
Kaufmann, D.E.2
Kiepiela, P.3
-
189
-
-
38949102301
-
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis
-
Boasso A., Shearer G.M. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008, 126:235-242.
-
(2008)
Clin Immunol
, vol.126
, pp. 235-242
-
-
Boasso, A.1
Shearer, G.M.2
-
190
-
-
77950525439
-
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection
-
Said E.A., Dupuy F.P., Trautmann L., et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010, 16:452-459.
-
(2010)
Nat Med
, vol.16
, pp. 452-459
-
-
Said, E.A.1
Dupuy, F.P.2
Trautmann, L.3
-
191
-
-
0027220025
-
Programmed cell death in AIDS-related HIV and SIV infections
-
Gougeon M.L., Garcia S., Heeney J., et al. Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses 1993, 9:553-563.
-
(1993)
AIDS Res Hum Retroviruses
, vol.9
, pp. 553-563
-
-
Gougeon, M.L.1
Garcia, S.2
Heeney, J.3
-
192
-
-
0029062573
-
Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein
-
Li C.J., Friedman D.J., Wang C., et al. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995, 268:429-431.
-
(1995)
Science
, vol.268
, pp. 429-431
-
-
Li, C.J.1
Friedman, D.J.2
Wang, C.3
-
193
-
-
0028912254
-
Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes
-
Finkel T.H., Tudor-Williams G., Banda N.K., et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995, 1:129-134.
-
(1995)
Nat Med
, vol.1
, pp. 129-134
-
-
Finkel, T.H.1
Tudor-Williams, G.2
Banda, N.K.3
-
194
-
-
0028074885
-
Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections
-
Estaquier J., Idziorek T., de Bels F., et al. Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A 1994, 91:9431-9435.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 9431-9435
-
-
Estaquier, J.1
Idziorek, T.2
de Bels, F.3
-
195
-
-
33749009709
-
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
-
Trautmann L., Janbazian L., Chomont N., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12:1198-1202.
-
(2006)
Nat Med
, vol.12
, pp. 1198-1202
-
-
Trautmann, L.1
Janbazian, L.2
Chomont, N.3
-
196
-
-
41849142985
-
Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut
-
Raffatellu M., Santos R.L., Verhoeven D.E., et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008, 14:421-428.
-
(2008)
Nat Med
, vol.14
, pp. 421-428
-
-
Raffatellu, M.1
Santos, R.L.2
Verhoeven, D.E.3
-
197
-
-
61449115882
-
Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection
-
Favre D., Lederer S., Kanwar B., et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 2009, 5:e1000295.
-
(2009)
PLoS Pathog
, vol.5
-
-
Favre, D.1
Lederer, S.2
Kanwar, B.3
-
198
-
-
77749295656
-
Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection
-
El Hed A., Khaitan A., Kozhaya L., et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis 2010, 201:843-854.
-
(2010)
J Infect Dis
, vol.201
, pp. 843-854
-
-
El Hed, A.1
Khaitan, A.2
Kozhaya, L.3
-
201
-
-
76949099874
-
Th17 cells in natural SIV hosts
-
Paiardini M. Th17 cells in natural SIV hosts. Curr Opin HIV AIDS 2010, 5:166-172.
-
(2010)
Curr Opin HIV AIDS
, vol.5
, pp. 166-172
-
-
Paiardini, M.1
-
202
-
-
37349126294
-
Natural regulatory T cells and persistent viral infection
-
Li S., Gowans E.J., Chougnet C., et al. Natural regulatory T cells and persistent viral infection. J Virol 2008, 82:21-30.
-
(2008)
J Virol
, vol.82
, pp. 21-30
-
-
Li, S.1
Gowans, E.J.2
Chougnet, C.3
-
203
-
-
67650711146
-
Lessons learned from the natural hosts of HIV-related viruses
-
Paiardini M., Pandrea I., Apetrei C., et al. Lessons learned from the natural hosts of HIV-related viruses. Annu Rev Med 2009, 60:485-495.
-
(2009)
Annu Rev Med
, vol.60
, pp. 485-495
-
-
Paiardini, M.1
Pandrea, I.2
Apetrei, C.3
-
204
-
-
76949108202
-
Th17 and regulatory T cells: implications for AIDS pathogenesis
-
Kanwar B., Favre D., McCune J.M. Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS 2010, 5:151-157.
-
(2010)
Curr Opin HIV AIDS
, vol.5
, pp. 151-157
-
-
Kanwar, B.1
Favre, D.2
McCune, J.M.3
-
206
-
-
76949087872
-
Th17 cells, HIV and the gut mucosal barrier
-
Dandekar S., George M.D., Baumler A.J. Th17 cells, HIV and the gut mucosal barrier. Curr Opin HIV AIDS 2010, 5:173-178.
-
(2010)
Curr Opin HIV AIDS
, vol.5
, pp. 173-178
-
-
Dandekar, S.1
George, M.D.2
Baumler, A.J.3
-
207
-
-
0036129320
-
AIDS vaccine models: challenging challenge viruses
-
Feinberg M.B., Moore J.P. AIDS vaccine models: challenging challenge viruses. Nat Med 2002, 8:207-210.
-
(2002)
Nat Med
, vol.8
, pp. 207-210
-
-
Feinberg, M.B.1
Moore, J.P.2
-
208
-
-
78650358966
-
The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection
-
Ling B., Mohan M., Lackner A.A., et al. The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection. J Infect Dis 2010, 202:1846-1854.
-
(2010)
J Infect Dis
, vol.202
, pp. 1846-1854
-
-
Ling, B.1
Mohan, M.2
Lackner, A.A.3
-
209
-
-
78649431227
-
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection
-
Mens H., Kearney M., Wiegand A., et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010, 84:12971-12981.
-
(2010)
J Virol
, vol.84
, pp. 12971-12981
-
-
Mens, H.1
Kearney, M.2
Wiegand, A.3
-
210
-
-
0030891167
-
Escape of human immunodeficiency virus from immune control
-
McMichael A.J., Phillips R.E. Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 1997, 15:271-296.
-
(1997)
Annu Rev Immunol
, vol.15
, pp. 271-296
-
-
McMichael, A.J.1
Phillips, R.E.2
-
211
-
-
0035862326
-
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection
-
Goulder P.J., Altfeld M.A., Rosenberg E.S., et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001, 193:181-194.
-
(2001)
J Exp Med
, vol.193
, pp. 181-194
-
-
Goulder, P.J.1
Altfeld, M.A.2
Rosenberg, E.S.3
-
212
-
-
0037122796
-
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
-
Barouch D.H., Kunstman J., Kuroda M.J., et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002, 415:335-339.
-
(2002)
Nature
, vol.415
, pp. 335-339
-
-
Barouch, D.H.1
Kunstman, J.2
Kuroda, M.J.3
-
213
-
-
0037791747
-
Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys
-
Barouch D.H., Kunstman J., Glowczwskie J., et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003, 77:7367-7375.
-
(2003)
J Virol
, vol.77
, pp. 7367-7375
-
-
Barouch, D.H.1
Kunstman, J.2
Glowczwskie, J.3
-
214
-
-
0036113306
-
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection
-
O'Connor D.H., Allen T.M., Vogel T.U., et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002, 8:493-499.
-
(2002)
Nat Med
, vol.8
, pp. 493-499
-
-
O'Connor, D.H.1
Allen, T.M.2
Vogel, T.U.3
-
215
-
-
1642264887
-
Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States
-
Nwanegbo E., Vardas E., Gao W., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004, 11:351-357.
-
(2004)
Clin Diagn Lab Immunol
, vol.11
, pp. 351-357
-
-
Nwanegbo, E.1
Vardas, E.2
Gao, W.3
-
216
-
-
1842741699
-
HIV evolution: CTL escape mutation and reversion after transmission
-
Leslie A.J., Pfafferott K.J., Chetty P., et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004, 10:282-289.
-
(2004)
Nat Med
, vol.10
, pp. 282-289
-
-
Leslie, A.J.1
Pfafferott, K.J.2
Chetty, P.3
-
217
-
-
20144384850
-
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection
-
Betts M.R., Exley B., Price D.A., et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A 2005, 102:4512-4517.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 4512-4517
-
-
Betts, M.R.1
Exley, B.2
Price, D.A.3
-
218
-
-
43549109265
-
Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients
-
Goepfert P.A., Lumm W., Farmer P., et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 2008, 205:1009-1017.
-
(2008)
J Exp Med
, vol.205
, pp. 1009-1017
-
-
Goepfert, P.A.1
Lumm, W.2
Farmer, P.3
-
219
-
-
33645240933
-
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1
-
Martinez-Picado J., Prado J.G., Fry E.E., et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006, 80:3617-3623.
-
(2006)
J Virol
, vol.80
, pp. 3617-3623
-
-
Martinez-Picado, J.1
Prado, J.G.2
Fry, E.E.3
-
220
-
-
36048949732
-
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication
-
Schneidewind A., Brockman M.A., Yang R., et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 2007, 81:12382-12393.
-
(2007)
J Virol
, vol.81
, pp. 12382-12393
-
-
Schneidewind, A.1
Brockman, M.A.2
Yang, R.3
-
221
-
-
77957560654
-
Viral evolution and escape during acute HIV-1 infection
-
Boutwell C.L., Rolland M.M., Herbeck J.T., et al. Viral evolution and escape during acute HIV-1 infection. J Infect Dis 2010, 202(suppl. 2):S309-S314.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 2
-
-
Boutwell, C.L.1
Rolland, M.M.2
Herbeck, J.T.3
-
222
-
-
0031041375
-
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues
-
Wong J.K., Ignacio C.C., Torriani F., et al. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997, 71:2059-2071.
-
(1997)
J Virol
, vol.71
, pp. 2059-2071
-
-
Wong, J.K.1
Ignacio, C.C.2
Torriani, F.3
-
223
-
-
0028874048
-
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
-
Ho D.D., Neumann A.U., Perelson A.S., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
-
(1995)
Nature
, vol.373
, pp. 123-126
-
-
Ho, D.D.1
Neumann, A.U.2
Perelson, A.S.3
-
224
-
-
0028811974
-
Viral dynamics in human immunodeficiency virus type 1 infection
-
Wei X., Ghosh S.K., Taylor M.E., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
-
(1995)
Nature
, vol.373
, pp. 117-122
-
-
Wei, X.1
Ghosh, S.K.2
Taylor, M.E.3
-
225
-
-
0028952146
-
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy
-
Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
-
(1995)
Science
, vol.267
, pp. 483-489
-
-
Coffin, J.M.1
-
226
-
-
0029967721
-
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time
-
Perelson A.S., Neumann A.U., Markowitz M., et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
-
(1996)
Science
, vol.271
, pp. 1582-1586
-
-
Perelson, A.S.1
Neumann, A.U.2
Markowitz, M.3
-
227
-
-
0025938499
-
A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease
-
Watanabe M., Ringler D.J., Fultz P.N., et al. A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. J Virol 1991, 65:3344-3348.
-
(1991)
J Virol
, vol.65
, pp. 3344-3348
-
-
Watanabe, M.1
Ringler, D.J.2
Fultz, P.N.3
-
228
-
-
84902052511
-
The role of broad HIV-1 neutralising antibodies and vaccine protection from heterologous HIV-1 infection in chimpanzees
-
Bogers W., Koornstra W., Bjömdal Å., et al. The role of broad HIV-1 neutralising antibodies and vaccine protection from heterologous HIV-1 infection in chimpanzees. Immunol Lett 1997, 56(pt 2):292.
-
(1997)
Immunol Lett
, vol.56
, Issue.PART 2
, pp. 292
-
-
Bogers, W.1
Koornstra, W.2
Bjömdal, A.3
-
229
-
-
2342660749
-
What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS?
-
Hirsch V.M. What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS?. AIDS Rev 2004, 6:40-53.
-
(2004)
AIDS Rev
, vol.6
, pp. 40-53
-
-
Hirsch, V.M.1
-
230
-
-
36048968755
-
Understanding the benign nature of SIV infection in natural hosts
-
Silvestri G., Paiardini M., Pandrea I., et al. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest 2007, 117:3148-3154.
-
(2007)
J Clin Invest
, vol.117
, pp. 3148-3154
-
-
Silvestri, G.1
Paiardini, M.2
Pandrea, I.3
-
231
-
-
49849088558
-
Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts
-
Pandrea I., Sodora D.L., Silvestri G., et al. Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immunol 2008, 29:419-428.
-
(2008)
Trends Immunol
, vol.29
, pp. 419-428
-
-
Pandrea, I.1
Sodora, D.L.2
Silvestri, G.3
-
232
-
-
59649097925
-
African non human primates infected by SIV: why don't they get sick? lessons from studies on the early phase of non-pathogenic SIV infection
-
Liovat A.S., Jacquelin B., Ploquin M.J., et al. African non human primates infected by SIV: why don't they get sick? lessons from studies on the early phase of non-pathogenic SIV infection. Curr HIV Res 2009, 7:39-50.
-
(2009)
Curr HIV Res
, vol.7
, pp. 39-50
-
-
Liovat, A.S.1
Jacquelin, B.2
Ploquin, M.J.3
-
233
-
-
68349157582
-
Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts
-
Sodora D.L., Allan J.S., Apetrei C., et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 2009, 15:861-865.
-
(2009)
Nat Med
, vol.15
, pp. 861-865
-
-
Sodora, D.L.1
Allan, J.S.2
Apetrei, C.3
-
234
-
-
0037343278
-
Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia
-
Silvestri G., Sodora D.L., Koup R.A., et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18:441-452.
-
(2003)
Immunity
, vol.18
, pp. 441-452
-
-
Silvestri, G.1
Sodora, D.L.2
Koup, R.A.3
-
235
-
-
33646452400
-
Comparison of simian immunodeficiency virus SIVagmVer replication and CD4+ T-cell dynamics in vervet and sabaeus African green monkeys
-
Goldstein S., Brown C.R., Ourmanov I., et al. Comparison of simian immunodeficiency virus SIVagmVer replication and CD4+ T-cell dynamics in vervet and sabaeus African green monkeys. J Virol 2006, 80:4868-4877.
-
(2006)
J Virol
, vol.80
, pp. 4868-4877
-
-
Goldstein, S.1
Brown, C.R.2
Ourmanov, I.3
-
236
-
-
33745945059
-
Simian immunodeficiency viruses replication dynamics in African non-human primate hosts: common patterns and species-specific differences
-
Pandrea I., Silvestri G., Onanga R., et al. Simian immunodeficiency viruses replication dynamics in African non-human primate hosts: common patterns and species-specific differences. J Med Primatol 2006, 35:194-201.
-
(2006)
J Med Primatol
, vol.35
, pp. 194-201
-
-
Pandrea, I.1
Silvestri, G.2
Onanga, R.3
-
237
-
-
33745627473
-
The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus
-
Dunham R., Pagliardini P., Gordon S., et al. The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood 2006, 108:209-217.
-
(2006)
Blood
, vol.108
, pp. 209-217
-
-
Dunham, R.1
Pagliardini, P.2
Gordon, S.3
-
238
-
-
77953901782
-
Nonprogressive and progressive primate immunodeficiency lentivirus infections
-
Brenchley J.M., Silvestri G., Douek D.C. Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 2010, 32:737-742.
-
(2010)
Immunity
, vol.32
, pp. 737-742
-
-
Brenchley, J.M.1
Silvestri, G.2
Douek, D.C.3
-
239
-
-
36048989052
-
Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence
-
Pandrea I.V., Gautam R., Ribeiro R.M., et al. Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol 2007, 179:3035-3046.
-
(2007)
J Immunol
, vol.179
, pp. 3035-3046
-
-
Pandrea, I.V.1
Gautam, R.2
Ribeiro, R.M.3
-
240
-
-
53549129725
-
Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy
-
Marchetti G., Bellistri G.M., Borghi E., et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 2008, 22:2035-2038.
-
(2008)
AIDS
, vol.22
, pp. 2035-2038
-
-
Marchetti, G.1
Bellistri, G.M.2
Borghi, E.3
-
241
-
-
53449093632
-
Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections
-
Brenchley J.M., Paiardini M., Knox K.S., et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008, 112:2826-2835.
-
(2008)
Blood
, vol.112
, pp. 2826-2835
-
-
Brenchley, J.M.1
Paiardini, M.2
Knox, K.S.3
-
242
-
-
39349088126
-
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
-
Hunt P.W., Brenchley J., Sinclair E., et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008, 197:126-133.
-
(2008)
J Infect Dis
, vol.197
, pp. 126-133
-
-
Hunt, P.W.1
Brenchley, J.2
Sinclair, E.3
-
243
-
-
79251480064
-
Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue
-
Doitsh G., Cavrois M., Lassen K.G., et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010, 143:789-801.
-
(2010)
Cell
, vol.143
, pp. 789-801
-
-
Doitsh, G.1
Cavrois, M.2
Lassen, K.G.3
-
244
-
-
0034988648
-
AIDS: an immune response against the immune system: role of a precise tridimensional molecular mimicry
-
Serres P.F. AIDS: an immune response against the immune system: role of a precise tridimensional molecular mimicry. J Autoimmun 2001, 16:287-291.
-
(2001)
J Autoimmun
, vol.16
, pp. 287-291
-
-
Serres, P.F.1
-
245
-
-
0028873681
-
Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression
-
Borrow P., Evans C.F., Oldstone M.B. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J Virol 1995, 69:1059-1070.
-
(1995)
J Virol
, vol.69
, pp. 1059-1070
-
-
Borrow, P.1
Evans, C.F.2
Oldstone, M.B.3
-
246
-
-
26444522325
-
HIV-1 induces IL-10 production in human monocytes via a CD4-independent pathway
-
Ji J., Sahu G.K., Braciale V.L., et al. HIV-1 induces IL-10 production in human monocytes via a CD4-independent pathway. Int Immunol 2005, 17:729-736.
-
(2005)
Int Immunol
, vol.17
, pp. 729-736
-
-
Ji, J.1
Sahu, G.K.2
Braciale, V.L.3
-
247
-
-
0025787430
-
Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure
-
Odermatt B., Eppler M., Leist T.P., et al. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc Natl Acad Sci U S A 1991, 88:8252-8256.
-
(1991)
Proc Natl Acad Sci U S A
, vol.88
, pp. 8252-8256
-
-
Odermatt, B.1
Eppler, M.2
Leist, T.P.3
-
248
-
-
0028825476
-
Follicular dendritic cells and human immunodeficiency virus infectivity
-
Heath S.L., Tew J.G., Szakal A.K. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995, 377:740-744.
-
(1995)
Nature
, vol.377
, pp. 740-744
-
-
Heath, S.L.1
Tew, J.G.2
Szakal, A.K.3
-
249
-
-
0026333671
-
Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?
-
Matsuyama T., Kobayashi N., Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?. AIDS 1991, 5:1405-1417.
-
(1991)
AIDS
, vol.5
, pp. 1405-1417
-
-
Matsuyama, T.1
Kobayashi, N.2
Yamamoto, N.3
-
250
-
-
20244368227
-
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai
-
Wawer M.J., Gray R.H., Sewankambo N.K., et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai. Uganda. J Infect Dis 2005, 191:1403-1409.
-
(2005)
Uganda. J Infect Dis
, vol.191
, pp. 1403-1409
-
-
Wawer, M.J.1
Gray, R.H.2
Sewankambo, N.K.3
-
251
-
-
50949118004
-
HIV-1 transmission, by stage of infection
-
Hollingsworth T.D., Anderson R.M., Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008, 198:687-693.
-
(2008)
J Infect Dis
, vol.198
, pp. 687-693
-
-
Hollingsworth, T.D.1
Anderson, R.M.2
Fraser, C.3
-
252
-
-
41849127131
-
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic
-
Cohen M.S., Hellmann N., Levy J.A., et al. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 2008, 118:1244-1254.
-
(2008)
J Clin Invest
, vol.118
, pp. 1244-1254
-
-
Cohen, M.S.1
Hellmann, N.2
Levy, J.A.3
-
253
-
-
77953614032
-
An overview of the relative risks of different sexual behaviours on HIV transmission
-
Dosekun O., Fox J. An overview of the relative risks of different sexual behaviours on HIV transmission. Curr Opin HIV AIDS 2010, 5:291-297.
-
(2010)
Curr Opin HIV AIDS
, vol.5
, pp. 291-297
-
-
Dosekun, O.1
Fox, J.2
-
254
-
-
0028181261
-
HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study
-
Kroner B.L., Rosenberg P.S., Aledort L.M., et al. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994, 7:279-286.
-
(1994)
J Acquir Immune Defic Syndr
, vol.7
, pp. 279-286
-
-
Kroner, B.L.1
Rosenberg, P.S.2
Aledort, L.M.3
-
255
-
-
0030590749
-
Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya
-
Fowke K.R., Nagelkerke N.J., Kimani J., et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996, 348:1347-1351.
-
(1996)
Lancet
, vol.348
, pp. 1347-1351
-
-
Fowke, K.R.1
Nagelkerke, N.J.2
Kimani, J.3
-
256
-
-
78049442075
-
Historical perspective on HIV-exposed seronegative individuals: has nature done the experiment for us?
-
Shearer G., Clerici M. Historical perspective on HIV-exposed seronegative individuals: has nature done the experiment for us?. J Infect Dis 2010, 202(suppl. 3):S329-S332.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 3
-
-
Shearer, G.1
Clerici, M.2
-
257
-
-
0033773876
-
Understanding the genetic diversity of HIV-1
-
McCutchan F.E. Understanding the genetic diversity of HIV-1. AIDS 2000, 14(suppl. 3):S31-S44.
-
(2000)
AIDS
, vol.14
, Issue.SUPPL.. 3
-
-
McCutchan, F.E.1
-
258
-
-
0023052240
-
Isolation of a new human retrovirus from West African patients with AIDS
-
Clavel F., Guetard D., Brun-Vezinet F., et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986, 233:343-346.
-
(1986)
Science
, vol.233
, pp. 343-346
-
-
Clavel, F.1
Guetard, D.2
Brun-Vezinet, F.3
-
259
-
-
0028116919
-
Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group
-
Charneau P., Borman A.M., Quillent C., et al. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology 1994, 205:247-253.
-
(1994)
Virology
, vol.205
, pp. 247-253
-
-
Charneau, P.1
Borman, A.M.2
Quillent, C.3
-
260
-
-
0031695516
-
Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
-
Simon F., Mauclere P., Roques P., et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998, 4:1032-1037.
-
(1998)
Nat Med
, vol.4
, pp. 1032-1037
-
-
Simon, F.1
Mauclere, P.2
Roques, P.3
-
261
-
-
68349125395
-
A new human immunodeficiency virus derived from gorillas
-
Plantier J.C., Leoz M., Dickerson J.E., et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009, 15:871-872.
-
(2009)
Nat Med
, vol.15
, pp. 871-872
-
-
Plantier, J.C.1
Leoz, M.2
Dickerson, J.E.3
-
262
-
-
74049090141
-
Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun
-
Vessiere A., Rousset D., Kfutwah A., et al. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J Acquir Immune Defic Syndr 2010, 53:107-110.
-
(2010)
J Acquir Immune Defic Syndr
, vol.53
, pp. 107-110
-
-
Vessiere, A.1
Rousset, D.2
Kfutwah, A.3
-
263
-
-
78651387208
-
Confirmation of putative HIV-1 group P in Cameroon
-
Vallari A., Holzmayer V., Harris B., et al. Confirmation of putative HIV-1 group P in Cameroon. J Virol 2011, 85:1403-1407.
-
(2011)
J Virol
, vol.85
, pp. 1403-1407
-
-
Vallari, A.1
Holzmayer, V.2
Harris, B.3
-
264
-
-
0035162494
-
Evolutionary and immunological implications of contemporary HIV-1 variation
-
Korber B., Gaschen B., Yusim K., et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001, 58:19-42.
-
(2001)
Br Med Bull
, vol.58
, pp. 19-42
-
-
Korber, B.1
Gaschen, B.2
Yusim, K.3
-
265
-
-
79952414942
-
Global trends in molecular epidemiology of HIV-1 during 2000-2007
-
Hemelaar J., Gouws E., Ghys P.D., et al. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
-
(2011)
AIDS
, vol.25
, pp. 679-689
-
-
Hemelaar, J.1
Gouws, E.2
Ghys, P.D.3
-
266
-
-
77954589754
-
Late for the epidemic: HIV/AIDS in Eastern Europe
-
Cohen J. Late for the epidemic: HIV/AIDS in Eastern Europe. Science 2010, 329:160-164.
-
(2010)
Science
, vol.329
, pp. 160-164
-
-
Cohen, J.1
-
268
-
-
0028947028
-
Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans
-
Artenstein A.W., VanCott T.C., Mascola J.R., et al. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis 1995, 171:805-810.
-
(1995)
J Infect Dis
, vol.171
, pp. 805-810
-
-
Artenstein, A.W.1
VanCott, T.C.2
Mascola, J.R.3
-
269
-
-
0031776457
-
A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1
-
Gao F., Robertson D.L., Carruthers C.D., et al. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol 1998, 72:5680-5698.
-
(1998)
J Virol
, vol.72
, pp. 5680-5698
-
-
Gao, F.1
Robertson, D.L.2
Carruthers, C.D.3
-
270
-
-
0033840552
-
Biological considerations in the development of a human immunodeficiency virus vaccine
-
Nathanson N., Mathieson B.J. Biological considerations in the development of a human immunodeficiency virus vaccine. J Infect Dis 2000, 182:579-589.
-
(2000)
J Infect Dis
, vol.182
, pp. 579-589
-
-
Nathanson, N.1
Mathieson, B.J.2
-
271
-
-
0036310370
-
Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users
-
Ramos A., Hu D.J., Nguyen L., et al. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol 2002, 76:7444-7452.
-
(2002)
J Virol
, vol.76
, pp. 7444-7452
-
-
Ramos, A.1
Hu, D.J.2
Nguyen, L.3
-
272
-
-
33750085591
-
Lack of neutralizing antibody response to HIV-1 predisposes to superinfection
-
Smith D.M., Strain M.C., Frost S.D., et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006, 355:1-5.
-
(2006)
Virology
, vol.355
, pp. 1-5
-
-
Smith, D.M.1
Strain, M.C.2
Frost, S.D.3
-
274
-
-
19944427052
-
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein
-
Gao F., Weaver E.A., Lu Z., et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005, 79:1154-1163.
-
(2005)
J Virol
, vol.79
, pp. 1154-1163
-
-
Gao, F.1
Weaver, E.A.2
Lu, Z.3
-
275
-
-
23844468382
-
Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope
-
Doria-Rose N.A., Learn G.H., Rodrigo A.G., et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 2005, 79:11214-11224.
-
(2005)
J Virol
, vol.79
, pp. 11214-11224
-
-
Doria-Rose, N.A.1
Learn, G.H.2
Rodrigo, A.G.3
-
276
-
-
23644454804
-
Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use
-
Thomson S.A., Jaramillo A.B., Shoobridge M., et al. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 2005, 23:4647-4657.
-
(2005)
Vaccine
, vol.23
, pp. 4647-4657
-
-
Thomson, S.A.1
Jaramillo, A.B.2
Shoobridge, M.3
-
277
-
-
38949176103
-
Centralized HIV-1 envelope immunogens and neutralizing antibodies
-
Gao F., Liao H.X., Hahn B.H., et al. Centralized HIV-1 envelope immunogens and neutralizing antibodies. Curr HIV Res 2007, 5:572-577.
-
(2007)
Curr HIV Res
, vol.5
, pp. 572-577
-
-
Gao, F.1
Liao, H.X.2
Hahn, B.H.3
-
278
-
-
69249211230
-
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces
-
Korber B.T., Letvin N.L., Haynes B.F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 2009, 83:8300-8314.
-
(2009)
J Virol
, vol.83
, pp. 8300-8314
-
-
Korber, B.T.1
Letvin, N.L.2
Haynes, B.F.3
-
279
-
-
33846111016
-
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
-
Fischer W., Perkins S., Theiler J., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007, 13:100-106.
-
(2007)
Nat Med
, vol.13
, pp. 100-106
-
-
Fischer, W.1
Perkins, S.2
Theiler, J.3
-
280
-
-
77749233746
-
HIV vaccines: mosaic approach to virus diversity
-
Corey L., McElrath M.J. HIV vaccines: mosaic approach to virus diversity. Nat Med 2010, 16:268-270.
-
(2010)
Nat Med
, vol.16
, pp. 268-270
-
-
Corey, L.1
McElrath, M.J.2
-
281
-
-
77955517246
-
Novel adenovirus vector-based vaccines for HIV-1
-
Barouch D.H. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 2010, 5:386-390.
-
(2010)
Curr Opin HIV AIDS
, vol.5
, pp. 386-390
-
-
Barouch, D.H.1
-
282
-
-
77949264937
-
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys
-
Santra S., Liao H.X., Zhang R., et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010, 16:324-328.
-
(2010)
Nat Med
, vol.16
, pp. 324-328
-
-
Santra, S.1
Liao, H.X.2
Zhang, R.3
-
283
-
-
0034723385
-
AIDS as a zoonosis: scientific and public health implications
-
Hahn B.H., Shaw G.M., De Cock K.M. AIDS as a zoonosis: scientific and public health implications. Science 2000, 287:607-614.
-
(2000)
Science
, vol.287
, pp. 607-614
-
-
Hahn, B.H.1
Shaw, G.M.2
De Cock, K.M.3
-
284
-
-
33745059199
-
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1
-
Keele B.F., Van Heuverswyn F., Li Y., et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313:523-526.
-
(2006)
Science
, vol.313
, pp. 523-526
-
-
Keele, B.F.1
Van Heuverswyn, F.2
Li, Y.3
-
285
-
-
0034625771
-
Timing the ancestor of the HIV-1 pandemic strains
-
Korber B., Muldoon M., Theiler J., et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000, 288:1789-1796.
-
(2000)
Science
, vol.288
, pp. 1789-1796
-
-
Korber, B.1
Muldoon, M.2
Theiler, J.3
-
286
-
-
67049119333
-
Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2
-
Wertheim J.O., Worobey M. Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2. PLoS Comput Biol 2009, 5:e1000377.
-
(2009)
PLoS Comput Biol
, vol.5
-
-
Wertheim, J.O.1
Worobey, M.2
-
288
-
-
0033521911
-
Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes
-
Gao F., Bailes E., Robertson D.L., et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999, 397:436-441.
-
(1999)
Nature
, vol.397
, pp. 436-441
-
-
Gao, F.1
Bailes, E.2
Robertson, D.L.3
-
290
-
-
73949151602
-
Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas
-
Neel C., Etienne L., Li Y., et al. Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas. J Virol 2010, 84:1464-1476.
-
(2010)
J Virol
, vol.84
, pp. 1464-1476
-
-
Neel, C.1
Etienne, L.2
Li, Y.3
-
291
-
-
30844450364
-
Widely varying SIV prevalence rates in naturally infected primate species from Cameroon
-
Aghokeng A.F., Liu W., Bibollet-Ruche F., et al. Widely varying SIV prevalence rates in naturally infected primate species from Cameroon. Virology 2006, 345:174-189.
-
(2006)
Virology
, vol.345
, pp. 174-189
-
-
Aghokeng, A.F.1
Liu, W.2
Bibollet-Ruche, F.3
-
292
-
-
78149375894
-
Les variants des groupes N, O et P du virus de l'immunodéficience humaine de type 1
-
Vessière A., Simon F., Plantier J.C. Les variants des groupes N, O et P du virus de l'immunodéficience humaine de type 1. Virologie 2010, 14:334-348.
-
(2010)
Virologie
, vol.14
, pp. 334-348
-
-
Vessière, A.1
Simon, F.2
Plantier, J.C.3
-
293
-
-
0028043670
-
Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild
-
Jin M.J., Rogers J., Phillips-Conroy J.E., et al. Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild. J Virol 1994, 68:8454-8460.
-
(1994)
J Virol
, vol.68
, pp. 8454-8460
-
-
Jin, M.J.1
Rogers, J.2
Phillips-Conroy, J.E.3
-
294
-
-
0038047665
-
Hybrid origin of SIV in chimpanzees
-
Bailes E., Gao F., Bibollet-Ruche F., et al. Hybrid origin of SIV in chimpanzees. Science 2003, 300:1713.
-
(2003)
Science
, vol.300
, pp. 1713
-
-
Bailes, E.1
Gao, F.2
Bibollet-Ruche, F.3
-
295
-
-
77956685623
-
Island biogeography reveals the deep history of SIV
-
Worobey M., Telfer P., Souquiere S., et al. Island biogeography reveals the deep history of SIV. Science 2010, 329:1487.
-
(2010)
Science
, vol.329
, pp. 1487
-
-
Worobey, M.1
Telfer, P.2
Souquiere, S.3
-
296
-
-
53349127137
-
Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960
-
Worobey M., Gemmel M., Teuwen D.E., et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008, 455:661-664.
-
(2008)
Nature
, vol.455
, pp. 661-664
-
-
Worobey, M.1
Gemmel, M.2
Teuwen, D.E.3
-
297
-
-
3843100510
-
The molecular population genetics of HIV-1 group O
-
Lemey P., Pybus O.G., Rambaut A., et al. The molecular population genetics of HIV-1 group O. Genetics 2004, 167:1059-1068.
-
(2004)
Genetics
, vol.167
, pp. 1059-1068
-
-
Lemey, P.1
Pybus, O.G.2
Rambaut, A.3
-
298
-
-
77956316616
-
High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains
-
De Sousa J.D., Müller V., Lemey P., et al. High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains. PLoS One 2010, 5:e9936.
-
(2010)
PLoS One
, vol.5
-
-
De Sousa, J.D.1
Müller, V.2
Lemey, P.3
-
299
-
-
0036093398
-
Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat
-
Peeters M., Courgnaud V., Abela B., et al. Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis 2002, 8:451-457.
-
(2002)
Emerg Infect Dis
, vol.8
, pp. 451-457
-
-
Peeters, M.1
Courgnaud, V.2
Abela, B.3
-
300
-
-
77951092393
-
Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions
-
Aghokeng A.F., Ayouba A., Mpoudi-Ngole E., et al. Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. Infect Genet Evol 2010, 10:386-396.
-
(2010)
Infect Genet Evol
, vol.10
, pp. 386-396
-
-
Aghokeng, A.F.1
Ayouba, A.2
Mpoudi-Ngole, E.3
-
301
-
-
32044468934
-
Amplified HIV transmission during early-stage infection
-
Hayes R.J., White R.G. Amplified HIV transmission during early-stage infection. J Infect Dis 2006, 193:604-606.
-
(2006)
J Infect Dis
, vol.193
, pp. 604-606
-
-
Hayes, R.J.1
White, R.G.2
-
302
-
-
33947375214
-
High rates of forward transmission events after acute/early HIV-1 infection
-
Brenner B.G., Roger M., Routy J.P., et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007, 195:951-959.
-
(2007)
J Infect Dis
, vol.195
, pp. 951-959
-
-
Brenner, B.G.1
Roger, M.2
Routy, J.P.3
-
303
-
-
34447527370
-
How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission?
-
Pinkerton S.D. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission?. AIDS 2007, 21:1625-1629.
-
(2007)
AIDS
, vol.21
, pp. 1625-1629
-
-
Pinkerton, S.D.1
-
304
-
-
63149127441
-
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection
-
Ma Z.M., Stone M., Piatak M., et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009, 83:3288-3297.
-
(2009)
J Virol
, vol.83
, pp. 3288-3297
-
-
Ma, Z.M.1
Stone, M.2
Piatak, M.3
-
305
-
-
77957569460
-
Acute HIV-1 infection: what's new? where are we going?
-
D'Souza M.P., Axten K.L., Hecht F.M. Acute HIV-1 infection: what's new? where are we going?. J Infect Dis 2010, 202(suppl. 2):S267-S269.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 2
-
-
D'Souza, M.P.1
Axten, K.L.2
Hecht, F.M.3
-
306
-
-
70449371426
-
Circumcision and risk of HIV infection in Australian homosexual men
-
Templeton D.J., Jin F., Mao L., et al. Circumcision and risk of HIV infection in Australian homosexual men. AIDS 2009, 23:2347-2351.
-
(2009)
AIDS
, vol.23
, pp. 2347-2351
-
-
Templeton, D.J.1
Jin, F.2
Mao, L.3
-
307
-
-
84855902980
-
Determinants of per-coital-act HIV-1 infectivity among African HIV-1 serodiscordant couples
-
Hughes J.P., Baeten J.M., Lingappa J.R., et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1 serodiscordant couples. J Infect Dis 2012, 205:358-365.
-
(2012)
J Infect Dis
, vol.205
, pp. 358-365
-
-
Hughes, J.P.1
Baeten, J.M.2
Lingappa, J.R.3
-
308
-
-
77951065603
-
-
UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva
-
UNAIDS AIDS Epidemic Update 2009 2009, Joint United Nations Programme on HIV/AIDS, Geneva.
-
(2009)
AIDS Epidemic Update 2009
-
-
-
309
-
-
77954572785
-
Tracing the regional rise of HIV
-
Cohen J. Tracing the regional rise of HIV. Science 2010, 329:161.
-
(2010)
Science
, vol.329
, pp. 161
-
-
Cohen, J.1
-
311
-
-
48749117983
-
Estimation of HIV incidence in the United States
-
Hall H.I., Song R., Rhodes P., et al. Estimation of HIV incidence in the United States. JAMA 2008, 300:520-529.
-
(2008)
JAMA
, vol.300
, pp. 520-529
-
-
Hall, H.I.1
Song, R.2
Rhodes, P.3
-
312
-
-
79953773356
-
Why is HIV ravaging D.C.?
-
McEnery R. Why is HIV ravaging D.C.?. IAVI Rep 2010, 14:10-13.
-
(2010)
IAVI Rep
, vol.14
, pp. 10-13
-
-
McEnery, R.1
-
313
-
-
67651049000
-
Risk factors driving the emergence of a generalized heterosexual HIV epidemic in Washington, District of Columbia networks at risk
-
Magnus M., Kuo I., Shelley K., et al. Risk factors driving the emergence of a generalized heterosexual HIV epidemic in Washington, District of Columbia networks at risk. AIDS 2009, 23:1277-1284.
-
(2009)
AIDS
, vol.23
, pp. 1277-1284
-
-
Magnus, M.1
Kuo, I.2
Shelley, K.3
-
314
-
-
77952156002
-
Fighting HIV/AIDS in Washington, D.C
-
Greenberg A.E., Hader S.L., Masur H., et al. Fighting HIV/AIDS in Washington, D.C. Health Aff (Millwood) 2009, 28:1677-1687.
-
(2009)
Health Aff (Millwood)
, vol.28
, pp. 1677-1687
-
-
Greenberg, A.E.1
Hader, S.L.2
Masur, H.3
-
315
-
-
4043060710
-
Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know
-
Pantaleo G., Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004, 10:806-810.
-
(2004)
Nat Med
, vol.10
, pp. 806-810
-
-
Pantaleo, G.1
Koup, R.A.2
-
316
-
-
42049102821
-
Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus
-
Friedrich T.C., Watkins D.I. Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus. Curr Opin HIV AIDS 2008, 3:393-398.
-
(2008)
Curr Opin HIV AIDS
, vol.3
, pp. 393-398
-
-
Friedrich, T.C.1
Watkins, D.I.2
-
317
-
-
78650598765
-
The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors
-
Koup R.A., Graham B.S., Douek D.C. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol 2011, 11:65-70.
-
(2011)
Nat Rev Immunol
, vol.11
, pp. 65-70
-
-
Koup, R.A.1
Graham, B.S.2
Douek, D.C.3
-
318
-
-
57349127300
-
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
-
Tomaras G.D., Yates N.L., Liu P., et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008, 82:12449-12463.
-
(2008)
J Virol
, vol.82
, pp. 12449-12463
-
-
Tomaras, G.D.1
Yates, N.L.2
Liu, P.3
-
319
-
-
49149118421
-
Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection
-
Bunnik E.M., Pisas L., van Nuenen A.C., et al. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008, 82:7932-7941.
-
(2008)
J Virol
, vol.82
, pp. 7932-7941
-
-
Bunnik, E.M.1
Pisas, L.2
van Nuenen, A.C.3
-
320
-
-
37848999666
-
The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen
-
Ching L.K., Vlachogiannis G., Bosch K.A., et al. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen. J Virol 2008, 82:949-956.
-
(2008)
J Virol
, vol.82
, pp. 949-956
-
-
Ching, L.K.1
Vlachogiannis, G.2
Bosch, K.A.3
-
321
-
-
0141788494
-
Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate
-
Srivastava I.K., Stamatatos L., Kan E., et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003, 77:11244-11259.
-
(2003)
J Virol
, vol.77
, pp. 11244-11259
-
-
Srivastava, I.K.1
Stamatatos, L.2
Kan, E.3
-
322
-
-
0025071687
-
Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant
-
LaRosa G.J., Davide J.P., Weinhold K., et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990, 249:932-935.
-
(1990)
Science
, vol.249
, pp. 932-935
-
-
LaRosa, G.J.1
Davide, J.P.2
Weinhold, K.3
-
323
-
-
0026361459
-
The role of the V3 loop of gp120 in HIV infection
-
Moore J.P., Nara P.L. The role of the V3 loop of gp120 in HIV infection. AIDS 1991, 5(suppl. 2):S21-S33.
-
(1991)
AIDS
, vol.5
, Issue.SUPPL.. 2
-
-
Moore, J.P.1
Nara, P.L.2
-
324
-
-
16244419386
-
Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles
-
Gorny M.K., Stamatatos L., Volsky B., et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 2005, 79:5232-5237.
-
(2005)
J Virol
, vol.79
, pp. 5232-5237
-
-
Gorny, M.K.1
Stamatatos, L.2
Volsky, B.3
-
325
-
-
33846556067
-
Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence
-
Honnen W.J., Krachmarov C., Kayman S.C., et al. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J Virol 2007, 81:1424-1432.
-
(2007)
J Virol
, vol.81
, pp. 1424-1432
-
-
Honnen, W.J.1
Krachmarov, C.2
Kayman, S.C.3
-
326
-
-
38949186531
-
Roles of HIV-1 Env variable regions in viral neutralization and vaccine development
-
Pinter A. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Curr HIV Res 2007, 5:542-553.
-
(2007)
Curr HIV Res
, vol.5
, pp. 542-553
-
-
Pinter, A.1
-
328
-
-
33646146379
-
GP120: target for neutralizing HIV-1 antibodies
-
Pantophlet R., Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006, 24:739-769.
-
(2006)
Annu Rev Immunol
, vol.24
, pp. 739-769
-
-
Pantophlet, R.1
Burton, D.R.2
-
329
-
-
56449131391
-
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
-
Binley J.M., Lybarger E.A., Crooks E.T., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008, 82:11651-11668.
-
(2008)
J Virol
, vol.82
, pp. 11651-11668
-
-
Binley, J.M.1
Lybarger, E.A.2
Crooks, E.T.3
-
330
-
-
70349887757
-
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
-
Walker L.M., Phogat S.K., Chan-Hui P.Y., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
-
(2009)
Science
, vol.326
, pp. 285-289
-
-
Walker, L.M.1
Phogat, S.K.2
Chan-Hui, P.Y.3
-
331
-
-
58149517700
-
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
-
Li Y., Svehla K., Louder M.K., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009, 83:1045-1059.
-
(2009)
J Virol
, vol.83
, pp. 1045-1059
-
-
Li, Y.1
Svehla, K.2
Louder, M.K.3
-
332
-
-
73949084963
-
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables
-
Doria-Rose N.A., Klein R.M., Daniels M.G., et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010, 84:1631-1636.
-
(2010)
J Virol
, vol.84
, pp. 1631-1636
-
-
Doria-Rose, N.A.1
Klein, R.M.2
Daniels, M.G.3
-
333
-
-
63849131879
-
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
-
Scheid J.F., Mouquet H., Feldhahn N., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
-
(2009)
Nature
, vol.458
, pp. 636-640
-
-
Scheid, J.F.1
Mouquet, H.2
Feldhahn, N.3
-
334
-
-
79551518897
-
Characteristics of the earliest cross-neutralizing antibody response to HIV-1
-
Mikell I., Sather D.N., Kalams S.A., et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011, 7:e1001251.
-
(2011)
PLoS Pathog
, vol.7
-
-
Mikell, I.1
Sather, D.N.2
Kalams, S.A.3
-
335
-
-
58149487645
-
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
-
Sather D.N., Armann J., Ching L.K., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009, 83:757-769.
-
(2009)
J Virol
, vol.83
, pp. 757-769
-
-
Sather, D.N.1
Armann, J.2
Ching, L.K.3
-
336
-
-
69149083668
-
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
-
Stamatatos L., Morris L., Burton D.R., et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15:866-870.
-
(2009)
Nat Med
, vol.15
, pp. 866-870
-
-
Stamatatos, L.1
Morris, L.2
Burton, D.R.3
-
337
-
-
70349298392
-
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression
-
Piantadosi A., Panteleeff D., Blish C.A., et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 2009, 83:10269-10274.
-
(2009)
J Virol
, vol.83
, pp. 10269-10274
-
-
Piantadosi, A.1
Panteleeff, D.2
Blish, C.A.3
-
338
-
-
58149399396
-
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
-
Doria-Rose N.A., Klein R.M., Manion M.M., et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009, 83:188-199.
-
(2009)
J Virol
, vol.83
, pp. 188-199
-
-
Doria-Rose, N.A.1
Klein, R.M.2
Manion, M.M.3
-
339
-
-
77957573505
-
The humoral response to HIV-1: new insights, renewed focus
-
Alter G., Moody M.A. The humoral response to HIV-1: new insights, renewed focus. J Infect Dis 2010, 202(suppl. 2):S315-S322.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 2
-
-
Alter, G.1
Moody, M.A.2
-
340
-
-
67650453747
-
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm
-
Simek M.D., Rida W., Priddy F.H., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009, 83:7337-7348.
-
(2009)
J Virol
, vol.83
, pp. 7337-7348
-
-
Simek, M.D.1
Rida, W.2
Priddy, F.H.3
-
341
-
-
77949411309
-
Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4
-
Robinson J.E., Franco K., Elliott D.H., et al. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J Virol 2010, 84:3443-3453.
-
(2010)
J Virol
, vol.84
, pp. 3443-3453
-
-
Robinson, J.E.1
Franco, K.2
Elliott, D.H.3
-
342
-
-
0032907674
-
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
-
Shibata R., Igarashi T., Haigwood N., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999, 5:204-210.
-
(1999)
Nat Med
, vol.5
, pp. 204-210
-
-
Shibata, R.1
Igarashi, T.2
Haigwood, N.3
-
343
-
-
0033952103
-
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
-
Baba T.W., Liska V., Hofmann-Lehmann R., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000, 6:200-206.
-
(2000)
Nat Med
, vol.6
, pp. 200-206
-
-
Baba, T.W.1
Liska, V.2
Hofmann-Lehmann, R.3
-
344
-
-
0037029924
-
Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1
-
Mascola J.R. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002, 20:1922-1925.
-
(2002)
Vaccine
, vol.20
, pp. 1922-1925
-
-
Mascola, J.R.1
-
345
-
-
0033951746
-
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
-
Mascola J.R., Stiegler G., VanCott T.C., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
-
(2000)
Nat Med
, vol.6
, pp. 207-210
-
-
Mascola, J.R.1
Stiegler, G.2
VanCott, T.C.3
-
346
-
-
38449097264
-
Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region
-
Mantis N.J., Palaia J., Hessell A.J., et al. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol 2007, 179:3144-3152.
-
(2007)
J Immunol
, vol.179
, pp. 3144-3152
-
-
Mantis, N.J.1
Palaia, J.2
Hessell, A.J.3
-
347
-
-
68349160853
-
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
-
Hessell A.J., Poignard P., Hunter M., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009, 15:951-954.
-
(2009)
Nat Med
, vol.15
, pp. 951-954
-
-
Hessell, A.J.1
Poignard, P.2
Hunter, M.3
-
348
-
-
67249131966
-
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
-
Hessell A.J., Rakasz E.G., Poignard P., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009, 5:e1000433.
-
(2009)
PLoS Pathog
, vol.5
-
-
Hessell, A.J.1
Rakasz, E.G.2
Poignard, P.3
-
349
-
-
68349150945
-
Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys
-
Johnson P.R., Schnepp B.C., Zhang J., et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009, 15:901-906.
-
(2009)
Nat Med
, vol.15
, pp. 901-906
-
-
Johnson, P.R.1
Schnepp, B.C.2
Zhang, J.3
-
350
-
-
0032947286
-
Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
-
Mascola J.R., Lewis M.G., Stiegler G., et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
-
(1999)
J Virol
, vol.73
, pp. 4009-4018
-
-
Mascola, J.R.1
Lewis, M.G.2
Stiegler, G.3
-
351
-
-
73949154006
-
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L
-
Hessell A.J., Rakasz E.G., Tehrani D.M., et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010, 84:1302-1313.
-
(2010)
J Virol
, vol.84
, pp. 1302-1313
-
-
Hessell, A.J.1
Rakasz, E.G.2
Tehrani, D.M.3
-
352
-
-
0034904087
-
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge
-
Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001, 75:7470-7480.
-
(2001)
J Virol
, vol.75
, pp. 7470-7480
-
-
Hofmann-Lehmann, R.1
Vlasak, J.2
Rasmussen, R.A.3
-
353
-
-
0033119374
-
Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
-
Poignard P., Sabbe R., Picchio G.R., et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999, 10:431-438.
-
(1999)
Immunity
, vol.10
, pp. 431-438
-
-
Poignard, P.1
Sabbe, R.2
Picchio, G.R.3
-
354
-
-
34249940652
-
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection
-
Gray E.S., Moore P.L., Choge I.A., et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007, 81:6187-6196.
-
(2007)
J Virol
, vol.81
, pp. 6187-6196
-
-
Gray, E.S.1
Moore, P.L.2
Choge, I.A.3
-
355
-
-
77749306129
-
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression
-
Euler Z., van Gils M.J., Bunnik E.M., et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 2010, 201:1045-1053.
-
(2010)
J Infect Dis
, vol.201
, pp. 1045-1053
-
-
Euler, Z.1
van Gils, M.J.2
Bunnik, E.M.3
-
356
-
-
1542317452
-
HIV vaccine design and the neutralizing antibody problem
-
Burton D.R., Desrosiers R.C., Doms R.W., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5:233-236.
-
(2004)
Nat Immunol
, vol.5
, pp. 233-236
-
-
Burton, D.R.1
Desrosiers, R.C.2
Doms, R.W.3
-
358
-
-
77955630528
-
AIDS/HIV: a boost for HIV vaccine design
-
Burton D.R., Weiss R.A. AIDS/HIV: a boost for HIV vaccine design. Science 2010, 329:770-773.
-
(2010)
Science
, vol.329
, pp. 770-773
-
-
Burton, D.R.1
Weiss, R.A.2
-
359
-
-
34347256384
-
Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets
-
Phogat S., Wyatt R.T., Karlsson Hedestam G.B. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med 2007, 262:26-43.
-
(2007)
J Intern Med
, vol.262
, pp. 26-43
-
-
Phogat, S.1
Wyatt, R.T.2
Karlsson Hedestam, G.B.3
-
360
-
-
77956689545
-
Pushing the envelope on HIV-1 neutralization
-
Joyce J.G., ter Meulen J. Pushing the envelope on HIV-1 neutralization. Nat Biotechnol 2010, 28:929-931.
-
(2010)
Nat Biotechnol
, vol.28
, pp. 929-931
-
-
Joyce, J.G.1
Ter Meulen, J.2
-
361
-
-
77951882041
-
Toward an antibody-based HIV-1 vaccine
-
Hoxie J.A. Toward an antibody-based HIV-1 vaccine. Annu Rev Med 2010, 61:135-152.
-
(2010)
Annu Rev Med
, vol.61
, pp. 135-152
-
-
Hoxie, J.A.1
-
363
-
-
0033524838
-
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
-
Schmitz J.E., Kuroda M.J., Santra S., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
-
(1999)
Science
, vol.283
, pp. 857-860
-
-
Schmitz, J.E.1
Kuroda, M.J.2
Santra, S.3
-
364
-
-
33744902339
-
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239
-
Wilson N.A., Reed J., Napoe G.S., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006, 80:5875-5885.
-
(2006)
J Virol
, vol.80
, pp. 5875-5885
-
-
Wilson, N.A.1
Reed, J.2
Napoe, G.S.3
-
365
-
-
58149267963
-
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
-
Liu J., O'Brien K.L., Lynch D.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91.
-
(2009)
Nature
, vol.457
, pp. 87-91
-
-
Liu, J.1
O'Brien, K.L.2
Lynch, D.M.3
-
366
-
-
61949216736
-
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge
-
Hansen S.G., Vieville C., Whizin N., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15:293-299.
-
(2009)
Nat Med
, vol.15
, pp. 293-299
-
-
Hansen, S.G.1
Vieville, C.2
Whizin, N.3
-
367
-
-
41949088384
-
Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques
-
Sadagopal S., Amara R.R., Kannanganat S., et al. Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J Virol 2008, 82:4149-4153.
-
(2008)
J Virol
, vol.82
, pp. 4149-4153
-
-
Sadagopal, S.1
Amara, R.R.2
Kannanganat, S.3
-
368
-
-
33947385340
-
Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication
-
Friedrich T.C., Valentine L.E., Yant L.J., et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol 2007, 81:3465-3476.
-
(2007)
J Virol
, vol.81
, pp. 3465-3476
-
-
Friedrich, T.C.1
Valentine, L.E.2
Yant, L.J.3
-
369
-
-
55549145769
-
With minimal systemic T-cell expansion, CD8+ T cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus
-
Genesca M., Skinner P.J., Hong J.J., et al. With minimal systemic T-cell expansion, CD8+ T cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol 2008, 82:11181-11196.
-
(2008)
J Virol
, vol.82
, pp. 11181-11196
-
-
Genesca, M.1
Skinner, P.J.2
Hong, J.J.3
-
370
-
-
57449114534
-
Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6
-
Genesca M., McChesney M.B., Miller C.J. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med 2009, 265:67-77.
-
(2009)
J Intern Med
, vol.265
, pp. 67-77
-
-
Genesca, M.1
McChesney, M.B.2
Miller, C.J.3
-
371
-
-
78049423723
-
Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations
-
Horton R.E., McLaren P.J., Fowke K., et al. Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations. J Infect Dis 2010, 202(suppl. 3):S377-S381.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 3
-
-
Horton, R.E.1
McLaren, P.J.2
Fowke, K.3
-
372
-
-
78049445926
-
Determinants of protection among HIV-exposed seronegative persons: an overview
-
Lederman M.M., Alter G., Daskalakis D.C., et al. Determinants of protection among HIV-exposed seronegative persons: an overview. J Infect Dis 2010, 202(suppl. 3):S333-S338.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 3
-
-
Lederman, M.M.1
Alter, G.2
Daskalakis, D.C.3
-
373
-
-
77953701383
-
Control of HIV-1 replication in elite suppressors
-
Blankson J.N. Control of HIV-1 replication in elite suppressors. Discov Med 2010, 9:261-266.
-
(2010)
Discov Med
, vol.9
, pp. 261-266
-
-
Blankson, J.N.1
-
374
-
-
58149375456
-
Elite control of HIV infection: implications for vaccine design
-
Baker B.M., Block B.L., Rothchild A.C., et al. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 2009, 9:55-69.
-
(2009)
Expert Opin Biol Ther
, vol.9
, pp. 55-69
-
-
Baker, B.M.1
Block, B.L.2
Rothchild, A.C.3
-
375
-
-
33646453478
-
Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy
-
Bailey J.R., Lassen K.G., Yang H.C., et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006, 80:4758-4770.
-
(2006)
J Virol
, vol.80
, pp. 4758-4770
-
-
Bailey, J.R.1
Lassen, K.G.2
Yang, H.C.3
-
376
-
-
33646869319
-
Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection
-
Duvall M.G., Jaye A., Dong T., et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol 2006, 176:6973-6981.
-
(2006)
J Immunol
, vol.176
, pp. 6973-6981
-
-
Duvall, M.G.1
Jaye, A.2
Dong, T.3
-
377
-
-
42049115065
-
Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection
-
Leligdowicz A., Rowland-Jones S. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection. Expert Rev Vaccines 2008, 7:319-331.
-
(2008)
Expert Rev Vaccines
, vol.7
, pp. 319-331
-
-
Leligdowicz, A.1
Rowland-Jones, S.2
-
378
-
-
0030997137
-
Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms
-
Yang O.O., Kalams S.A., Trocha A., et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997, 71:3120-3128.
-
(1997)
J Virol
, vol.71
, pp. 3120-3128
-
-
Yang, O.O.1
Kalams, S.A.2
Trocha, A.3
-
379
-
-
0034646143
-
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
-
Migueles S.A., Sabbaghian M.S., Shupert W.L., et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000, 97:2709-2714.
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 2709-2714
-
-
Migueles, S.A.1
Sabbaghian, M.S.2
Shupert, W.L.3
-
380
-
-
33750822983
-
Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection
-
Horton H., Frank I., Baydo R., et al. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol 2006, 177:7406-7415.
-
(2006)
J Immunol
, vol.177
, pp. 7406-7415
-
-
Horton, H.1
Frank, I.2
Baydo, R.3
-
381
-
-
33646472100
-
HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently
-
Turnbull E.L., Lopes A.R., Jones N.A., et al. HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J Immunol 2006, 176:6130-6146.
-
(2006)
J Immunol
, vol.176
, pp. 6130-6146
-
-
Turnbull, E.L.1
Lopes, A.R.2
Jones, N.A.3
-
382
-
-
33644755541
-
Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control
-
Zuniga R., Lucchetti A., Galvan P., et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006, 80:3122-3125.
-
(2006)
J Virol
, vol.80
, pp. 3122-3125
-
-
Zuniga, R.1
Lucchetti, A.2
Galvan, P.3
-
383
-
-
38949168855
-
Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads
-
Rolland M., Heckerman D., Deng W., et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 2008, 3:e1424.
-
(2008)
PLoS One
, vol.3
-
-
Rolland, M.1
Heckerman, D.2
Deng, W.3
-
384
-
-
78650165514
-
Genetics: first-class control of HIV-1
-
McMichael A.J., Jones E.Y. Genetics: first-class control of HIV-1. Science 2010, 330:1488-1490.
-
(2010)
Science
, vol.330
, pp. 1488-1490
-
-
McMichael, A.J.1
Jones, E.Y.2
-
385
-
-
79952452307
-
An additive effect of protective host genetic factors correlates with HIV nonprogression status
-
Salgado M., Simon A., Sanz-Minguela B., et al. An additive effect of protective host genetic factors correlates with HIV nonprogression status. J Acquir Immune Defic Syndr 2011, 56:300-305.
-
(2011)
J Acquir Immune Defic Syndr
, vol.56
, pp. 300-305
-
-
Salgado, M.1
Simon, A.2
Sanz-Minguela, B.3
-
386
-
-
0036171258
-
Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma
-
Edwards B.H., Bansal A., Sabbaj S., et al. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002, 76:2298-2305.
-
(2002)
J Virol
, vol.76
, pp. 2298-2305
-
-
Edwards, B.H.1
Bansal, A.2
Sabbaj, S.3
-
387
-
-
34249852256
-
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype
-
Saez-Cirion A., Lacabaratz C., Lambotte O., et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007, 104:6776-6781.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 6776-6781
-
-
Saez-Cirion, A.1
Lacabaratz, C.2
Lambotte, O.3
-
388
-
-
34249774014
-
Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection
-
Critchfield J.W., Lemongello D., Walker D.H., et al. Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol 2007, 81:5460-5471.
-
(2007)
J Virol
, vol.81
, pp. 5460-5471
-
-
Critchfield, J.W.1
Lemongello, D.2
Walker, D.H.3
-
389
-
-
33646686040
-
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
-
Betts M.R., Nason M.C., West S.M., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
-
(2006)
Blood
, vol.107
, pp. 4781-4789
-
-
Betts, M.R.1
Nason, M.C.2
West, S.M.3
-
390
-
-
0036852179
-
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors
-
Migueles S.A., Laborico A.C., Shupert W.L., et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002, 3:1061-1068.
-
(2002)
Nat Immunol
, vol.3
, pp. 1061-1068
-
-
Migueles, S.A.1
Laborico, A.C.2
Shupert, W.L.3
-
391
-
-
33845761848
-
Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection
-
Day C.L., Kiepiela P., Leslie A.J., et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol 2007, 81:434-438.
-
(2007)
J Virol
, vol.81
, pp. 434-438
-
-
Day, C.L.1
Kiepiela, P.2
Leslie, A.J.3
-
392
-
-
57449109484
-
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control
-
Migueles S.A., Osborne C.M., Royce C., et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29:1009-1021.
-
(2008)
Immunity
, vol.29
, pp. 1009-1021
-
-
Migueles, S.A.1
Osborne, C.M.2
Royce, C.3
-
393
-
-
70350322293
-
Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy
-
Migueles S.A., Weeks K.A., Nou E., et al. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 2009, 83:11876-11889.
-
(2009)
J Virol
, vol.83
, pp. 11876-11889
-
-
Migueles, S.A.1
Weeks, K.A.2
Nou, E.3
-
394
-
-
77954080011
-
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control
-
Hersperger A.R., Pereyra F., Nason M., et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010, 6:e1000917.
-
(2010)
PLoS Pathog
, vol.6
-
-
Hersperger, A.R.1
Pereyra, F.2
Nason, M.3
-
395
-
-
67649213034
-
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses
-
Saez-Cirion A., Sinet M., Shin S.Y., et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 2009, 182:7828-7837.
-
(2009)
J Immunol
, vol.182
, pp. 7828-7837
-
-
Saez-Cirion, A.1
Sinet, M.2
Shin, S.Y.3
-
396
-
-
77956793480
-
Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers
-
Ferre A.L., Lemongello D., Hunt P.W., et al. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. J Virol 2010, 84:10354-10365.
-
(2010)
J Virol
, vol.84
, pp. 10354-10365
-
-
Ferre, A.L.1
Lemongello, D.2
Hunt, P.W.3
-
397
-
-
65449126294
-
Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control
-
Ferre A.L., Hunt P.W., Critchfield J.W., et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113:3978-3989.
-
(2009)
Blood
, vol.113
, pp. 3978-3989
-
-
Ferre, A.L.1
Hunt, P.W.2
Critchfield, J.W.3
-
398
-
-
78651397483
-
Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function
-
Richmond M., McKinnon L.R., Kiazyk S.A., et al. Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function. J Virol 2011, 85:1275-1286.
-
(2011)
J Virol
, vol.85
, pp. 1275-1286
-
-
Richmond, M.1
McKinnon, L.R.2
Kiazyk, S.A.3
-
399
-
-
18344418801
-
Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
-
Rowland-Jones S.L., Dong T., Fowke K.R., et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998, 102:1758-1765.
-
(1998)
J Clin Invest
, vol.102
, pp. 1758-1765
-
-
Rowland-Jones, S.L.1
Dong, T.2
Fowke, K.R.3
-
400
-
-
0026534763
-
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1
-
Clerici M., Giorgi J.V., Chou C.C., et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992, 165:1012-1019.
-
(1992)
J Infect Dis
, vol.165
, pp. 1012-1019
-
-
Clerici, M.1
Giorgi, J.V.2
Chou, C.C.3
-
401
-
-
0035134669
-
Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses
-
Kaul R., Rowland-Jones S.L., Kimani J., et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest 2001, 107:341-349.
-
(2001)
J Clin Invest
, vol.107
, pp. 341-349
-
-
Kaul, R.1
Rowland-Jones, S.L.2
Kimani, J.3
-
402
-
-
34249786561
-
A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells
-
Belyakov I.M., Isakov D., Zhu Q., et al. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 2007, 178:7211-7221.
-
(2007)
J Immunol
, vol.178
, pp. 7211-7221
-
-
Belyakov, I.M.1
Isakov, D.2
Zhu, Q.3
-
403
-
-
33645748846
-
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa
-
Belyakov I.M., Kuznetsov V.A., Kelsall B., et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006, 107:3258-3264.
-
(2006)
Blood
, vol.107
, pp. 3258-3264
-
-
Belyakov, I.M.1
Kuznetsov, V.A.2
Kelsall, B.3
-
404
-
-
44949154503
-
CD8+ T cell efficacy in vaccination and disease
-
Appay V., Douek D.C., Price D.A. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008, 14:623-628.
-
(2008)
Nat Med
, vol.14
, pp. 623-628
-
-
Appay, V.1
Douek, D.C.2
Price, D.A.3
-
405
-
-
60049098638
-
Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination
-
Kong W.P., Wu L., Wallstrom T.C., et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009, 83:2201-2215.
-
(2009)
J Virol
, vol.83
, pp. 2201-2215
-
-
Kong, W.P.1
Wu, L.2
Wallstrom, T.C.3
-
406
-
-
77749242569
-
Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS
-
Ahlers J.D., Belyakov I.M. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol 2010, 31:120-130.
-
(2010)
Trends Immunol
, vol.31
, pp. 120-130
-
-
Ahlers, J.D.1
Belyakov, I.M.2
-
407
-
-
0034958413
-
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells
-
Forthal D.N., Landucci G., Daar E.S. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001, 75:6953-6961.
-
(2001)
J Virol
, vol.75
, pp. 6953-6961
-
-
Forthal, D.N.1
Landucci, G.2
Daar, E.S.3
-
408
-
-
69549103041
-
Fc receptor-mediated antiviral antibodies
-
Forthal D.N., Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009, 4:388-393.
-
(2009)
Curr Opin HIV AIDS
, vol.4
, pp. 388-393
-
-
Forthal, D.N.1
Moog, C.2
-
409
-
-
17344370858
-
Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection
-
Van Rompay K.K., Berardi C.J., Dillard-Telm S., et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998, 177:1247-1259.
-
(1998)
J Infect Dis
, vol.177
, pp. 1247-1259
-
-
Van Rompay, K.K.1
Berardi, C.J.2
Dillard-Telm, S.3
-
410
-
-
0042709478
-
Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120
-
Patterson L.J., Malkevitch N., Pinczewski J., et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol 2003, 77:8607-8620.
-
(2003)
J Virol
, vol.77
, pp. 8607-8620
-
-
Patterson, L.J.1
Malkevitch, N.2
Pinczewski, J.3
-
411
-
-
10744220328
-
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting
-
Patterson L.J., Malkevitch N., Venzon D., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004, 78:2212-2221.
-
(2004)
J Virol
, vol.78
, pp. 2212-2221
-
-
Patterson, L.J.1
Malkevitch, N.2
Venzon, D.3
-
412
-
-
13544277161
-
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251
-
Gomez-Roman V.R., Patterson L.J., Venzon D., et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005, 174:2185-2189.
-
(2005)
J Immunol
, vol.174
, pp. 2185-2189
-
-
Gomez-Roman, V.R.1
Patterson, L.J.2
Venzon, D.3
-
413
-
-
58149526770
-
Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques
-
Hidajat R., Xiao P., Zhou Q., et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009, 83:791-801.
-
(2009)
J Virol
, vol.83
, pp. 791-801
-
-
Hidajat, R.1
Xiao, P.2
Zhou, Q.3
-
414
-
-
77953756732
-
Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques
-
Xiao P., Zhao J., Patterson L.J., et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010, 84:7161-7173.
-
(2010)
J Virol
, vol.84
, pp. 7161-7173
-
-
Xiao, P.1
Zhao, J.2
Patterson, L.J.3
-
415
-
-
42649138896
-
Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques
-
Patterson L.J., Beal J., Demberg T., et al. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Virology 2008, 374:322-337.
-
(2008)
Virology
, vol.374
, pp. 322-337
-
-
Patterson, L.J.1
Beal, J.2
Demberg, T.3
-
416
-
-
0031974863
-
Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities
-
Alsmadi O., Tilley S.A. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities. J Virol 1998, 72:286-293.
-
(1998)
J Virol
, vol.72
, pp. 286-293
-
-
Alsmadi, O.1
Tilley, S.A.2
-
417
-
-
0025238850
-
Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects
-
Tyler D.S., Stanley S.D., Nastala C.A., et al. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990, 144:3375-3384.
-
(1990)
J Immunol
, vol.144
, pp. 3375-3384
-
-
Tyler, D.S.1
Stanley, S.D.2
Nastala, C.A.3
-
418
-
-
33744916994
-
Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells
-
Holl V., Peressin M., Decoville T., et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006, 80:6177-6181.
-
(2006)
J Virol
, vol.80
, pp. 6177-6181
-
-
Holl, V.1
Peressin, M.2
Decoville, T.3
-
419
-
-
77951480441
-
Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity
-
Pietzsch J., Scheid J.F., Mouquet H., et al. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol 2010, 84:5032-5042.
-
(2010)
J Virol
, vol.84
, pp. 5032-5042
-
-
Pietzsch, J.1
Scheid, J.F.2
Mouquet, H.3
-
420
-
-
33144486096
-
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
-
Moore P.L., Crooks E.T., Porter L., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006, 80:2515-2528.
-
(2006)
J Virol
, vol.80
, pp. 2515-2528
-
-
Moore, P.L.1
Crooks, E.T.2
Porter, L.3
-
421
-
-
78649804618
-
Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region
-
Nicely N.I., Dennison S.M., Spicer L., et al. Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nat Struct Mol Biol 2010, 17:1492-1494.
-
(2010)
Nat Struct Mol Biol
, vol.17
, pp. 1492-1494
-
-
Nicely, N.I.1
Dennison, S.M.2
Spicer, L.3
-
422
-
-
34548496893
-
Fc receptor but not complement binding is important in antibody protection against HIV
-
Hessell A.J., Hangartner L., Hunter M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
-
(2007)
Nature
, vol.449
, pp. 101-104
-
-
Hessell, A.J.1
Hangartner, L.2
Hunter, M.3
-
423
-
-
78650656127
-
Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12
-
Forthal D.N., Gach J.S., Landucci G., et al. Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 2010, 185:6876-6882.
-
(2010)
J Immunol
, vol.185
, pp. 6876-6882
-
-
Forthal, D.N.1
Gach, J.S.2
Landucci, G.3
-
424
-
-
33744481004
-
Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation
-
Holl V., Peressin M., Schmidt S., et al. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 2006, 107:4466-4474.
-
(2006)
Blood
, vol.107
, pp. 4466-4474
-
-
Holl, V.1
Peressin, M.2
Schmidt, S.3
-
425
-
-
67650882680
-
Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41
-
Perez L.G., Costa M.R., Todd C.A., et al. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J Virol 2009, 83:7397-7410.
-
(2009)
J Virol
, vol.83
, pp. 7397-7410
-
-
Perez, L.G.1
Costa, M.R.2
Todd, C.A.3
-
426
-
-
79953736960
-
The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI-dependent manner
-
Tudor D., Bomsel M. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI-dependent manner. AIDS 2011, 25:751-759.
-
(2011)
AIDS
, vol.25
, pp. 751-759
-
-
Tudor, D.1
Bomsel, M.2
-
427
-
-
67149120819
-
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers
-
Lambotte O., Ferrari G., Moog C., et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23:897-906.
-
(2009)
AIDS
, vol.23
, pp. 897-906
-
-
Lambotte, O.1
Ferrari, G.2
Moog, C.3
-
428
-
-
0024596133
-
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera
-
Koup R.A., Sullivan J.L., Levine P.H., et al. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol 1989, 63:584-590.
-
(1989)
J Virol
, vol.63
, pp. 584-590
-
-
Koup, R.A.1
Sullivan, J.L.2
Levine, P.H.3
-
429
-
-
0031023496
-
Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier
-
Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997, 3:42-47.
-
(1997)
Nat Med
, vol.3
, pp. 42-47
-
-
Bomsel, M.1
-
430
-
-
18844470061
-
Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM
-
Bomsel M., Heyman M., Hocini H., et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998, 9:277-287.
-
(1998)
Immunity
, vol.9
, pp. 277-287
-
-
Bomsel, M.1
Heyman, M.2
Hocini, H.3
-
431
-
-
0034327707
-
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells
-
Devito C., Broliden K., Kaul R., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000, 165:5170-5176.
-
(2000)
J Immunol
, vol.165
, pp. 5170-5176
-
-
Devito, C.1
Broliden, K.2
Kaul, R.3
-
432
-
-
0035500882
-
Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers
-
Broliden K., Hinkula J., Devito C., et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001, 79:29-36.
-
(2001)
Immunol Lett
, vol.79
, pp. 29-36
-
-
Broliden, K.1
Hinkula, J.2
Devito, C.3
-
433
-
-
44649098153
-
Not just sheer luck! immune correlates of protection against HIV-1 infection
-
Piacentini L., Fenizia C., Naddeo V., et al. Not just sheer luck! immune correlates of protection against HIV-1 infection. Vaccine 2008, 26:3002-3007.
-
(2008)
Vaccine
, vol.26
, pp. 3002-3007
-
-
Piacentini, L.1
Fenizia, C.2
Naddeo, V.3
-
434
-
-
72049111744
-
Genital and oral mucosal immune response against HIV-1 in exposed uninfected individuals
-
Hasselrot K. Genital and oral mucosal immune response against HIV-1 in exposed uninfected individuals. Crit Rev Immunol 2009, 29:369-377.
-
(2009)
Crit Rev Immunol
, vol.29
, pp. 369-377
-
-
Hasselrot, K.1
-
435
-
-
33745906244
-
HIV-specific antibodies but not T-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia
-
Nguyen M., Pean P., Lopalco L., et al. HIV-specific antibodies but not T-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J Acquir Immune Defic Syndr 2006, 42:412-419.
-
(2006)
J Acquir Immune Defic Syndr
, vol.42
, pp. 412-419
-
-
Nguyen, M.1
Pean, P.2
Lopalco, L.3
-
436
-
-
33646465596
-
Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals
-
Shacklett B.L. Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals. Curr HIV/AIDS Rep 2006, 3:26-31.
-
(2006)
Curr HIV/AIDS Rep
, vol.3
, pp. 26-31
-
-
Shacklett, B.L.1
-
437
-
-
58949097921
-
The "immunologic advantage" of HIV-exposed seronegative individuals
-
Miyazawa M., Lopalco L., Mazzotta F., et al. The "immunologic advantage" of HIV-exposed seronegative individuals. AIDS 2009, 23:161-175.
-
(2009)
AIDS
, vol.23
, pp. 161-175
-
-
Miyazawa, M.1
Lopalco, L.2
Mazzotta, F.3
-
438
-
-
0034622980
-
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate
-
Devito C., Hinkula J., Kaul R., et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000, 14:1917-1920.
-
(2000)
AIDS
, vol.14
, pp. 1917-1920
-
-
Devito, C.1
Hinkula, J.2
Kaul, R.3
-
439
-
-
13644254926
-
Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin
-
Lopalco L., Barassi C., Paolucci C., et al. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J Gen Virol 2005, 86(pt 2):339-348.
-
(2005)
J Gen Virol
, vol.86
, Issue.PART 2
, pp. 339-348
-
-
Lopalco, L.1
Barassi, C.2
Paolucci, C.3
-
440
-
-
41349105330
-
HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers
-
Hirbod T., Kaul R., Reichard C., et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008, 22:727-735.
-
(2008)
AIDS
, vol.22
, pp. 727-735
-
-
Hirbod, T.1
Kaul, R.2
Reichard, C.3
-
441
-
-
60549116730
-
Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV
-
Horton R.E., Ball T.B., Wachichi C., et al. Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res Hum Retroviruses 2009, 25:83-92.
-
(2009)
AIDS Res Hum Retroviruses
, vol.25
, pp. 83-92
-
-
Horton, R.E.1
Ball, T.B.2
Wachichi, C.3
-
442
-
-
0037067741
-
HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide
-
Alfsen A., Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem 2002, 277:25649-25659.
-
(2002)
J Biol Chem
, vol.277
, pp. 25649-25659
-
-
Alfsen, A.1
Bomsel, M.2
-
443
-
-
0035873475
-
Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1
-
Alfsen A., Iniguez P., Bouguyon E., et al. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001, 166:6257-6265.
-
(2001)
J Immunol
, vol.166
, pp. 6257-6265
-
-
Alfsen, A.1
Iniguez, P.2
Bouguyon, E.3
-
444
-
-
69249086612
-
HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis
-
Tudor D., Derrien M., Diomede L., et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009, 2:412-426.
-
(2009)
Mucosal Immunol
, vol.2
, pp. 412-426
-
-
Tudor, D.1
Derrien, M.2
Diomede, L.3
-
445
-
-
73649143882
-
Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load
-
Hasselrot K., Bratt G., Hirbod T., et al. Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load. AIDS 2010, 24:35-43.
-
(2010)
AIDS
, vol.24
, pp. 35-43
-
-
Hasselrot, K.1
Bratt, G.2
Hirbod, T.3
-
446
-
-
59849117394
-
Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men
-
Hasselrot K., Saberg P., Hirbod T., et al. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 2009, 23:329-333.
-
(2009)
AIDS
, vol.23
, pp. 329-333
-
-
Hasselrot, K.1
Saberg, P.2
Hirbod, T.3
-
447
-
-
77649236000
-
Innate immunity and chronic immune activation in HCV/HIV-1 co-infection
-
Gonzalez V.D., Landay A.L., Sandberg J.K. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 2010, 135:12-25.
-
(2010)
Clin Immunol
, vol.135
, pp. 12-25
-
-
Gonzalez, V.D.1
Landay, A.L.2
Sandberg, J.K.3
-
448
-
-
77957582392
-
Innate immune activation in primary HIV-1 infection
-
Chang J.J., Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis 2010, 202(suppl. 2):S297-S301.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 2
-
-
Chang, J.J.1
Altfeld, M.2
-
449
-
-
72849136282
-
Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response
-
Jacquelin B., Mayau V., Targat B., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009, 119:3544-3555.
-
(2009)
J Clin Invest
, vol.119
, pp. 3544-3555
-
-
Jacquelin, B.1
Mayau, V.2
Targat, B.3
-
450
-
-
72849132344
-
Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys
-
Bosinger S.E., Li Q., Gordon S.N., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009, 119:3556-3572.
-
(2009)
J Clin Invest
, vol.119
, pp. 3556-3572
-
-
Bosinger, S.E.1
Li, Q.2
Gordon, S.N.3
-
451
-
-
34547130280
-
MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands
-
Meier A., Alter G., Frahm N., et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 2007, 81:8180-8191.
-
(2007)
J Virol
, vol.81
, pp. 8180-8191
-
-
Meier, A.1
Alter, G.2
Frahm, N.3
-
452
-
-
53549103852
-
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections
-
Mandl J.N., Barry A.P., Vanderford T.H., et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008, 14:1077-1087.
-
(2008)
Nat Med
, vol.14
, pp. 1077-1087
-
-
Mandl, J.N.1
Barry, A.P.2
Vanderford, T.H.3
-
453
-
-
64049116643
-
Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections
-
Stacey A.R., Norris P.J., Qin L., et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009, 83:3719-3733.
-
(2009)
J Virol
, vol.83
, pp. 3719-3733
-
-
Stacey, A.R.1
Norris, P.J.2
Qin, L.3
-
454
-
-
33748757742
-
Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection
-
Norris P.J., Pappalardo B.L., Custer B., et al. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006, 22:757-762.
-
(2006)
AIDS Res Hum Retroviruses
, vol.22
, pp. 757-762
-
-
Norris, P.J.1
Pappalardo, B.L.2
Custer, B.3
-
455
-
-
43949088825
-
Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome
-
Diop O.M., Ploquin M.J., Mortara L., et al. Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol 2008, 82:5145-5152.
-
(2008)
J Virol
, vol.82
, pp. 5145-5152
-
-
Diop, O.M.1
Ploquin, M.J.2
Mortara, L.3
-
456
-
-
58149380860
-
Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression
-
Malleret B., Maneglier B., Karlsson I., et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 2008, 112:4598-4608.
-
(2008)
Blood
, vol.112
, pp. 4598-4608
-
-
Malleret, B.1
Maneglier, B.2
Karlsson, I.3
-
457
-
-
78650065600
-
Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection
-
Singh R., Gaiha G., Werner L., et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol 2011, 85:208-216.
-
(2011)
J Virol
, vol.85
, pp. 208-216
-
-
Singh, R.1
Gaiha, G.2
Werner, L.3
-
458
-
-
62849103646
-
Human TRIM gene expression in response to interferons
-
Carthagena L., Bergamaschi A., Luna J.M., et al. Human TRIM gene expression in response to interferons. PLoS One 2009, 4:e4894.
-
(2009)
PLoS One
, vol.4
-
-
Carthagena, L.1
Bergamaschi, A.2
Luna, J.M.3
-
459
-
-
23844483865
-
APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia
-
Jin X., Brooks A., Chen H., et al. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005, 79:11513-11516.
-
(2005)
J Virol
, vol.79
, pp. 11513-11516
-
-
Jin, X.1
Brooks, A.2
Chen, H.3
-
460
-
-
33947654818
-
APOBEC3G levels predict rates of progression to AIDS
-
Jin X., Wu H., Smith H. APOBEC3G levels predict rates of progression to AIDS. Retrovirology 2007, 4:20.
-
(2007)
Retrovirology
, vol.4
, pp. 20
-
-
Jin, X.1
Wu, H.2
Smith, H.3
-
461
-
-
33845906383
-
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection
-
Pion M., Granelli-Piperno A., Mangeat B., et al. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med 2006, 203:2887-2893.
-
(2006)
J Exp Med
, vol.203
, pp. 2887-2893
-
-
Pion, M.1
Granelli-Piperno, A.2
Mangeat, B.3
-
462
-
-
70349310335
-
APOBEC3B deletion and risk of HIV-1 acquisition
-
An P., Johnson R., Phair J., et al. APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis 2009, 200:1054-1058.
-
(2009)
J Infect Dis
, vol.200
, pp. 1054-1058
-
-
An, P.1
Johnson, R.2
Phair, J.3
-
463
-
-
34248140162
-
Evolution of innate and adaptive effector cell functions during acute HIV-1 infection
-
Alter G., Teigen N., Ahern R., et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007, 195:1452-1460.
-
(2007)
J Infect Dis
, vol.195
, pp. 1452-1460
-
-
Alter, G.1
Teigen, N.2
Ahern, R.3
-
464
-
-
67449101826
-
HLA class I subtype-dependent expansion of KIR3DS1 + and KIR3DL1 + NK cells during acute human immunodeficiency virus type 1 infection
-
Alter G., Rihn S., Walter K., et al. HLA class I subtype-dependent expansion of KIR3DS1 + and KIR3DL1 + NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009, 83:6798-6805.
-
(2009)
J Virol
, vol.83
, pp. 6798-6805
-
-
Alter, G.1
Rihn, S.2
Walter, K.3
-
465
-
-
0031019163
-
Activation and function of natural killer cell responses during viral infections
-
Biron C.A. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 1997, 9:24-34.
-
(1997)
Curr Opin Immunol
, vol.9
, pp. 24-34
-
-
Biron, C.A.1
-
466
-
-
34249802335
-
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1
-
Martin M.P., Qi Y., Gao X., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007, 39:733-740.
-
(2007)
Nat Genet
, vol.39
, pp. 733-740
-
-
Martin, M.P.1
Qi, Y.2
Gao, X.3
-
468
-
-
78049445214
-
Natural resistance to HIV infection: lessons learned from HIV-exposed uninfected individuals
-
Pancino G., Saez-Cirion A., Scott-Algara D., et al. Natural resistance to HIV infection: lessons learned from HIV-exposed uninfected individuals. J Infect Dis 2010, 202(suppl. 3):S345-S350.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 3
-
-
Pancino, G.1
Saez-Cirion, A.2
Scott-Algara, D.3
-
469
-
-
67651148089
-
HIV-1-specific T Cell-dependent natural killer (NK) cell activation: major contribution by NK cells to interferon-gamma production in response to HIV-1 antigens
-
Loo C.P., Long B.R., Hecht F.M., et al. HIV-1-specific T Cell-dependent natural killer (NK) cell activation: major contribution by NK cells to interferon-gamma production in response to HIV-1 antigens. AIDS Res Hum Retroviruses 2009, 25:603-605.
-
(2009)
AIDS Res Hum Retroviruses
, vol.25
, pp. 603-605
-
-
Loo, C.P.1
Long, B.R.2
Hecht, F.M.3
-
470
-
-
36549019907
-
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes
-
Alter G., Martin M.P., Teigen N., et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007, 204:3027-3036.
-
(2007)
J Exp Med
, vol.204
, pp. 3027-3036
-
-
Alter, G.1
Martin, M.P.2
Teigen, N.3
-
471
-
-
34248368553
-
Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals
-
Ravet S., Scott-Algara D., Bonnet E., et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007, 109:4296-4305.
-
(2007)
Blood
, vol.109
, pp. 4296-4305
-
-
Ravet, S.1
Scott-Algara, D.2
Bonnet, E.3
-
472
-
-
33746039265
-
Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals
-
Montoya C.J., Velilla P.A., Chougnet C., et al. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006, 120:138-146.
-
(2006)
Clin Immunol
, vol.120
, pp. 138-146
-
-
Montoya, C.J.1
Velilla, P.A.2
Chougnet, C.3
-
473
-
-
55049083095
-
Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection
-
Pereira L.E., Johnson R.P., Ansari A.A. Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. Cell Immunol 2008, 254:10-19.
-
(2008)
Cell Immunol
, vol.254
, pp. 10-19
-
-
Pereira, L.E.1
Johnson, R.P.2
Ansari, A.A.3
-
474
-
-
78649747999
-
Innate immunity in HIV infection and implications for vaccine design: a summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25-26, 2010
-
Bansal G.P., Leitner W.W. Innate immunity in HIV infection and implications for vaccine design: a summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25-26, 2010. Vaccine 2010, 28:8229-8235.
-
(2010)
Vaccine
, vol.28
, pp. 8229-8235
-
-
Bansal, G.P.1
Leitner, W.W.2
-
475
-
-
78650970845
-
Innate or adaptive immunity? the example of natural killer cells
-
Vivier E., Raulet D.H., Moretta A., et al. Innate or adaptive immunity? the example of natural killer cells. Science 2011, 331:44-49.
-
(2011)
Science
, vol.331
, pp. 44-49
-
-
Vivier, E.1
Raulet, D.H.2
Moretta, A.3
-
476
-
-
77649282342
-
Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination
-
Scott-Algara D., Mancini-Bourgine M., Fontaine H., et al. Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS One 2010, 5:e8761.
-
(2010)
PLoS One
, vol.5
-
-
Scott-Algara, D.1
Mancini-Bourgine, M.2
Fontaine, H.3
-
477
-
-
33748501031
-
The French Asymptomatiques à Long Terme (ALT) study group. Specific adaptive humoral response against a gp41 motif inhibits CD4 T cell sensitivity to NK lysis during HIV-1 infection
-
Sep 11
-
Vieillard V., Costagliola D., Simon A. The French Asymptomatiques à Long Terme (ALT) study group. Specific adaptive humoral response against a gp41 motif inhibits CD4 T cell sensitivity to NK lysis during HIV-1 infection. AIDS 2006; Sep 11, 20(14):1795-1804.
-
(2006)
AIDS
, vol.20
, Issue.14
, pp. 1795-1804
-
-
Vieillard, V.1
Costagliola, D.2
Simon, A.3
-
478
-
-
77957658572
-
HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the P1P3/H2O2 pathway
-
Jul 1;6:e1000975.
-
Fausther-Bovendo H., Vieillard V., Sagan S. HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the P1P3/H2O2 pathway. PLoS Pathog 2010, Jul 1;6:e1000975.
-
(2010)
PLoS Pathog
-
-
Fausther-Bovendo, H.1
Vieillard, V.2
Sagan, S.3
-
479
-
-
33846809447
-
Primitive hematopoietic cells resist HIV-1 infection via p21
-
Zhang J., Scadden D.T., Crumpacker C.S. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007, 117:473-481.
-
(2007)
J Clin Invest
, vol.117
, pp. 473-481
-
-
Zhang, J.1
Scadden, D.T.2
Crumpacker, C.S.3
-
480
-
-
70450193060
-
The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages
-
Bergamaschi A., David A., Le Rouzic E., et al. The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. J Virol 2009, 83:12253-12265.
-
(2009)
J Virol
, vol.83
, pp. 12253-12265
-
-
Bergamaschi, A.1
David, A.2
Le Rouzic, E.3
-
481
-
-
77950422606
-
Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells
-
Makedonas G., Hutnick N., Haney D., et al. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog 2010, 6:e1000798.
-
(2010)
PLoS Pathog
, vol.6
-
-
Makedonas, G.1
Hutnick, N.2
Haney, D.3
-
482
-
-
78650655851
-
Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy
-
Palermo R.E., Patterson L.J., Aicher L.D., et al. Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy. J Virol 2010, 85:1099-1116.
-
(2010)
J Virol
, vol.85
, pp. 1099-1116
-
-
Palermo, R.E.1
Patterson, L.J.2
Aicher, L.D.3
-
483
-
-
77954758455
-
A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort
-
Price H., Lacap P., Tuff J., et al. A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort. AIDS 2010, 24:1813-1821.
-
(2010)
AIDS
, vol.24
, pp. 1813-1821
-
-
Price, H.1
Lacap, P.2
Tuff, J.3
-
484
-
-
79953305839
-
CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21
-
Chen H., Li C., Huang J., et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011, 121:1549-1560.
-
(2011)
J Clin Invest
, vol.121
, pp. 1549-1560
-
-
Chen, H.1
Li, C.2
Huang, J.3
-
485
-
-
78650542340
-
Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)
-
Mallery D.L., McEwan W.A., Bidgood S.R., et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A 2010, 107:19985-19990.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 19985-19990
-
-
Mallery, D.L.1
McEwan, W.A.2
Bidgood, S.R.3
-
486
-
-
77949384495
-
Immunology and the elusive AIDS vaccine
-
Virgin H.W., Walker B.D. Immunology and the elusive AIDS vaccine. Nature 2010, 464:224-231.
-
(2010)
Nature
, vol.464
, pp. 224-231
-
-
Virgin, H.W.1
Walker, B.D.2
-
487
-
-
32944477067
-
The rational design of an AIDS vaccine
-
Douek D.C., Kwong P.D., Nabel G.J. The rational design of an AIDS vaccine. Cell 2006, 124:677-681.
-
(2006)
Cell
, vol.124
, pp. 677-681
-
-
Douek, D.C.1
Kwong, P.D.2
Nabel, G.J.3
-
489
-
-
33845207660
-
Progress and obstacles in the development of an AIDS vaccine
-
Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006, 6:930-939.
-
(2006)
Nat Rev Immunol
, vol.6
, pp. 930-939
-
-
Letvin, N.L.1
-
490
-
-
34249068954
-
An HIV vaccine--evolving concepts
-
Johnston M.I., Fauci A.S. An HIV vaccine--evolving concepts. N Engl J Med 2007, 356:2073-2081.
-
(2007)
N Engl J Med
, vol.356
, pp. 2073-2081
-
-
Johnston, M.I.1
Fauci, A.S.2
-
491
-
-
13944250922
-
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
-
Gilbert P.B., Peterson M.L., Follmann D., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005, 191:666-677.
-
(2005)
J Infect Dis
, vol.191
, pp. 666-677
-
-
Gilbert, P.B.1
Peterson, M.L.2
Follmann, D.3
-
492
-
-
13944254982
-
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
-
Flynn N.M., Forthal D.N., Harro C.D., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
-
(2005)
J Infect Dis
, vol.191
, pp. 654-665
-
-
Flynn, N.M.1
Forthal, D.N.2
Harro, C.D.3
-
493
-
-
33845433434
-
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
-
Pitisuttithum P., Gilbert P., Gurwith M., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
-
(2006)
J Infect Dis
, vol.194
, pp. 1661-1671
-
-
Pitisuttithum, P.1
Gilbert, P.2
Gurwith, M.3
-
494
-
-
56649114351
-
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
-
McElrath M.J., De Rosa S.C., Moodie Z., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
-
(2008)
Lancet
, vol.372
, pp. 1894-1905
-
-
McElrath, M.J.1
De Rosa, S.C.2
Moodie, Z.3
-
495
-
-
56649105122
-
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
-
Buchbinder S.P., Mehrotra D.V., Duerr A., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
-
(2008)
Lancet
, vol.372
, pp. 1881-1893
-
-
Buchbinder, S.P.1
Mehrotra, D.V.2
Duerr, A.3
-
496
-
-
77953543379
-
Rational antibody-based HIV-1 vaccine design: current approaches and future directions
-
Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22:358-366.
-
(2010)
Curr Opin Immunol
, vol.22
, pp. 358-366
-
-
Walker, L.M.1
Burton, D.R.2
-
498
-
-
77957226429
-
Antiviral immune responses in the genital tract: clues for vaccines
-
Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol 2010, 10:699-711.
-
(2010)
Nat Rev Immunol
, vol.10
, pp. 699-711
-
-
Iwasaki, A.1
-
499
-
-
77955513465
-
The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise
-
Voronin Y., Manrique A., Bernstein A. The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise. Curr Opin HIV AIDS 2010, 5:414-420.
-
(2010)
Curr Opin HIV AIDS
, vol.5
, pp. 414-420
-
-
Voronin, Y.1
Manrique, A.2
Bernstein, A.3
-
500
-
-
77956450707
-
The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise
-
Council of the Global HIV Vaccine Enterprise
-
Berkley S., Bertram K., Delfraissy J-F. The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nat Med 2010, 16:981-989. Council of the Global HIV Vaccine Enterprise.
-
(2010)
Nat Med
, vol.16
, pp. 981-989
-
-
Berkley, S.1
Bertram, K.2
Delfraissy, J.-F.3
-
501
-
-
0030175426
-
Immune strategies utilized by lentivirus infected chimpanzees to resist progression to AIDS
-
Heeney J., Bogers W., Buijs L., et al. Immune strategies utilized by lentivirus infected chimpanzees to resist progression to AIDS. Immunol Lett 1996, 51:45-52.
-
(1996)
Immunol Lett
, vol.51
, pp. 45-52
-
-
Heeney, J.1
Bogers, W.2
Buijs, L.3
-
502
-
-
0030801253
-
Human immunodeficiency virus type 1 intersubtype (B/E) recombination in a superinfected chimpanzee
-
Fultz P.N., Yue L., Wei Q., et al. Human immunodeficiency virus type 1 intersubtype (B/E) recombination in a superinfected chimpanzee. J Virol 1997, 71:7990-7995.
-
(1997)
J Virol
, vol.71
, pp. 7990-7995
-
-
Fultz, P.N.1
Yue, L.2
Wei, Q.3
-
503
-
-
0025907920
-
Human immunodeficiency virus infection of human-PBL-SCID mice
-
Mosier D.E., Gulizia R.J., Baird S.M., et al. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 1991, 251:791-794.
-
(1991)
Science
, vol.251
, pp. 791-794
-
-
Mosier, D.E.1
Gulizia, R.J.2
Baird, S.M.3
-
504
-
-
57349129555
-
RAG2-/- gamma(c)-/- mice transplanted with CD34 + cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus
-
Hofer U., Baenziger S., Heikenwalder M., et al. RAG2-/- gamma(c)-/- mice transplanted with CD34 + cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus. J Virol 2008, 82:12145-12153.
-
(2008)
J Virol
, vol.82
, pp. 12145-12153
-
-
Hofer, U.1
Baenziger, S.2
Heikenwalder, M.3
-
505
-
-
67749106469
-
Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse
-
Choudhary S.K., Rezk N.L., Ince W.L., et al. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse. J Virol 2009, 83:8254-8258.
-
(2009)
J Virol
, vol.83
, pp. 8254-8258
-
-
Choudhary, S.K.1
Rezk, N.L.2
Ince, W.L.3
-
506
-
-
77649099626
-
Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model
-
Ince W.L., Zhang L., Jiang Q., et al. Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model. J Virol 2010, 84:2740-2752.
-
(2010)
J Virol
, vol.84
, pp. 2740-2752
-
-
Ince, W.L.1
Zhang, L.2
Jiang, Q.3
-
507
-
-
2542490305
-
Primate models for AIDS vaccine development
-
Heeney J.L. Primate models for AIDS vaccine development. AIDS 1996, 10(suppl. A):S115-S122.
-
(1996)
AIDS
, vol.10
, Issue.SUPPL.. A
-
-
Heeney, J.L.1
-
508
-
-
0037137568
-
Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model
-
Franchini G., Nacsa J., Hel Z., et al. Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. Vaccine 2002, 20(suppl. 4):A52-A60.
-
(2002)
Vaccine
, vol.20
, Issue.SUPPL.. 4
-
-
Franchini, G.1
Nacsa, J.2
Hel, Z.3
-
509
-
-
25844482131
-
Perils at mucosal front lines for HIV and SIV and their hosts
-
Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005, 5:783-792.
-
(2005)
Nat Rev Immunol
, vol.5
, pp. 783-792
-
-
Haase, A.T.1
-
510
-
-
50949114906
-
The use of nonhuman primate models in HIV vaccine development
-
Morgan C., Marthas M., Miller C., et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008, 5:e173.
-
(2008)
PLoS Med
, vol.5
-
-
Morgan, C.1
Marthas, M.2
Miller, C.3
-
511
-
-
66049157864
-
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1
-
Keele B.F., Li H., Learn G.H., et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009, 206:1117-1134.
-
(2009)
J Exp Med
, vol.206
, pp. 1117-1134
-
-
Keele, B.F.1
Li, H.2
Learn, G.H.3
-
512
-
-
0032540418
-
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection
-
Veazey R.S., DeMaria M., Chalifoux L.V., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
-
(1998)
Science
, vol.280
, pp. 427-431
-
-
Veazey, R.S.1
DeMaria, M.2
Chalifoux, L.V.3
-
513
-
-
4644342929
-
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract
-
Brenchley J.M., Schacker T.W., Ruff L.E., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749-759.
-
(2004)
J Exp Med
, vol.200
, pp. 749-759
-
-
Brenchley, J.M.1
Schacker, T.W.2
Ruff, L.E.3
-
514
-
-
4644289983
-
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract
-
Mehandru S., Poles M.A., Tenner-Racz K., et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004, 200:761-770.
-
(2004)
J Exp Med
, vol.200
, pp. 761-770
-
-
Mehandru, S.1
Poles, M.A.2
Tenner-Racz, K.3
-
515
-
-
17844374605
-
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection
-
Mattapallil J.J., Douek D.C., Hill B., et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1097.
-
(2005)
Nature
, vol.434
, pp. 1093-1097
-
-
Mattapallil, J.J.1
Douek, D.C.2
Hill, B.3
-
516
-
-
17844376742
-
Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells
-
Li Q., Duan L., Estes J.D., et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148-1152.
-
(2005)
Nature
, vol.434
, pp. 1148-1152
-
-
Li, Q.1
Duan, L.2
Estes, J.D.3
-
517
-
-
18844375363
-
HIV swiftly guts the immune system
-
Veazey R.S., Lackner A.A. HIV swiftly guts the immune system. Nat Med 2005, 11:469-470.
-
(2005)
Nat Med
, vol.11
, pp. 469-470
-
-
Veazey, R.S.1
Lackner, A.A.2
-
518
-
-
0034756397
-
Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics
-
Parker R.A., Regan M.M., Reimann K.A. Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics. J Virol 2001, 75:11234-11238.
-
(2001)
J Virol
, vol.75
, pp. 11234-11238
-
-
Parker, R.A.1
Regan, M.M.2
Reimann, K.A.3
-
519
-
-
34548689151
-
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy
-
Deeks S.G., Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406-416.
-
(2007)
Immunity
, vol.27
, pp. 406-416
-
-
Deeks, S.G.1
Walker, B.D.2
-
520
-
-
34547737913
-
Mamu-B*08-positive macaques control simian immunodeficiency virus replication
-
Loffredo J.T., Maxwell J., Qi Y., et al. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 2007, 81:8827-8832.
-
(2007)
J Virol
, vol.81
, pp. 8827-8832
-
-
Loffredo, J.T.1
Maxwell, J.2
Qi, Y.3
-
521
-
-
21244495175
-
Rhesus macaque MHC class I molecules present HLA-B-like peptides
-
Hickman-Miller H.D., Bardet W., Gilb A., et al. Rhesus macaque MHC class I molecules present HLA-B-like peptides. J Immunol 2005, 175:367-375.
-
(2005)
J Immunol
, vol.175
, pp. 367-375
-
-
Hickman-Miller, H.D.1
Bardet, W.2
Gilb, A.3
-
522
-
-
12144287434
-
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection
-
Altfeld M., Addo M.M., Rosenberg E.S., et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003, 17:2581-2591.
-
(2003)
AIDS
, vol.17
, pp. 2581-2591
-
-
Altfeld, M.1
Addo, M.M.2
Rosenberg, E.S.3
-
524
-
-
10644267588
-
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA
-
Kiepiela P., Leslie A.J., Honeyborne I., et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004, 432:769-775.
-
(2004)
Nature
, vol.432
, pp. 769-775
-
-
Kiepiela, P.1
Leslie, A.J.2
Honeyborne, I.3
-
525
-
-
23244463622
-
HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load
-
Frahm N., Adams S., Kiepiela P., et al. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol 2005, 79:10218-10225.
-
(2005)
J Virol
, vol.79
, pp. 10218-10225
-
-
Frahm, N.1
Adams, S.2
Kiepiela, P.3
-
526
-
-
40949093660
-
A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef
-
Navis M., Schellens I.M., van Swieten P., et al. A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef. J Infect Dis 2008, 197:871-879.
-
(2008)
J Infect Dis
, vol.197
, pp. 871-879
-
-
Navis, M.1
Schellens, I.M.2
van Swieten, P.3
-
527
-
-
77956827161
-
Additive contribution of HLA class I alleles in the immune control of HIV-1 infection
-
Leslie A., Matthews P.C., Listgarten J., et al. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol 2010, 84:9879-9888.
-
(2010)
J Virol
, vol.84
, pp. 9879-9888
-
-
Leslie, A.1
Matthews, P.C.2
Listgarten, J.3
-
528
-
-
77950229250
-
Host determinants of HIV-1 control in African Americans
-
Pelak K., Goldstein D.B., Walley N.M., et al. Host determinants of HIV-1 control in African Americans. J Infect Dis 2010, 201:1141-1149.
-
(2010)
J Infect Dis
, vol.201
, pp. 1141-1149
-
-
Pelak, K.1
Goldstein, D.B.2
Walley, N.M.3
-
529
-
-
3042626395
-
The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines
-
Staprans S.I., Feinberg M.B. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines 2004, 3(suppl. 4):S5-32.
-
(2004)
Expert Rev Vaccines
, vol.3
, Issue.SUPPL.. 4
-
-
Staprans, S.I.1
Feinberg, M.B.2
-
530
-
-
0028826088
-
Persistent infection of macaques with simian-human immunodeficiency viruses
-
Li J.T., Halloran M., Lord C.I., et al. Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol 1995, 69:7061-7067.
-
(1995)
J Virol
, vol.69
, pp. 7061-7067
-
-
Li, J.T.1
Halloran, M.2
Lord, C.I.3
-
531
-
-
9244224075
-
An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
-
Reimann K.A., Li J.T., Voss G., et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996, 70:3198-3206.
-
(1996)
J Virol
, vol.70
, pp. 3198-3206
-
-
Reimann, K.A.1
Li, J.T.2
Voss, G.3
-
532
-
-
0029794529
-
A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
-
Reimann K.A., Li J.T., Veazey R., et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996, 70:6922-6928.
-
(1996)
J Virol
, vol.70
, pp. 6922-6928
-
-
Reimann, K.A.1
Li, J.T.2
Veazey, R.3
-
533
-
-
0030944595
-
Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS
-
Joag S.V., Adany I., Li Z., et al. Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS. J Virol 1997, 71:4016-4023.
-
(1997)
J Virol
, vol.71
, pp. 4016-4023
-
-
Joag, S.V.1
Adany, I.2
Li, Z.3
-
534
-
-
0037227768
-
Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120
-
Hsu M., Harouse J.M., Gettie A., et al. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J Virol 2003, 77:989-998.
-
(2003)
J Virol
, vol.77
, pp. 989-998
-
-
Hsu, M.1
Harouse, J.M.2
Gettie, A.3
-
535
-
-
77950196210
-
Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes
-
Chenine A.L., Siddappa N.B., Kramer V.G., et al. Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis 2010, 201:1155-1163.
-
(2010)
J Infect Dis
, vol.201
, pp. 1155-1163
-
-
Chenine, A.L.1
Siddappa, N.B.2
Kramer, V.G.3
-
536
-
-
33745937684
-
Differential mucosal susceptibility in HIV-1 transmission and infection
-
Moutsopoulos N.M., Greenwell-Wild T., Wahl S.M. Differential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res 2006, 19:52-56.
-
(2006)
Adv Dent Res
, vol.19
, pp. 52-56
-
-
Moutsopoulos, N.M.1
Greenwell-Wild, T.2
Wahl, S.M.3
-
537
-
-
57349175481
-
Systematic review of orogenital HIV-1 transmission probabilities
-
Baggaley R.F., White R.G., Boily M.C. Systematic review of orogenital HIV-1 transmission probabilities. Int J Epidemiol 2008, 37:1255-1265.
-
(2008)
Int J Epidemiol
, vol.37
, pp. 1255-1265
-
-
Baggaley, R.F.1
White, R.G.2
Boily, M.C.3
-
538
-
-
44349159423
-
Setting the stage: host invasion by HIV
-
Hladik F., McElrath M.J. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008, 8:447-457.
-
(2008)
Nat Rev Immunol
, vol.8
, pp. 447-457
-
-
Hladik, F.1
McElrath, M.J.2
-
539
-
-
61449159825
-
HIV infection of the genital mucosa in women
-
Hladik F., Hope T.J. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009, 6:20-28.
-
(2009)
Curr HIV/AIDS Rep
, vol.6
, pp. 20-28
-
-
Hladik, F.1
Hope, T.J.2
-
540
-
-
70349470783
-
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials
-
Shedlock D.J., Silvestri G., Weiner D.B. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol 2009, 9:717-728.
-
(2009)
Nat Rev Immunol
, vol.9
, pp. 717-728
-
-
Shedlock, D.J.1
Silvestri, G.2
Weiner, D.B.3
-
541
-
-
0035970644
-
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model
-
Chakraborty H., Sen P.K., Helms R.W., et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001, 15:621-627.
-
(2001)
AIDS
, vol.15
, pp. 621-627
-
-
Chakraborty, H.1
Sen, P.K.2
Helms, R.W.3
-
542
-
-
0035857959
-
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai
-
Gray R.H., Wawer M.J., Brookmeyer R., et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai. Uganda. Lancet 2001, 357:1149-1153.
-
(2001)
Uganda. Lancet
, vol.357
, pp. 1149-1153
-
-
Gray, R.H.1
Wawer, M.J.2
Brookmeyer, R.3
-
543
-
-
1542287436
-
Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates
-
McDermott A.B., Mitchen J., Piaskowski S., et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol 2004, 78:3140-3144.
-
(2004)
J Virol
, vol.78
, pp. 3140-3144
-
-
McDermott, A.B.1
Mitchen, J.2
Piaskowski, S.3
-
544
-
-
3543148237
-
Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
-
Joag S.V., Liu Z.Q., Stephens E.B., et al. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J Virol 1998, 72:9069-9078.
-
(1998)
J Virol
, vol.72
, pp. 9069-9078
-
-
Joag, S.V.1
Liu, Z.Q.2
Stephens, E.B.3
-
545
-
-
0029951823
-
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus
-
Wyand M.S., Manson K.H., Garcia-Moll M., et al. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996, 70:3724-3733.
-
(1996)
J Virol
, vol.70
, pp. 3724-3733
-
-
Wyand, M.S.1
Manson, K.H.2
Garcia-Moll, M.3
-
546
-
-
0030806029
-
Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus
-
Johnson R.P., Glickman R.L., Yang J.Q., et al. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 1997, 71:7711-7718.
-
(1997)
J Virol
, vol.71
, pp. 7711-7718
-
-
Johnson, R.P.1
Glickman, R.L.2
Yang, J.Q.3
-
547
-
-
0033598706
-
Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production
-
Gauduin M.C., Glickman R.L., Ahmad S., et al. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production. Proc Natl Acad Sci U S A 1999, 96:14031-14036.
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, pp. 14031-14036
-
-
Gauduin, M.C.1
Glickman, R.L.2
Ahmad, S.3
-
548
-
-
1842415425
-
Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission
-
Putkonen P., Makitalo B., Bottiger D., et al. Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission. J Virol 1997, 71:4981-4984.
-
(1997)
J Virol
, vol.71
, pp. 4981-4984
-
-
Putkonen, P.1
Makitalo, B.2
Bottiger, D.3
-
549
-
-
0032905068
-
Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
-
Baba T.W., Liska V., Khimani A.H., et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999, 5:194-203.
-
(1999)
Nat Med
, vol.5
, pp. 194-203
-
-
Baba, T.W.1
Liska, V.2
Khimani, A.H.3
-
550
-
-
0029031494
-
Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence
-
Whatmore A.M., Cook N., Hall G.A., et al. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 1995, 69:5117-5123.
-
(1995)
J Virol
, vol.69
, pp. 5117-5123
-
-
Whatmore, A.M.1
Cook, N.2
Hall, G.A.3
-
551
-
-
0031023570
-
Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques
-
Giavedoni L., Ahmad S., Jones L., et al. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J Virol 1997, 71:866-872.
-
(1997)
J Virol
, vol.71
, pp. 866-872
-
-
Giavedoni, L.1
Ahmad, S.2
Jones, L.3
-
552
-
-
0029824662
-
A candidate live inactivatable attenuated vaccine for AIDS
-
Chakrabarti B.K., Maitra R.K., Ma X.Z., et al. A candidate live inactivatable attenuated vaccine for AIDS. Proc Natl Acad Sci U S A 1996, 93:9810-9815.
-
(1996)
Proc Natl Acad Sci U S A
, vol.93
, pp. 9810-9815
-
-
Chakrabarti, B.K.1
Maitra, R.K.2
Ma, X.Z.3
-
553
-
-
0028804160
-
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
-
Deacon N.J., Tsykin A., Solomon A., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
-
(1995)
Science
, vol.270
, pp. 988-991
-
-
Deacon, N.J.1
Tsykin, A.2
Solomon, A.3
-
554
-
-
0029846223
-
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection
-
Mariani R., Kirchhoff F., Greenough T.C., et al. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol 1996, 70:7752-7764.
-
(1996)
J Virol
, vol.70
, pp. 7752-7764
-
-
Mariani, R.1
Kirchhoff, F.2
Greenough, T.C.3
-
555
-
-
0033590405
-
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1
-
Greenough T.C., Sullivan J.L., Desrosiers R.C. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med 1999, 340:236-237.
-
(1999)
N Engl J Med
, vol.340
, pp. 236-237
-
-
Greenough, T.C.1
Sullivan, J.L.2
Desrosiers, R.C.3
-
556
-
-
0033519616
-
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: a report from the Sydney Blood Bank Cohort
-
Learmont J.C., Geczy A.F., Mills J., et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: a report from the Sydney Blood Bank Cohort. N Engl J Med 1999, 340:1715-1722.
-
(1999)
N Engl J Med
, vol.340
, pp. 1715-1722
-
-
Learmont, J.C.1
Geczy, A.F.2
Mills, J.3
-
557
-
-
0036633807
-
Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence
-
Jekle A., Schramm B., Jayakumar P., et al. Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol 2002, 76:6966-6973.
-
(2002)
J Virol
, vol.76
, pp. 6966-6973
-
-
Jekle, A.1
Schramm, B.2
Jayakumar, P.3
-
558
-
-
0031694872
-
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins
-
Rossio J.L., Esser M.T., Suryanarayana K., et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998, 72:7992-8001.
-
(1998)
J Virol
, vol.72
, pp. 7992-8001
-
-
Rossio, J.L.1
Esser, M.T.2
Suryanarayana, K.3
-
559
-
-
0030895045
-
Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
-
Lin L., Cook D.N., Wiesehahn G.P., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997, 37:423-435.
-
(1997)
Transfusion
, vol.37
, pp. 423-435
-
-
Lin, L.1
Cook, D.N.2
Wiesehahn, G.P.3
-
560
-
-
3843059028
-
Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins
-
Lifson J.D., Rossio J.L., Piatak M., et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses 2004, 20:772-787.
-
(2004)
AIDS Res Hum Retroviruses
, vol.20
, pp. 772-787
-
-
Lifson, J.D.1
Rossio, J.L.2
Piatak, M.3
-
561
-
-
14844300825
-
Virus-like particles as HIV-1 vaccines
-
Doan L.X., Li M., Chen C., et al. Virus-like particles as HIV-1 vaccines. Rev Med Virol 2005, 15:75-88.
-
(2005)
Rev Med Virol
, vol.15
, pp. 75-88
-
-
Doan, L.X.1
Li, M.2
Chen, C.3
-
562
-
-
25144495663
-
Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses
-
Zanotto C., Paganini M., Elli V., et al. Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses. Vaccine 2005, 23:4745-4753.
-
(2005)
Vaccine
, vol.23
, pp. 4745-4753
-
-
Zanotto, C.1
Paganini, M.2
Elli, V.3
-
563
-
-
0037333412
-
Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus
-
Kang S.M., Compans R.W. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol 2003, 77:3615-3623.
-
(2003)
J Virol
, vol.77
, pp. 3615-3623
-
-
Kang, S.M.1
Compans, R.W.2
-
564
-
-
34249950861
-
Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state
-
Kim M., Qiao Z., Yu J., et al. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine 2007, 25:5102-5114.
-
(2007)
Vaccine
, vol.25
, pp. 5102-5114
-
-
Kim, M.1
Qiao, Z.2
Yu, J.3
-
565
-
-
40649095248
-
Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles
-
Phogat S., Svehla K., Tang M., et al. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008, 373:72-84.
-
(2008)
Virology
, vol.373
, pp. 72-84
-
-
Phogat, S.1
Svehla, K.2
Tang, M.3
-
566
-
-
3242660762
-
Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles
-
Zhang H., Huang Y., Fayad R., et al. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. J Virol 2004, 78:8342-8348.
-
(2004)
J Virol
, vol.78
, pp. 8342-8348
-
-
Zhang, H.1
Huang, Y.2
Fayad, R.3
-
567
-
-
0036239831
-
Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses
-
Liu X.S., Liu W.J., Zhao K.N., et al. Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol 2002, 80:21-29.
-
(2002)
Immunol Cell Biol
, vol.80
, pp. 21-29
-
-
Liu, X.S.1
Liu, W.J.2
Zhao, K.N.3
-
568
-
-
0025331727
-
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
-
Berman P.W., Gregory T.J., Riddle L., et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990, 345:622-625.
-
(1990)
Nature
, vol.345
, pp. 622-625
-
-
Berman, P.W.1
Gregory, T.J.2
Riddle, L.3
-
569
-
-
0025965050
-
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
-
Girard M., Kieny M.P., Pinter A., et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A 1991, 88:542-546.
-
(1991)
Proc Natl Acad Sci U S A
, vol.88
, pp. 542-546
-
-
Girard, M.1
Kieny, M.P.2
Pinter, A.3
-
570
-
-
0026752976
-
Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells
-
Fultz P.N., Nara P., Barre-Sinoussi F., et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992, 256:1687-1690.
-
(1992)
Science
, vol.256
, pp. 1687-1690
-
-
Fultz, P.N.1
Nara, P.2
Barre-Sinoussi, F.3
-
571
-
-
0028169641
-
HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees
-
Bruck C., Thiriart C., Fabry L., et al. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 1994, 12:1141-1148.
-
(1994)
Vaccine
, vol.12
, pp. 1141-1148
-
-
Bruck, C.1
Thiriart, C.2
Fabry, L.3
-
572
-
-
0029154345
-
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
-
Girard M., Meignier B., Barre-Sinoussi F., et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 1995, 69:6239-6248.
-
(1995)
J Virol
, vol.69
, pp. 6239-6248
-
-
Girard, M.1
Meignier, B.2
Barre-Sinoussi, F.3
-
573
-
-
19144370387
-
Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1
-
Berman P.W., Murthy K.K., Wrin T., et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 1996, 173:52-59.
-
(1996)
J Infect Dis
, vol.173
, pp. 52-59
-
-
Berman, P.W.1
Murthy, K.K.2
Wrin, T.3
-
574
-
-
0025284794
-
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees
-
Emini E.A., Nara P.L., Schleif W.A., et al. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol 1990, 64:3674-3678.
-
(1990)
J Virol
, vol.64
, pp. 3674-3678
-
-
Emini, E.A.1
Nara, P.L.2
Schleif, W.A.3
-
575
-
-
15444345624
-
A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection
-
Mooij P., van der Kolk M., Bogers W.M., et al. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 1998, 12:F15-F22.
-
(1998)
AIDS
, vol.12
-
-
Mooij, P.1
van der Kolk, M.2
Bogers, W.M.3
-
576
-
-
15444349408
-
Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus
-
Stott E.J., Almond N., Kent K., et al. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J Gen Virol 1998, 79(pt 3):423-432.
-
(1998)
J Gen Virol
, vol.79
, Issue.PART 3
, pp. 423-432
-
-
Stott, E.J.1
Almond, N.2
Kent, K.3
-
577
-
-
0026689113
-
Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies
-
Browning M., Reid G., Osborne R., Jarrett O. Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies. Vaccine 1992, 10:585-590.
-
(1992)
Vaccine
, vol.10
, pp. 585-590
-
-
Browning, M.1
Reid, G.2
Osborne, R.3
Jarrett, O.4
-
578
-
-
0029151884
-
Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5)
-
Hulskotte E.G., Geretti A.M., Siebelink K.H., et al. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). J Virol 1995, 69:6289-6296.
-
(1995)
J Virol
, vol.69
, pp. 6289-6296
-
-
Hulskotte, E.G.1
Geretti, A.M.2
Siebelink, K.H.3
-
579
-
-
78649725224
-
Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies
-
Vaine M., Wang S., Liu Q., et al. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One 2010, 5:e13916.
-
(2010)
PLoS One
, vol.5
-
-
Vaine, M.1
Wang, S.2
Liu, Q.3
-
580
-
-
0036231093
-
Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin
-
Yang X., Lee J., Mahony E.M., et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002, 76:4634-4642.
-
(2002)
J Virol
, vol.76
, pp. 4634-4642
-
-
Yang, X.1
Lee, J.2
Mahony, E.M.3
-
581
-
-
23844451664
-
Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus
-
Forsell M.N., Li Y., Sundback M., et al. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J Virol 2005, 79:10902-10914.
-
(2005)
J Virol
, vol.79
, pp. 10902-10914
-
-
Forsell, M.N.1
Li, Y.2
Sundback, M.3
-
582
-
-
0035000679
-
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
-
Barnett S.W., Lu S., Srivastava I., et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001, 75:5526-5540.
-
(2001)
J Virol
, vol.75
, pp. 5526-5540
-
-
Barnett, S.W.1
Lu, S.2
Srivastava, I.3
-
583
-
-
0037321708
-
Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region
-
Srivastava I.K., VanDorsten K., Vojtech L., et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003, 77:2310-2320.
-
(2003)
J Virol
, vol.77
, pp. 2310-2320
-
-
Srivastava, I.K.1
VanDorsten, K.2
Vojtech, L.3
-
584
-
-
38149096202
-
Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope
-
Barnett S.W., Srivastava I.K., Kan E., et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22:339-348.
-
(2008)
AIDS
, vol.22
, pp. 339-348
-
-
Barnett, S.W.1
Srivastava, I.K.2
Kan, E.3
-
585
-
-
0036333661
-
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
-
Sanders R.W., Vesanen M., Schuelke N., et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002, 76:8875-8889.
-
(2002)
J Virol
, vol.76
, pp. 8875-8889
-
-
Sanders, R.W.1
Vesanen, M.2
Schuelke, N.3
-
586
-
-
21644445378
-
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
-
Beddows S., Schulke N., Kirschner M., et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005, 79:8812-8827.
-
(2005)
J Virol
, vol.79
, pp. 8812-8827
-
-
Beddows, S.1
Schulke, N.2
Kirschner, M.3
-
587
-
-
0029927680
-
Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates
-
Devico A., Silver A., Thronton A.M., et al. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology 1996, 218:258-263.
-
(1996)
Virology
, vol.218
, pp. 258-263
-
-
Devico, A.1
Silver, A.2
Thronton, A.M.3
-
588
-
-
0034467954
-
Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex
-
Fouts T.R., Tuskan R., Godfrey K., et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 2000, 74:11427-11436.
-
(2000)
J Virol
, vol.74
, pp. 11427-11436
-
-
Fouts, T.R.1
Tuskan, R.2
Godfrey, K.3
-
589
-
-
0037015043
-
Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques
-
Fouts T., Godfrey K., Bobb K., et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A 2002, 99:11842-11847.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 11842-11847
-
-
Fouts, T.1
Godfrey, K.2
Bobb, K.3
-
590
-
-
36849031146
-
Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens
-
DeVico A., Fouts T., Lewis G.K., et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A 2007, 104:17477-17482.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 17477-17482
-
-
DeVico, A.1
Fouts, T.2
Lewis, G.K.3
-
591
-
-
21744447837
-
Immunology: close to the edge: neutralizing the HIV-1 envelope
-
Nabel G.J. Immunology: close to the edge: neutralizing the HIV-1 envelope. Science 2005, 308:1878-1879.
-
(2005)
Science
, vol.308
, pp. 1878-1879
-
-
Nabel, G.J.1
-
593
-
-
13944277994
-
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys
-
Seaman M.S., Xu L., Beaudry K., et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005, 79:2956-2963.
-
(2005)
J Virol
, vol.79
, pp. 2956-2963
-
-
Seaman, M.S.1
Xu, L.2
Beaudry, K.3
-
594
-
-
34447262868
-
Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines
-
McBurney S.P., Ross T.M. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines. Curr Pharm Des 2007, 13:1957-1964.
-
(2007)
Curr Pharm Des
, vol.13
, pp. 1957-1964
-
-
McBurney, S.P.1
Ross, T.M.2
-
596
-
-
33747041588
-
Ancestral and consensus envelope immunogens for HIV-1 subtype C
-
Kothe D.L., Li Y., Decker J.M., et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006, 352:438-449.
-
(2006)
Virology
, vol.352
, pp. 438-449
-
-
Kothe, D.L.1
Li, Y.2
Decker, J.M.3
-
597
-
-
33847266930
-
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins
-
Kothe D.L., Decker J.M., Li Y., et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 2007, 360:218-234.
-
(2007)
Virology
, vol.360
, pp. 218-234
-
-
Kothe, D.L.1
Decker, J.M.2
Li, Y.3
-
598
-
-
77954662179
-
Challenges of antibody-mediated protection against HIV-1
-
Lewis G.K. Challenges of antibody-mediated protection against HIV-1. Expert Rev Vaccines 2010, 9:683-687.
-
(2010)
Expert Rev Vaccines
, vol.9
, pp. 683-687
-
-
Lewis, G.K.1
-
599
-
-
0030975067
-
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160
-
VanCott T.C., Mascola J.R., Kaminski R.W., et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997, 71:4319-4330.
-
(1997)
J Virol
, vol.71
, pp. 4319-4330
-
-
VanCott, T.C.1
Mascola, J.R.2
Kaminski, R.W.3
-
600
-
-
0034663142
-
Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses
-
Kumar A., Lifson J.D., Silverstein P.S., et al. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses. Virology 2000, 274:149-164.
-
(2000)
Virology
, vol.274
, pp. 149-164
-
-
Kumar, A.1
Lifson, J.D.2
Silverstein, P.S.3
-
601
-
-
27144524041
-
Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain
-
Lian Y., Srivastava I., Gomez-Roman V.R., et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol 2005, 79:13338-13349.
-
(2005)
J Virol
, vol.79
, pp. 13338-13349
-
-
Lian, Y.1
Srivastava, I.2
Gomez-Roman, V.R.3
-
602
-
-
31144451337
-
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants
-
Li Y., Svehla K., Mathy N.L., et al. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006, 80:1414-1426.
-
(2006)
J Virol
, vol.80
, pp. 1414-1426
-
-
Li, Y.1
Svehla, K.2
Mathy, N.L.3
-
603
-
-
0037195784
-
Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro: implications for vaccine design
-
Joyce J.G., Hurni W.M., Bogusky M.J., et al. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro: implications for vaccine design. J Biol Chem 2002, 277:45811-45820.
-
(2002)
J Biol Chem
, vol.277
, pp. 45811-45820
-
-
Joyce, J.G.1
Hurni, W.M.2
Bogusky, M.J.3
-
604
-
-
13444280027
-
Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response
-
Ho J., Uger R.A., Zwick M.B., et al. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 2005, 23:1559-1573.
-
(2005)
Vaccine
, vol.23
, pp. 1559-1573
-
-
Ho, J.1
Uger, R.A.2
Zwick, M.B.3
-
605
-
-
77954892934
-
Structural characterization of HIV gp41 with the membrane-proximal external region
-
Shi W., Bohon J., Han D.P., et al. Structural characterization of HIV gp41 with the membrane-proximal external region. J Biol Chem 2010, 285:24290-24298.
-
(2010)
J Biol Chem
, vol.285
, pp. 24290-24298
-
-
Shi, W.1
Bohon, J.2
Han, D.P.3
-
606
-
-
78649613568
-
Synthesis and analysis of the membrane proximal external region epitopes of HIV-1
-
Ingale S., Gach J.S., Zwick M.B., et al. Synthesis and analysis of the membrane proximal external region epitopes of HIV-1. J Pept Sci 2010, 16:716-722.
-
(2010)
J Pept Sci
, vol.16
, pp. 716-722
-
-
Ingale, S.1
Gach, J.S.2
Zwick, M.B.3
-
607
-
-
14244264413
-
Trimeric membrane-anchored gp41 inhibits HIV membrane fusion
-
Lenz O., Dittmar M.T., Wagner A., et al. Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. J Biol Chem 2005, 280:4095-4101.
-
(2005)
J Biol Chem
, vol.280
, pp. 4095-4101
-
-
Lenz, O.1
Dittmar, M.T.2
Wagner, A.3
-
608
-
-
78650126176
-
Autonomous folding in the membrane proximal HIV peptide gp41(659-671): pH tuneability at micelle interfaces
-
Gregor C.R., Cerasoli E., Tulip P.R., et al. Autonomous folding in the membrane proximal HIV peptide gp41(659-671): pH tuneability at micelle interfaces. Phys Chem Chem Phys 2010, 13:127-135.
-
(2010)
Phys Chem Chem Phys
, vol.13
, pp. 127-135
-
-
Gregor, C.R.1
Cerasoli, E.2
Tulip, P.R.3
-
609
-
-
67649506170
-
Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41
-
Watson D.S., Szoka F.C. Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41. Vaccine 2009, 27:4672-4683.
-
(2009)
Vaccine
, vol.27
, pp. 4672-4683
-
-
Watson, D.S.1
Szoka, F.C.2
-
610
-
-
0029840636
-
HIV-1 Tat protein as a potential AIDS vaccine
-
Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1996, 2:960-964.
-
(1996)
Nat Med
, vol.2
, pp. 960-964
-
-
Goldstein, G.1
-
611
-
-
4544301217
-
Recent advances in the development of HIV-1 Tat-based vaccines
-
Caputo A., Gavioli R., Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2004, 2:357-376.
-
(2004)
Curr HIV Res
, vol.2
, pp. 357-376
-
-
Caputo, A.1
Gavioli, R.2
Ensoli, B.3
-
612
-
-
73949092256
-
A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting
-
Goldstein G., Chicca J.J. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting. Vaccine 2010, 28:1008-1014.
-
(2010)
Vaccine
, vol.28
, pp. 1008-1014
-
-
Goldstein, G.1
Chicca, J.J.2
-
613
-
-
0032057349
-
Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine
-
Zagury J.F., Sill A., Blattner W., et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1998, 1:282-292.
-
(1998)
J Hum Virol
, vol.1
, pp. 282-292
-
-
Zagury, J.F.1
Sill, A.2
Blattner, W.3
-
614
-
-
0035114575
-
Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients
-
Re M.C., Vignoli M., Furlini G., et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 2001, 21:81-89.
-
(2001)
J Clin Virol
, vol.21
, pp. 81-89
-
-
Re, M.C.1
Vignoli, M.2
Furlini, G.3
-
615
-
-
12944273609
-
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
-
Pauza C.D., Trivedi P., Wallace M., et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci U S A 2000, 97:3515-3519.
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 3515-3519
-
-
Pauza, C.D.1
Trivedi, P.2
Wallace, M.3
-
616
-
-
0034660318
-
Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33)
-
Goldstein G., Manson K., Tribbick G., et al. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 2000, 18:2789-2795.
-
(2000)
Vaccine
, vol.18
, pp. 2789-2795
-
-
Goldstein, G.1
Manson, K.2
Tribbick, G.3
-
617
-
-
0036194524
-
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication
-
Allen T.M., Mortara L., Mothe B.R., et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002, 76:4108-4112.
-
(2002)
J Virol
, vol.76
, pp. 4108-4112
-
-
Allen, T.M.1
Mortara, L.2
Mothe, B.R.3
-
618
-
-
25144485385
-
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
-
Liang X., Casimiro D.R., Schleif W.A., et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005, 79:12321-12331.
-
(2005)
J Virol
, vol.79
, pp. 12321-12331
-
-
Liang, X.1
Casimiro, D.R.2
Schleif, W.A.3
-
619
-
-
0033026062
-
Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
-
Cafaro A., Caputo A., Fracasso C., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999, 5:643-650.
-
(1999)
Nat Med
, vol.5
, pp. 643-650
-
-
Cafaro, A.1
Caputo, A.2
Fracasso, C.3
-
620
-
-
0035815501
-
Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)
-
Cafaro A., Titti F., Fracasso C., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001, 19:2862-2877.
-
(2001)
Vaccine
, vol.19
, pp. 2862-2877
-
-
Cafaro, A.1
Titti, F.2
Fracasso, C.3
-
621
-
-
4043096335
-
Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys
-
Maggiorella M.T., Baroncelli S., Michelini Z., et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004, 22:3258-3269.
-
(2004)
Vaccine
, vol.22
, pp. 3258-3269
-
-
Maggiorella, M.T.1
Baroncelli, S.2
Michelini, Z.3
-
622
-
-
65249088382
-
Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243)
-
Borsetti A., Baroncelli S., Maggiorella M.T., et al. Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243). Viral Immunol 2009, 22:117-124.
-
(2009)
Viral Immunol
, vol.22
, pp. 117-124
-
-
Borsetti, A.1
Baroncelli, S.2
Maggiorella, M.T.3
-
623
-
-
0037223760
-
Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine
-
Voss G., Manson K., Montefiori D., et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 2003, 77:1049-1058.
-
(2003)
J Virol
, vol.77
, pp. 1049-1058
-
-
Voss, G.1
Manson, K.2
Montefiori, D.3
-
624
-
-
41649098046
-
Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination
-
Koopman G., Mortier D., Hofman S., et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J Gen Virol 2008, 89(pt 2):540-553.
-
(2008)
J Gen Virol
, vol.89
, Issue.PART 2
, pp. 540-553
-
-
Koopman, G.1
Mortier, D.2
Hofman, S.3
-
625
-
-
29644446139
-
Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes
-
Hel Z., Tsai W.P., Tryniszewska E., et al. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J Immunol 2006, 176:85-96.
-
(2006)
J Immunol
, vol.176
, pp. 85-96
-
-
Hel, Z.1
Tsai, W.P.2
Tryniszewska, E.3
-
626
-
-
33947380960
-
A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques
-
Demberg T., Florese R.H., Heath M.J., et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007, 81:3414-3427.
-
(2007)
J Virol
, vol.81
, pp. 3414-3427
-
-
Demberg, T.1
Florese, R.H.2
Heath, M.J.3
-
627
-
-
44749092729
-
Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection
-
Florese R.H., Wiseman R.W., Venzon D., et al. Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. Vaccine 2008, 26:3312-3321.
-
(2008)
Vaccine
, vol.26
, pp. 3312-3321
-
-
Florese, R.H.1
Wiseman, R.W.2
Venzon, D.3
-
628
-
-
65449179917
-
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines
-
Florese R.H., Demberg T., Xiao P., et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009, 182:3718-3727.
-
(2009)
J Immunol
, vol.182
, pp. 3718-3727
-
-
Florese, R.H.1
Demberg, T.2
Xiao, P.3
-
629
-
-
73349086222
-
HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development
-
Caputo A., Gavioli R., Bellino S., et al. HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int Rev Immunol 2009, 28:285-334.
-
(2009)
Int Rev Immunol
, vol.28
, pp. 285-334
-
-
Caputo, A.1
Gavioli, R.2
Bellino, S.3
-
630
-
-
77957584418
-
T cell immunity in acute HIV-1 infection
-
Streeck H., Nixon D.F. T cell immunity in acute HIV-1 infection. J Infect Dis 2010, 202(suppl. 2):S302-S308.
-
(2010)
J Infect Dis
, vol.202
, Issue.SUPPL.. 2
-
-
Streeck, H.1
Nixon, D.F.2
-
631
-
-
18844459354
-
AIDS vaccine development: perspectives, challenges & hopes
-
Excler J.L. AIDS vaccine development: perspectives, challenges & hopes. Indian J Med Res 2005, 121:568-581.
-
(2005)
Indian J Med Res
, vol.121
, pp. 568-581
-
-
Excler, J.L.1
-
632
-
-
0027284896
-
Gene inoculation generates immune responses against human immunodeficiency virus type 1
-
Wang B., Ugen K.E., Srikantan V., et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993, 90:4156-4160.
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, pp. 4156-4160
-
-
Wang, B.1
Ugen, K.E.2
Srikantan, V.3
-
633
-
-
0029131261
-
Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation
-
Wang B., Boyer J., Srikantan V., et al. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. Virology 1995, 211:102-112.
-
(1995)
Virology
, vol.211
, pp. 102-112
-
-
Wang, B.1
Boyer, J.2
Srikantan, V.3
-
634
-
-
0029655928
-
Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys
-
Yasutomi Y., Robinson H.L., Lu S., et al. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 1996, 70:678-681.
-
(1996)
J Virol
, vol.70
, pp. 678-681
-
-
Yasutomi, Y.1
Robinson, H.L.2
Lu, S.3
-
635
-
-
2042522699
-
DNA vaccines against human immunodeficiency virus type 1 in the past decade
-
Giri M., Ugen K.E., Weiner D.B. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 2004, 17:370-389.
-
(2004)
Clin Microbiol Rev
, vol.17
, pp. 370-389
-
-
Giri, M.1
Ugen, K.E.2
Weiner, D.B.3
-
636
-
-
0005457558
-
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response
-
MacGregor R.R., Boyer J.D., Ugen K.E., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998, 178:92-100.
-
(1998)
J Infect Dis
, vol.178
, pp. 92-100
-
-
MacGregor, R.R.1
Boyer, J.D.2
Ugen, K.E.3
-
638
-
-
0030111265
-
Codon usage limitation in the expression of HIV-1 envelope glycoprotein
-
Haas J., Park E.C., Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996, 6:315-324.
-
(1996)
Curr Biol
, vol.6
, pp. 315-324
-
-
Haas, J.1
Park, E.C.2
Seed, B.3
-
639
-
-
0033766645
-
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
-
Barouch D.H., Santra S., Schmitz J.E., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290:486-492.
-
(2000)
Science
, vol.290
, pp. 486-492
-
-
Barouch, D.H.1
Santra, S.2
Schmitz, J.E.3
-
640
-
-
21244447927
-
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help
-
Kutzler M.A., Robinson T.M., Chattergoon M.A., et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005, 175:112-123.
-
(2005)
J Immunol
, vol.175
, pp. 112-123
-
-
Kutzler, M.A.1
Robinson, T.M.2
Chattergoon, M.A.3
-
641
-
-
33646835940
-
A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques
-
Schadeck E.B., Sidhu M., Egan M.A., et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24:4677-4687.
-
(2006)
Vaccine
, vol.24
, pp. 4677-4687
-
-
Schadeck, E.B.1
Sidhu, M.2
Egan, M.A.3
-
642
-
-
36749042670
-
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid
-
Boyer J.D., Robinson T.M., Kutzler M.A., et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A 2007, 104:18648-18653.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 18648-18653
-
-
Boyer, J.D.1
Robinson, T.M.2
Kutzler, M.A.3
-
643
-
-
49549106212
-
Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines
-
Xu R., Megati S., Roopchand V., et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008, 26:4819-4829.
-
(2008)
Vaccine
, vol.26
, pp. 4819-4829
-
-
Xu, R.1
Megati, S.2
Roopchand, V.3
-
644
-
-
41149180540
-
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business"
-
Schoenly K.A., Weiner D.B. Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol 2008, 82:3166-3180.
-
(2008)
J Virol
, vol.82
, pp. 3166-3180
-
-
Schoenly, K.A.1
Weiner, D.B.2
-
645
-
-
28444497720
-
Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery
-
Brave A., Ljungberg K., Boberg A., et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 2005, 12:1197-1205.
-
(2005)
Mol Ther
, vol.12
, pp. 1197-1205
-
-
Brave, A.1
Ljungberg, K.2
Boberg, A.3
-
646
-
-
29044440477
-
Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model
-
Rao S.S., Gomez P., Mascola J.R., et al. Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model. Vaccine 2006, 24:367-373.
-
(2006)
Vaccine
, vol.24
, pp. 367-373
-
-
Rao, S.S.1
Gomez, P.2
Mascola, J.R.3
-
647
-
-
0034849493
-
Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines
-
O'Hagan D., Singh M., Ugozzoli M., et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 2001, 75:9037-9043.
-
(2001)
J Virol
, vol.75
, pp. 9037-9043
-
-
O'Hagan, D.1
Singh, M.2
Ugozzoli, M.3
-
648
-
-
0033228367
-
DNA vaccines: basic mechanism and immune responses (review)
-
Robinson H.L. DNA vaccines: basic mechanism and immune responses (review). Int J Mol Med 1999, 4:549-555.
-
(1999)
Int J Mol Med
, vol.4
, pp. 549-555
-
-
Robinson, H.L.1
-
649
-
-
12244263558
-
Gene transfer to subdermal tissues via a new gene gun design
-
Dileo J., Miller T.E., Chesnoy S., et al. Gene transfer to subdermal tissues via a new gene gun design. Hum Gene Ther 2003, 14:79-87.
-
(2003)
Hum Gene Ther
, vol.14
, pp. 79-87
-
-
Dileo, J.1
Miller, T.E.2
Chesnoy, S.3
-
650
-
-
77958163907
-
DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge
-
Kask A.S., Chen X., Marshak J.O., et al. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 2010, 28:7483-7491.
-
(2010)
Vaccine
, vol.28
, pp. 7483-7491
-
-
Kask, A.S.1
Chen, X.2
Marshak, J.O.3
-
651
-
-
78649802326
-
Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays
-
Chen X., Kask A.S., Crichton M.L., et al. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. J Control Release 2010, 148:327-333.
-
(2010)
J Control Release
, vol.148
, pp. 327-333
-
-
Chen, X.1
Kask, A.S.2
Crichton, M.L.3
-
652
-
-
77955624546
-
Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice
-
Prow T.W., Chen X., Prow N.A., et al. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 2010, 6:1776-1784.
-
(2010)
Small
, vol.6
, pp. 1776-1784
-
-
Prow, T.W.1
Chen, X.2
Prow, N.A.3
-
653
-
-
34248382494
-
Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques
-
Luckay A., Sidhu M.K., Kjeken R., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81:5257-5269.
-
(2007)
J Virol
, vol.81
, pp. 5257-5269
-
-
Luckay, A.1
Sidhu, M.K.2
Kjeken, R.3
-
654
-
-
37549037877
-
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques
-
Hirao L.A., Wu L., Khan A.S., et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008, 26:440-448.
-
(2008)
Vaccine
, vol.26
, pp. 440-448
-
-
Hirao, L.A.1
Wu, L.2
Khan, A.S.3
-
655
-
-
77950957345
-
Basic principles and clinical advancements of muscle electrotransfer
-
Hojman P. Basic principles and clinical advancements of muscle electrotransfer. Curr Gene Ther 2010, 10:128-138.
-
(2010)
Curr Gene Ther
, vol.10
, pp. 128-138
-
-
Hojman, P.1
-
656
-
-
78649658963
-
Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation
-
Brave A., Gudmundsdotter L., Sandstrom E., et al. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine 2010, 28:8203-8209.
-
(2010)
Vaccine
, vol.28
, pp. 8203-8209
-
-
Brave, A.1
Gudmundsdotter, L.2
Sandstrom, E.3
-
658
-
-
70349471292
-
DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge
-
Rosati M., Bergamaschi C., Valentin A., et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A 2009, 106:15831-15836.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 15831-15836
-
-
Rosati, M.1
Bergamaschi, C.2
Valentin, A.3
-
659
-
-
80052285787
-
High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation
-
Yin J., Dai A., Lecureux J., et al. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine 2011, 29:6763-6770.
-
(2011)
Vaccine
, vol.29
, pp. 6763-6770
-
-
Yin, J.1
Dai, A.2
Lecureux, J.3
-
660
-
-
14844322130
-
DermaVir, a novel HIV immunisation technology
-
Lori F., Trocio J., Bakare N., et al. DermaVir, a novel HIV immunisation technology. Vaccine 2005, 23:2030-2034.
-
(2005)
Vaccine
, vol.23
, pp. 2030-2034
-
-
Lori, F.1
Trocio, J.2
Bakare, N.3
-
661
-
-
34547668503
-
Nanochemistry-based immunotherapy for HIV-1
-
Lori F., Calarota S.A., Lisziewicz J. Nanochemistry-based immunotherapy for HIV-1. Curr Med Chem 2007, 14:1911-1919.
-
(2007)
Curr Med Chem
, vol.14
, pp. 1911-1919
-
-
Lori, F.1
Calarota, S.A.2
Lisziewicz, J.3
-
662
-
-
50849133565
-
IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine
-
Calarota S.A., Dai A., Trocio J.N., et al. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine 2008, 26:5188-5195.
-
(2008)
Vaccine
, vol.26
, pp. 5188-5195
-
-
Calarota, S.A.1
Dai, A.2
Trocio, J.N.3
-
663
-
-
0034176364
-
The prime-boost strategy: exciting prospects for improved vaccination
-
Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000, 21:163-165.
-
(2000)
Immunol Today
, vol.21
, pp. 163-165
-
-
Ramshaw, I.A.1
Ramsay, A.J.2
-
664
-
-
0036113771
-
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine
-
Amara R.R., Smith J.M., Staprans S.I., et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002, 76:6138-6146.
-
(2002)
J Virol
, vol.76
, pp. 6138-6146
-
-
Amara, R.R.1
Smith, J.M.2
Staprans, S.I.3
-
665
-
-
14544290129
-
Progress toward an HIV vaccine
-
Letvin N.L. Progress toward an HIV vaccine. Annu Rev Med 2005, 56:213-223.
-
(2005)
Annu Rev Med
, vol.56
, pp. 213-223
-
-
Letvin, N.L.1
-
666
-
-
0035948229
-
Viral vectors as potential HIV-1 vaccines
-
Schnell M.J. Viral vectors as potential HIV-1 vaccines. FEMS Microbiol Lett 2001, 200:123-129.
-
(2001)
FEMS Microbiol Lett
, vol.200
, pp. 123-129
-
-
Schnell, M.J.1
-
667
-
-
18144386590
-
Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system
-
Sauter S.L., Rahman A., Muralidhar G. Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system. Curr HIV Res 2005, 3:157-181.
-
(2005)
Curr HIV Res
, vol.3
, pp. 157-181
-
-
Sauter, S.L.1
Rahman, A.2
Muralidhar, G.3
-
668
-
-
0028786661
-
Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals
-
Honda M., Matsuo K., Nakasone T., et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci U S A 1995, 92:10693-10697.
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 10693-10697
-
-
Honda, M.1
Matsuo, K.2
Nakasone, T.3
-
669
-
-
26444589093
-
Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity
-
Ami Y., Izumi Y., Matsuo K., et al. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 2005, 79:12871-12879.
-
(2005)
J Virol
, vol.79
, pp. 12871-12879
-
-
Ami, Y.1
Izumi, Y.2
Matsuo, K.3
-
670
-
-
0037029902
-
Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1
-
Devico A.L., Fouts T.R., Shata M.T., et al. Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 2002, 20:1968-1974.
-
(2002)
Vaccine
, vol.20
, pp. 1968-1974
-
-
Devico, A.L.1
Fouts, T.R.2
Shata, M.T.3
-
671
-
-
0038771229
-
Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1
-
Fouts T.R., DeVico A.L., Onyabe D.Y., et al. Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol Med Microbiol 2003, 37:129-134.
-
(2003)
FEMS Immunol Med Microbiol
, vol.37
, pp. 129-134
-
-
Fouts, T.R.1
DeVico, A.L.2
Onyabe, D.Y.3
-
672
-
-
4344573008
-
Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens
-
Paterson Y., Johnson R.S. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines 2004, 3(suppl. 4):S119-S134.
-
(2004)
Expert Rev Vaccines
, vol.3
, Issue.SUPPL.. 4
-
-
Paterson, Y.1
Johnson, R.S.2
-
674
-
-
0037771077
-
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity
-
Vogels R., Zuijdgeest D., van Rijnsoever R., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003, 77:8263-8271.
-
(2003)
J Virol
, vol.77
, pp. 8263-8271
-
-
Vogels, R.1
Zuijdgeest, D.2
van Rijnsoever, R.3
-
675
-
-
2442611810
-
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
-
Barouch D.H., Pau M.G., Custers J.H., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172:6290-6297.
-
(2004)
J Immunol
, vol.172
, pp. 6290-6297
-
-
Barouch, D.H.1
Pau, M.G.2
Custers, J.H.3
-
676
-
-
34247585475
-
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
-
Abbink P., Lemckert A.A., Ewald B.A., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007, 81:4654-4663.
-
(2007)
J Virol
, vol.81
, pp. 4654-4663
-
-
Abbink, P.1
Lemckert, A.A.2
Ewald, B.A.3
-
677
-
-
0037310512
-
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag
-
Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003, 170:1416-1422.
-
(2003)
J Immunol
, vol.170
, pp. 1416-1422
-
-
Fitzgerald, J.C.1
Gao, G.P.2
Reyes-Sandoval, A.3
-
678
-
-
34249930119
-
Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors
-
McCoy K., Tatsis N., Korioth-Schmitz B., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007, 81:6594-6604.
-
(2007)
J Virol
, vol.81
, pp. 6594-6604
-
-
McCoy, K.1
Tatsis, N.2
Korioth-Schmitz, B.3
-
679
-
-
33847222746
-
A CD46-binding chimpanzee adenovirus vector as a vaccine carrier
-
Tatsis N., Blejer A., Lasaro M.O., et al. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther 2007, 15:608-617.
-
(2007)
Mol Ther
, vol.15
, pp. 608-617
-
-
Tatsis, N.1
Blejer, A.2
Lasaro, M.O.3
-
680
-
-
0031012007
-
Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins
-
Anderson M.J., Porter D.C., Moldoveanu Z., et al. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins. AIDS Res Hum Retroviruses 1997, 13:53-62.
-
(1997)
AIDS Res Hum Retroviruses
, vol.13
, pp. 53-62
-
-
Anderson, M.J.1
Porter, D.C.2
Moldoveanu, Z.3
-
681
-
-
65349118744
-
Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope
-
Arnold G.F., Velasco P.K., Holmes A.K., et al. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 2009, 83:5087-5100.
-
(2009)
J Virol
, vol.83
, pp. 5087-5100
-
-
Arnold, G.F.1
Velasco, P.K.2
Holmes, A.K.3
-
682
-
-
0141521625
-
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector
-
Perri S., Greer C.E., Thudium K., et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 2003, 77:10394-10403.
-
(2003)
J Virol
, vol.77
, pp. 10394-10403
-
-
Perri, S.1
Greer, C.E.2
Thudium, K.3
-
683
-
-
19944425988
-
Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques
-
Johnson P.R., Schnepp B.C., Connell M.J., et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005, 79:955-965.
-
(2005)
J Virol
, vol.79
, pp. 955-965
-
-
Johnson, P.R.1
Schnepp, B.C.2
Connell, M.J.3
-
684
-
-
0042389496
-
Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model
-
Takeda A., Igarashi H., Nakamura H., et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J Virol 2003, 77:9710-9715.
-
(2003)
J Virol
, vol.77
, pp. 9710-9715
-
-
Takeda, A.1
Igarashi, H.2
Nakamura, H.3
-
685
-
-
3042545965
-
Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial
-
Matano T., Kobayashi M., Igarashi H., et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004, 199:1709-1718.
-
(2004)
J Exp Med
, vol.199
, pp. 1709-1718
-
-
Matano, T.1
Kobayashi, M.2
Igarashi, H.3
-
686
-
-
0034467097
-
Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
-
Rose N.F., Roberts A., Buonocore L., et al. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 2000, 74:10903-10910.
-
(2000)
J Virol
, vol.74
, pp. 10903-10910
-
-
Rose, N.F.1
Roberts, A.2
Buonocore, L.3
-
687
-
-
27144515268
-
A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector
-
Publicover J., Ramsburg E., Rose J.K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 2005, 79:13231-13238.
-
(2005)
J Virol
, vol.79
, pp. 13231-13238
-
-
Publicover, J.1
Ramsburg, E.2
Rose, J.K.3
-
688
-
-
58149526762
-
Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses
-
Carnero E., Li W., Borderia A.V., et al. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol 2009, 83:584-597.
-
(2009)
J Virol
, vol.83
, pp. 584-597
-
-
Carnero, E.1
Li, W.2
Borderia, A.V.3
-
689
-
-
0345734199
-
A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV
-
Lorin C., Mollet L., Delebecque F., et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004, 78:146-157.
-
(2004)
J Virol
, vol.78
, pp. 146-157
-
-
Lorin, C.1
Mollet, L.2
Delebecque, F.3
-
690
-
-
70149088017
-
Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity
-
Honda M., Wang R., Kong W.P., et al. Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity. J Immunol 2009, 183:2425-2434.
-
(2009)
J Immunol
, vol.183
, pp. 2425-2434
-
-
Honda, M.1
Wang, R.2
Kong, W.P.3
-
691
-
-
78650041204
-
Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors
-
Rhee E.G., Blattman J.N., Kasturi S.P., et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol 2011, 85:315-323.
-
(2011)
J Virol
, vol.85
, pp. 315-323
-
-
Rhee, E.G.1
Blattman, J.N.2
Kasturi, S.P.3
-
692
-
-
0029940996
-
Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
-
Hirsch V.M., Fuerst T.R., Sutter G., et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996, 70:3741-3752.
-
(1996)
J Virol
, vol.70
, pp. 3741-3752
-
-
Hirsch, V.M.1
Fuerst, T.R.2
Sutter, G.3
-
693
-
-
0034093217
-
Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
-
Ourmanov I., Brown C.R., Moss B., et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol 2000, 74:2740-2751.
-
(2000)
J Virol
, vol.74
, pp. 2740-2751
-
-
Ourmanov, I.1
Brown, C.R.2
Moss, B.3
-
694
-
-
0035025623
-
Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
-
Barouch D.H., Santra S., Kuroda M.J., et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001, 75:5151-5158.
-
(2001)
J Virol
, vol.75
, pp. 5151-5158
-
-
Barouch, D.H.1
Santra, S.2
Kuroda, M.J.3
-
695
-
-
18344405225
-
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure
-
Benson J., Chougnet C., Robert-Guroff M., et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol 1998, 72:4170-4182.
-
(1998)
J Virol
, vol.72
, pp. 4170-4182
-
-
Benson, J.1
Chougnet, C.2
Robert-Guroff, M.3
-
696
-
-
0037122719
-
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
-
Shiver J.W., Fu T.M., Chen L., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335.
-
(2002)
Nature
, vol.415
, pp. 331-335
-
-
Shiver, J.W.1
Fu, T.M.2
Chen, L.3
-
697
-
-
29244455769
-
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag
-
Casimiro D.R., Wang F., Schleif W.A., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005, 79:15547-15555.
-
(2005)
J Virol
, vol.79
, pp. 15547-15555
-
-
Casimiro, D.R.1
Wang, F.2
Schleif, W.A.3
-
698
-
-
29744438821
-
Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques
-
McDermott A.B., O'Connor D.H., Fuenger S., et al. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J Virol 2005, 79:15556-15566.
-
(2005)
J Virol
, vol.79
, pp. 15556-15566
-
-
McDermott, A.B.1
O'Connor, D.H.2
Fuenger, S.3
-
699
-
-
0033988633
-
Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
-
Davis N.L., Caley I.J., Brown K.W., et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 2000, 74:371-378.
-
(2000)
J Virol
, vol.74
, pp. 371-378
-
-
Davis, N.L.1
Caley, I.J.2
Brown, K.W.3
-
700
-
-
24644447713
-
Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660
-
Johnston R.E., Johnson P.R., Connell M.J., et al. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 2005, 23:4969-4979.
-
(2005)
Vaccine
, vol.23
, pp. 4969-4979
-
-
Johnston, R.E.1
Johnson, P.R.2
Connell, M.J.3
-
701
-
-
33644866612
-
Mucosal and systemic adjuvant activity of alphavirus replicon particles
-
Thompson J.M., Whitmore A.C., Konopka J.L., et al. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A 2006, 103:3722-3727.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 3722-3727
-
-
Thompson, J.M.1
Whitmore, A.C.2
Konopka, J.L.3
-
702
-
-
77649339799
-
Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected]
-
Lapelosa M., Arnold G.F., Gallicchio E., et al. Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected]. J Mol Biol 2010, 397:752-766.
-
(2010)
J Mol Biol
, vol.397
, pp. 752-766
-
-
Lapelosa, M.1
Arnold, G.F.2
Gallicchio, E.3
-
703
-
-
0036547263
-
New hope for an AIDS vaccine
-
Robinson H.L. New hope for an AIDS vaccine. Nat Rev Immunol 2002, 2:239-250.
-
(2002)
Nat Rev Immunol
, vol.2
, pp. 239-250
-
-
Robinson, H.L.1
-
704
-
-
19944425960
-
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins
-
Mascola J.R., Sambor A., Beaudry K., et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005, 79:771-779.
-
(2005)
J Virol
, vol.79
, pp. 771-779
-
-
Mascola, J.R.1
Sambor, A.2
Beaudry, K.3
-
705
-
-
20744452323
-
Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens
-
Wu L., Kong W.P., Nabel G.J. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 2005, 79:8024-8031.
-
(2005)
J Virol
, vol.79
, pp. 8024-8031
-
-
Wu, L.1
Kong, W.P.2
Nabel, G.J.3
-
706
-
-
67049086871
-
Heterologous prime-boost vaccination
-
Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009, 21:346-351.
-
(2009)
Curr Opin Immunol
, vol.21
, pp. 346-351
-
-
Lu, S.1
-
707
-
-
77749322238
-
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
-
Koup R.A., Roederer M., Lamoreaux L., et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5:e9015.
-
(2010)
PLoS One
, vol.5
-
-
Koup, R.A.1
Roederer, M.2
Lamoreaux, L.3
-
708
-
-
12144289214
-
Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates
-
Bertley F.M., Kozlowski P.A., Wang S.W., et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 2004, 172:3745-3757.
-
(2004)
J Immunol
, vol.172
, pp. 3745-3757
-
-
Bertley, F.M.1
Kozlowski, P.A.2
Wang, S.W.3
-
709
-
-
41449096780
-
DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory
-
Manrique M., Micewicz E., Kozlowski P.A., et al. DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. AIDS Res Hum Retroviruses 2008, 24:505-519.
-
(2008)
AIDS Res Hum Retroviruses
, vol.24
, pp. 505-519
-
-
Manrique, M.1
Micewicz, E.2
Kozlowski, P.A.3
-
710
-
-
0036839574
-
Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses
-
Hel Z., Nacsa J., Tryniszewska E., et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 2002, 169:4778-4787.
-
(2002)
J Immunol
, vol.169
, pp. 4778-4787
-
-
Hel, Z.1
Nacsa, J.2
Tryniszewska, E.3
-
711
-
-
58549099671
-
Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89. 6P challenge
-
Schell J., Rose N.F., Fazo N., et al. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89. 6P challenge. Vaccine 2009, 27:979-986.
-
(2009)
Vaccine
, vol.27
, pp. 979-986
-
-
Schell, J.1
Rose, N.F.2
Fazo, N.3
-
712
-
-
32544446124
-
Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model
-
Suh Y.S., Park K.S., Sauermann U., et al. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 2006, 24:1811-1820.
-
(2006)
Vaccine
, vol.24
, pp. 1811-1820
-
-
Suh, Y.S.1
Park, K.S.2
Sauermann, U.3
-
713
-
-
33745015013
-
Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge
-
Mattapallil J.J., Douek D.C., Buckler-White A., et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 2006, 203:1533-1541.
-
(2006)
J Exp Med
, vol.203
, pp. 1533-1541
-
-
Mattapallil, J.J.1
Douek, D.C.2
Buckler-White, A.3
-
714
-
-
48749130188
-
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys
-
Santra S., Korber B.T., Muldoon M., et al. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A 2008, 105:10489-10494.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 10489-10494
-
-
Santra, S.1
Korber, B.T.2
Muldoon, M.3
-
715
-
-
67449101823
-
Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge
-
Wilson N.A., Keele B.F., Reed J.S., et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009, 83:6508-6521.
-
(2009)
J Virol
, vol.83
, pp. 6508-6521
-
-
Wilson, N.A.1
Keele, B.F.2
Reed, J.S.3
-
716
-
-
71949122352
-
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens
-
Asmuth D.M., Brown E.L., DiNubile M.J., et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis 2010, 201:132-141.
-
(2010)
J Infect Dis
, vol.201
, pp. 132-141
-
-
Asmuth, D.M.1
Brown, E.L.2
DiNubile, M.J.3
-
717
-
-
77950819099
-
T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge
-
Martins M.A., Wilson N.A., Reed J.S., et al. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol 2010, 84:4352-4365.
-
(2010)
J Virol
, vol.84
, pp. 4352-4365
-
-
Martins, M.A.1
Wilson, N.A.2
Reed, J.S.3
-
718
-
-
34248373768
-
Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine
-
Kawada M., Tsukamoto T., Yamamoto H., et al. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J Virol 2007, 81:5202-5211.
-
(2007)
J Virol
, vol.81
, pp. 5202-5211
-
-
Kawada, M.1
Tsukamoto, T.2
Yamamoto, H.3
-
719
-
-
32444446673
-
Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques
-
Kawada M., Igarashi H., Takeda A., et al. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J Virol 2006, 80:1949-1958.
-
(2006)
J Virol
, vol.80
, pp. 1949-1958
-
-
Kawada, M.1
Igarashi, H.2
Takeda, A.3
-
720
-
-
69449108369
-
Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys
-
Barouch D.H., Liu J., Lynch D.M., et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 2009, 83:9584-9590.
-
(2009)
J Virol
, vol.83
, pp. 9584-9590
-
-
Barouch, D.H.1
Liu, J.2
Lynch, D.M.3
-
721
-
-
34548182353
-
HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3
-
Cristillo A.D., Lisziewicz J., He L., et al. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 2007, 366:197-211.
-
(2007)
Virology
, vol.366
, pp. 197-211
-
-
Cristillo, A.D.1
Lisziewicz, J.2
He, L.3
-
722
-
-
0032920019
-
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
-
Robinson H.L., Montefiori D.C., Johnson R.P., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999, 5:526-534.
-
(1999)
Nat Med
, vol.5
, pp. 526-534
-
-
Robinson, H.L.1
Montefiori, D.C.2
Johnson, R.P.3
-
723
-
-
0035815437
-
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
-
Amara R.R., Villinger F., Altman J.D., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
-
(2001)
Science
, vol.292
, pp. 69-74
-
-
Amara, R.R.1
Villinger, F.2
Altman, J.D.3
-
724
-
-
4344714042
-
MVA as a vector for vaccines against HIV-1
-
Im E.J., Hanke T. MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 2004, 3(suppl. 4):S89-S97.
-
(2004)
Expert Rev Vaccines
, vol.3
, Issue.SUPPL.. 4
-
-
Im, E.J.1
Hanke, T.2
-
725
-
-
34548070699
-
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice
-
Brave A., Boberg A., Gudmundsdotter L., et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther 2007, 15:1724-1733.
-
(2007)
Mol Ther
, vol.15
, pp. 1724-1733
-
-
Brave, A.1
Boberg, A.2
Gudmundsdotter, L.3
-
726
-
-
37549023073
-
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells
-
Robinson H.L., Sharma S., Zhao J., et al. Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses 2007, 23:1555-1562.
-
(2007)
AIDS Res Hum Retroviruses
, vol.23
, pp. 1555-1562
-
-
Robinson, H.L.1
Sharma, S.2
Zhao, J.3
-
727
-
-
35649027418
-
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine
-
Lai L., Vodros D., Kozlowski P.A., et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007, 369:153-167.
-
(2007)
Virology
, vol.369
, pp. 153-167
-
-
Lai, L.1
Vodros, D.2
Kozlowski, P.A.3
-
728
-
-
66149097337
-
Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia
-
Zhao J., Lai L., Amara R.R., et al. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 2009, 83:4102-4111.
-
(2009)
J Virol
, vol.83
, pp. 4102-4111
-
-
Zhao, J.1
Lai, L.2
Amara, R.R.3
-
729
-
-
77956177746
-
Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys
-
Sun Y., Santra S., Buzby A.P., et al. Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys. Virology 2010, 406:48-55.
-
(2010)
Virology
, vol.406
, pp. 48-55
-
-
Sun, Y.1
Santra, S.2
Buzby, A.P.3
-
730
-
-
33750701498
-
Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge
-
Sun Y., Schmitz J.E., Buzby A.P., et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 2006, 80:10950-10956.
-
(2006)
J Virol
, vol.80
, pp. 10950-10956
-
-
Sun, Y.1
Schmitz, J.E.2
Buzby, A.P.3
-
731
-
-
4644225721
-
Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors
-
Casimiro D.R., Bett A.J., Fu T.M., et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 2004, 78:11434-11438.
-
(2004)
J Virol
, vol.78
, pp. 11434-11438
-
-
Casimiro, D.R.1
Bett, A.J.2
Fu, T.M.3
-
732
-
-
22544467274
-
Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity
-
Lemckert A.A., Sumida S.M., Holterman L., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005, 79:9694-9701.
-
(2005)
J Virol
, vol.79
, pp. 9694-9701
-
-
Lemckert, A.A.1
Sumida, S.M.2
Holterman, L.3
-
733
-
-
66149141072
-
Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses
-
Cayabyab M.J., Korioth-Schmitz B., Sun Y., et al. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 2009, 83:5505-5513.
-
(2009)
J Virol
, vol.83
, pp. 5505-5513
-
-
Cayabyab, M.J.1
Korioth-Schmitz, B.2
Sun, Y.3
-
735
-
-
0036133208
-
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency
-
Pal R., Venzon D., Letvin N.L., et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002, 76:292-302.
-
(2002)
J Virol
, vol.76
, pp. 292-302
-
-
Pal, R.1
Venzon, D.2
Letvin, N.L.3
-
736
-
-
33645793093
-
+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels
-
+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006, 80:3732-3742.
-
(2006)
J Virol
, vol.80
, pp. 3732-3742
-
-
Pal, R.1
Venzon, D.2
Santra, S.3
-
737
-
-
0038784862
-
Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen
-
Zhao J., Pinczewski J., Gomez-Roman V.R., et al. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J Virol 2003, 77:8354-8365.
-
(2003)
J Virol
, vol.77
, pp. 8354-8365
-
-
Zhao, J.1
Pinczewski, J.2
Gomez-Roman, V.R.3
-
738
-
-
12644271200
-
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
-
Letvin N.L., Montefiori D.C., Yasutomi Y., et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 1997, 94:9378-9383.
-
(1997)
Proc Natl Acad Sci U S A
, vol.94
, pp. 9378-9383
-
-
Letvin, N.L.1
Montefiori, D.C.2
Yasutomi, Y.3
-
739
-
-
0030872511
-
Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
-
Barnett S.W., Rajasekar S., Legg H., et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 1997, 15:869-873.
-
(1997)
Vaccine
, vol.15
, pp. 869-873
-
-
Barnett, S.W.1
Rajasekar, S.2
Legg, H.3
-
740
-
-
40549094977
-
Human versus HIV: round 2 defeat in AIDS vaccine development
-
Lu S. Human versus HIV: round 2 defeat in AIDS vaccine development. Expert Rev Vaccines 2008, 7:151-153.
-
(2008)
Expert Rev Vaccines
, vol.7
, pp. 151-153
-
-
Lu, S.1
-
741
-
-
33746651142
-
Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E
-
Wang S., Pal R., Mascola J.R., et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006, 350:34-47.
-
(2006)
Virology
, vol.350
, pp. 34-47
-
-
Wang, S.1
Pal, R.2
Mascola, J.R.3
-
742
-
-
0026047610
-
Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen
-
Wang C.Y., Looney D.J., Li M.L., et al. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991, 254:285-288.
-
(1991)
Science
, vol.254
, pp. 285-288
-
-
Wang, C.Y.1
Looney, D.J.2
Li, M.L.3
-
743
-
-
0442292287
-
Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy
-
Liu Z., Chen Y.H. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy. J Immunol Methods 2004, 285:93-97.
-
(2004)
J Immunol Methods
, vol.285
, pp. 93-97
-
-
Liu, Z.1
Chen, Y.H.2
-
744
-
-
14844302633
-
HIV vaccine development by computer assisted design: the GAIA vaccine
-
De Groot A.S., Marcon L., Bishop E.A., et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005, 23:2136-2148.
-
(2005)
Vaccine
, vol.23
, pp. 2136-2148
-
-
De Groot, A.S.1
Marcon, L.2
Bishop, E.A.3
-
745
-
-
24944542364
-
HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach
-
Gahery H., Choppin J., Bourgault I., et al. HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach. Therapie 2005, 60:243-248.
-
(2005)
Therapie
, vol.60
, pp. 243-248
-
-
Gahery, H.1
Choppin, J.2
Bourgault, I.3
-
746
-
-
33646365642
-
Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults
-
Durier C., Launay O., Meiffredy V., et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006, 20:1039-1049.
-
(2006)
AIDS
, vol.20
, pp. 1039-1049
-
-
Durier, C.1
Launay, O.2
Meiffredy, V.3
-
747
-
-
77953752637
-
Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates
-
Bianchi E., Joyce J.G., Miller M.D., et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 2010, 107:10655-10660.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 10655-10660
-
-
Bianchi, E.1
Joyce, J.G.2
Miller, M.D.3
-
748
-
-
0030012266
-
Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL
-
Deprez B., Sauzet J.P., Boutillon C., et al. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 1996, 14:375-382.
-
(1996)
Vaccine
, vol.14
, pp. 375-382
-
-
Deprez, B.1
Sauzet, J.P.2
Boutillon, C.3
-
749
-
-
0342647378
-
Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
-
Gahery-Segard H., Pialoux G., Charmeteau B., et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 2000, 74:1694-1703.
-
(2000)
J Virol
, vol.74
, pp. 1694-1703
-
-
Gahery-Segard, H.1
Pialoux, G.2
Charmeteau, B.3
-
750
-
-
38849188390
-
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial
-
Launay O., Durier C., Desaint C., et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS One 2007, 2:e725.
-
(2007)
PLoS One
, vol.2
-
-
Launay, O.1
Durier, C.2
Desaint, C.3
-
751
-
-
42049102863
-
Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA Study
-
Pialoux G., Quercia R.P., Gahery H., et al. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA Study. Clin Vaccine Immunol 2008, 15:562-568.
-
(2008)
Clin Vaccine Immunol
, vol.15
, pp. 562-568
-
-
Pialoux, G.1
Quercia, R.P.2
Gahery, H.3
-
752
-
-
77952581247
-
Mucosal HIV vaccines: a holy grail or a dud?
-
Azizi A., Ghunaim H., Diaz-Mitoma F., et al. Mucosal HIV vaccines: a holy grail or a dud?. Vaccine 2010, 28:4015-4026.
-
(2010)
Vaccine
, vol.28
, pp. 4015-4026
-
-
Azizi, A.1
Ghunaim, H.2
Diaz-Mitoma, F.3
-
753
-
-
77958452906
-
Vaccination strategies to promote mucosal antibody responses
-
Chen K., Cerutti A. Vaccination strategies to promote mucosal antibody responses. Immunity 2010, 33:479-491.
-
(2010)
Immunity
, vol.33
, pp. 479-491
-
-
Chen, K.1
Cerutti, A.2
-
754
-
-
77954672442
-
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes
-
Yu M., Vajdy M. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther 2010, 10:1181-1195.
-
(2010)
Expert Opin Biol Ther
, vol.10
, pp. 1181-1195
-
-
Yu, M.1
Vajdy, M.2
-
755
-
-
57449084255
-
The great barrier
-
Von Bubnoff A. The great barrier. IAVI Rep 2008, 12:10-14.
-
(2008)
IAVI Rep
, vol.12
, pp. 10-14
-
-
Von Bubnoff, A.1
-
756
-
-
41149163239
-
Conquering sexually transmitted diseases
-
Starnbach M.N., Roan N.R. Conquering sexually transmitted diseases. Nat Rev Immunol 2008, 8:313-317.
-
(2008)
Nat Rev Immunol
, vol.8
, pp. 313-317
-
-
Starnbach, M.N.1
Roan, N.R.2
-
757
-
-
2442517281
-
Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule
-
Gherardi M.M., Perez-Jimenez E., Najera J.L., et al. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 2004, 172:6209-6220.
-
(2004)
J Immunol
, vol.172
, pp. 6209-6220
-
-
Gherardi, M.M.1
Perez-Jimenez, E.2
Najera, J.L.3
-
758
-
-
17844394454
-
Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE
-
Pinczewski J., Zhao J., Malkevitch N., et al. Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. Viral Immunol 2005, 18:236-243.
-
(2005)
Viral Immunol
, vol.18
, pp. 236-243
-
-
Pinczewski, J.1
Zhao, J.2
Malkevitch, N.3
-
759
-
-
35449000608
-
Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251)
-
Zhou Q., Hidajat R., Peng B., et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine 2007, 25:8021-8035.
-
(2007)
Vaccine
, vol.25
, pp. 8021-8035
-
-
Zhou, Q.1
Hidajat, R.2
Peng, B.3
-
760
-
-
79951754740
-
Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges
-
Bomsel M., Tudor D., Drillet A.S., et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
-
(2011)
Immunity
, vol.34
, pp. 269-280
-
-
Bomsel, M.1
Tudor, D.2
Drillet, A.S.3
-
761
-
-
79951745043
-
Standing guard at the mucosa
-
McElrath M.J. Standing guard at the mucosa. Immunity 2011, 34:146-148.
-
(2011)
Immunity
, vol.34
, pp. 146-148
-
-
McElrath, M.J.1
-
762
-
-
33646872613
-
Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate
-
Matoba N., Geyer B.C., Kilbourne J., et al. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006, 24:5047-5055.
-
(2006)
Vaccine
, vol.24
, pp. 5047-5055
-
-
Matoba, N.1
Geyer, B.C.2
Kilbourne, J.3
-
763
-
-
34447509610
-
DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
-
Buonaguro L., Devito C., Tornesello M.L., et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007, 25:5968-5977.
-
(2007)
Vaccine
, vol.25
, pp. 5968-5977
-
-
Buonaguro, L.1
Devito, C.2
Tornesello, M.L.3
-
764
-
-
77952001983
-
Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
-
Binley J.M., Ban Y.E., Crooks E.T., et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 2010, 84:5637-5655.
-
(2010)
J Virol
, vol.84
, pp. 5637-5655
-
-
Binley, J.M.1
Ban, Y.E.2
Crooks, E.T.3
-
765
-
-
41649090223
-
A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies
-
Frey G., Peng H., Rits-Volloch S., et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A 2008, 105:3739-3744.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 3739-3744
-
-
Frey, G.1
Peng, H.2
Rits-Volloch, S.3
-
766
-
-
21344434534
-
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
-
Haynes B.F., Fleming J., St Clair E.W., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
-
(2005)
Science
, vol.308
, pp. 1906-1908
-
-
Haynes, B.F.1
Fleming, J.2
St Clair, E.W.3
-
767
-
-
76249083814
-
Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance
-
Verkoczy L., Diaz M., Holl T.M., et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A 2010, 107:181-186.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 181-186
-
-
Verkoczy, L.1
Diaz, M.2
Holl, T.M.3
-
768
-
-
0027985431
-
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
-
Burton D.R., Pyati J., Koduri R., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1047.
-
(1994)
Science
, vol.266
, pp. 1024-1047
-
-
Burton, D.R.1
Pyati, J.2
Koduri, R.3
-
769
-
-
0028291731
-
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
-
Roben P., Moore J.P., Thali M., et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994, 68:4821-4828.
-
(1994)
J Virol
, vol.68
, pp. 4821-4828
-
-
Roben, P.1
Moore, J.P.2
Thali, M.3
-
770
-
-
34249950588
-
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
-
Dhillon A.K., Donners H., Pantophlet R., et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007, 81:6548-6562.
-
(2007)
J Virol
, vol.81
, pp. 6548-6562
-
-
Dhillon, A.K.1
Donners, H.2
Pantophlet, R.3
-
771
-
-
70450182950
-
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120
-
Chen L., Do Kwon Y., Zhou T., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009, 326:1123-1127.
-
(2009)
Science
, vol.326
, pp. 1123-1127
-
-
Chen, L.1
Do Kwon, Y.2
Zhou, T.3
-
772
-
-
33847101745
-
Structural definition of a conserved neutralization epitope on HIV-1 gp120
-
Zhou T., Xu L., Dey B., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
-
(2007)
Nature
, vol.445
, pp. 732-737
-
-
Zhou, T.1
Xu, L.2
Dey, B.3
-
773
-
-
0028208268
-
Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody
-
Conley A.J., Kessler J.A., Boots L.J., et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A 1994, 91:3348-3352.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 3348-3352
-
-
Conley, A.J.1
Kessler, J.A.2
Boots, L.J.3
-
774
-
-
0028865465
-
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
-
Trkola A., Pomales A.B., Yuan H., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995, 69:6609-6617.
-
(1995)
J Virol
, vol.69
, pp. 6609-6617
-
-
Trkola, A.1
Pomales, A.B.2
Yuan, H.3
-
775
-
-
0035701421
-
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1
-
Stiegler G., Kunert R., Purtscher M., et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765.
-
(2001)
AIDS Res Hum Retroviruses
, vol.17
, pp. 1757-1765
-
-
Stiegler, G.1
Kunert, R.2
Purtscher, M.3
-
776
-
-
0034759882
-
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41
-
Zwick M.B., Labrijn A.F., Wang M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892-10905.
-
(2001)
J Virol
, vol.75
, pp. 10892-10905
-
-
Zwick, M.B.1
Labrijn, A.F.2
Wang, M.3
-
777
-
-
34247106331
-
An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10
-
Nelson J.D., Brunel F.M., Jensen R., et al. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 2007, 81:4033-4043.
-
(2007)
J Virol
, vol.81
, pp. 4033-4043
-
-
Nelson, J.D.1
Brunel, F.M.2
Jensen, R.3
-
778
-
-
13844255333
-
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41
-
Cardoso R.M., Zwick M.B., Stanfield R.L., et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22:163-173.
-
(2005)
Immunity
, vol.22
, pp. 163-173
-
-
Cardoso, R.M.1
Zwick, M.B.2
Stanfield, R.L.3
-
779
-
-
4544379899
-
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope
-
Ofek G., Tang M., Sambor A., et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004, 78:10724-10737.
-
(2004)
J Virol
, vol.78
, pp. 10724-10737
-
-
Ofek, G.1
Tang, M.2
Sambor, A.3
-
780
-
-
73949133588
-
Role of HIV membrane in neutralization by two broadly neutralizing antibodies
-
Alam S.M., Morelli M., Dennison S.M., et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 2009, 106:20234-20239.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 20234-20239
-
-
Alam, S.M.1
Morelli, M.2
Dennison, S.M.3
-
781
-
-
77649132440
-
Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region
-
Ofek G., McKee K., Yang Y., et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010, 84:2955-2962.
-
(2010)
J Virol
, vol.84
, pp. 2955-2962
-
-
Ofek, G.1
McKee, K.2
Yang, Y.3
-
782
-
-
0036637385
-
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120
-
Sanders R.W., Venturi M., Schiffner L., et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002, 76:7293-7305.
-
(2002)
J Virol
, vol.76
, pp. 7293-7305
-
-
Sanders, R.W.1
Venturi, M.2
Schiffner, L.3
-
783
-
-
18244422922
-
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120
-
Scanlan C.N., Pantophlet R., Wormald M.R., et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 2002, 76:7306-7321.
-
(2002)
J Virol
, vol.76
, pp. 7306-7321
-
-
Scanlan, C.N.1
Pantophlet, R.2
Wormald, M.R.3
-
784
-
-
77957189612
-
Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged
-
Doores K.J., Fulton Z., Huber M., et al. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 2010, 84:10690-10699.
-
(2010)
J Virol
, vol.84
, pp. 10690-10699
-
-
Doores, K.J.1
Fulton, Z.2
Huber, M.3
-
785
-
-
77954920017
-
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
-
Wu X., Yang Z.Y., Li Y., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
-
(2010)
Science
, vol.329
, pp. 856-861
-
-
Wu, X.1
Yang, Z.Y.2
Li, Y.3
-
786
-
-
77649318846
-
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
-
Corti D., Langedijk J.P., Hinz A., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5:e8805.
-
(2010)
PLoS One
, vol.5
-
-
Corti, D.1
Langedijk, J.P.2
Hinz, A.3
-
787
-
-
77958115264
-
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
-
Walker L.M., Simek M.D., Priddy F., et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010, 6:e1001028.
-
(2010)
PLoS Pathog
, vol.6
-
-
Walker, L.M.1
Simek, M.D.2
Priddy, F.3
-
788
-
-
80052470370
-
High through-put functional screening of activated B cells from 4 African elite neutralizers yields a panel of novel broadly neutralizing antibodies
-
Walker L., Chan-Hui P., Ramos A., et al. High through-put functional screening of activated B cells from 4 African elite neutralizers yields a panel of novel broadly neutralizing antibodies. AIDS Res Hum Retroviruses 2010, 26:A149-A150.
-
(2010)
AIDS Res Hum Retroviruses
, vol.26
-
-
Walker, L.1
Chan-Hui, P.2
Ramos, A.3
-
789
-
-
0034823216
-
Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development
-
Meffre E., Milili M., Blanco-Betancourt C., et al. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest 2001, 108:879-886.
-
(2001)
J Clin Invest
, vol.108
, pp. 879-886
-
-
Meffre, E.1
Milili, M.2
Blanco-Betancourt, C.3
-
790
-
-
0033563012
-
IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth
-
Shiokawa S., Mortari F., Lima J.O., et al. IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. J Immunol 1999, 162:6060-6070.
-
(1999)
J Immunol
, vol.162
, pp. 6060-6070
-
-
Shiokawa, S.1
Mortari, F.2
Lima, J.O.3
-
792
-
-
44049108744
-
Toward an AIDS vaccine
-
Walker B.D., Burton D.R. Toward an AIDS vaccine. Science 2008, 320:760-764.
-
(2008)
Science
, vol.320
, pp. 760-764
-
-
Walker, B.D.1
Burton, D.R.2
-
793
-
-
77956247505
-
Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies
-
Bhattacharyya S., Rajan R.E., Swarupa Y., et al. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies. J Biol Chem 2010, 285:27100-27110.
-
(2010)
J Biol Chem
, vol.285
, pp. 27100-27110
-
-
Bhattacharyya, S.1
Rajan, R.E.2
Swarupa, Y.3
-
794
-
-
69549095803
-
The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility
-
Korber B., Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr Opin HIV AIDS 2009, 4:408-417.
-
(2009)
Curr Opin HIV AIDS
, vol.4
, pp. 408-417
-
-
Korber, B.1
Gnanakaran, S.2
-
795
-
-
78349299783
-
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies
-
Gnanakaran S., Daniels M.G., Bhattacharya T., et al. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol 2010, 6:e1000955.
-
(2010)
PLoS Comput Biol
, vol.6
-
-
Gnanakaran, S.1
Daniels, M.G.2
Bhattacharya, T.3
-
796
-
-
80051558293
-
Quantitative assessment of masking of neutralization epitopes in HIV-1
-
Agarwal A., Hioe C.E., Swetnam J., et al. Quantitative assessment of masking of neutralization epitopes in HIV-1. Vaccine 2011, 29:6736-6741.
-
(2011)
Vaccine
, vol.29
, pp. 6736-6741
-
-
Agarwal, A.1
Hioe, C.E.2
Swetnam, J.3
-
797
-
-
54849437925
-
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site
-
Burioni R., Mancini N., De Marco D., et al. Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS One 2008, 3:e3423.
-
(2008)
PLoS One
, vol.3
-
-
Burioni, R.1
Mancini, N.2
De Marco, D.3
-
798
-
-
77956385205
-
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens
-
Doores K.J., Bonomelli C., Harvey D.J., et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 2010, 107:13800-13805.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 13800-13805
-
-
Doores, K.J.1
Bonomelli, C.2
Harvey, D.J.3
-
799
-
-
35248867927
-
A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006
-
Bansal G.P. A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006. Biologicals 2007, 35:367-371.
-
(2007)
Biologicals
, vol.35
, pp. 367-371
-
-
Bansal, G.P.1
-
800
-
-
78349286286
-
Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization
-
Lohman-Payne B., Slyker J., Rowland-Jones S.L. Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization. Clin Perinatol 2010, 37:787-805.
-
(2010)
Clin Perinatol
, vol.37
, pp. 787-805
-
-
Lohman-Payne, B.1
Slyker, J.2
Rowland-Jones, S.L.3
-
802
-
-
33645218704
-
Engineered antibody Fc variants with enhanced effector function
-
Lazar G.A., Dang W., Karki S., et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006, 103:4005-4010.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 4005-4010
-
-
Lazar, G.A.1
Dang, W.2
Karki, S.3
-
803
-
-
76349123565
-
Enhanced antibody half-life improves in vivo activity
-
Zalevsky J., Chamberlain A.K., Horton H.M., et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010, 28:157-159.
-
(2010)
Nat Biotechnol
, vol.28
, pp. 157-159
-
-
Zalevsky, J.1
Chamberlain, A.K.2
Horton, H.M.3
-
804
-
-
61649087668
-
Glycosylation as a strategy to improve antibody-based therapeutics
-
Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009, 8:226-234.
-
(2009)
Nat Rev Drug Discov
, vol.8
, pp. 226-234
-
-
Jefferis, R.1
-
805
-
-
0036340378
-
Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer
-
Lewis A.D., Chen R., Montefiori D.C., et al. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 2002, 76:8769-8775.
-
(2002)
J Virol
, vol.76
, pp. 8769-8775
-
-
Lewis, A.D.1
Chen, R.2
Montefiori, D.C.3
-
806
-
-
61849122809
-
Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes
-
Luo X.M., Maarschalk E., O'Connell R.M., et al. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 2009, 113:1422-1431.
-
(2009)
Blood
, vol.113
, pp. 1422-1431
-
-
Luo, X.M.1
Maarschalk, E.2
O'Connell, R.M.3
-
807
-
-
77953311689
-
Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody
-
Joseph A., Zheng J.H., Chen K., et al. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 2010, 84:6645-6653.
-
(2010)
J Virol
, vol.84
, pp. 6645-6653
-
-
Joseph, A.1
Zheng, J.H.2
Chen, K.3
-
808
-
-
2442689092
-
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies
-
Haigwood N.L., Montefiori D.C., Sutton W.F., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004, 78:5983-5995.
-
(2004)
J Virol
, vol.78
, pp. 5983-5995
-
-
Haigwood, N.L.1
Montefiori, D.C.2
Sutton, W.F.3
-
809
-
-
68649084966
-
Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue
-
Murakami T., Eda Y., Nakasone T., et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS 2009, 23:1485-1494.
-
(2009)
AIDS
, vol.23
, pp. 1485-1494
-
-
Murakami, T.1
Eda, Y.2
Nakasone, T.3
-
810
-
-
20944446452
-
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
-
Trkola A., Kuster H., Rusert P., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11:615-622.
-
(2005)
Nat Med
, vol.11
, pp. 615-622
-
-
Trkola, A.1
Kuster, H.2
Rusert, P.3
-
811
-
-
41949106267
-
Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked
-
Huber M., von Wyl V., Ammann C.G., et al. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol 2008, 82:3834-3842.
-
(2008)
J Virol
, vol.82
, pp. 3834-3842
-
-
Huber, M.1
von Wyl, V.2
Ammann, C.G.3
-
812
-
-
79951823624
-
An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers
-
Van Braeckel E., Bourguignon P., Koutsoukos M., et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis 2011, 52:522-531.
-
(2011)
Clin Infect Dis
, vol.52
, pp. 522-531
-
-
Van Braeckel, E.1
Bourguignon, P.2
Koutsoukos, M.3
-
813
-
-
77956231717
-
Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial
-
Salmon-Ceron D., Durier C., Desaint C., et al. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 2010, 24:2211-2223.
-
(2010)
AIDS
, vol.24
, pp. 2211-2223
-
-
Salmon-Ceron, D.1
Durier, C.2
Desaint, C.3
-
814
-
-
33845433434
-
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
-
Pitisuttithum P., Gilbert P., Gurwith M., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
-
(2006)
J Infect Dis
, vol.194
, pp. 1661-1671
-
-
Pitisuttithum, P.1
Gilbert, P.2
Gurwith, M.3
-
815
-
-
34247201441
-
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
-
Catanzaro A.T., Roederer M., Koup R.A., et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25:4085-4092.
-
(2007)
Vaccine
, vol.25
, pp. 4085-4092
-
-
Catanzaro, A.T.1
Roederer, M.2
Koup, R.A.3
-
816
-
-
78650568204
-
Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in electroporation
-
Dolter K.E., Evans C.F., Ellefsen B., et al. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in electroporation. Vaccine 2011, 29:795-803.
-
(2011)
Vaccine
, vol.29
, pp. 795-803
-
-
Dolter, K.E.1
Evans, C.F.2
Ellefsen, B.3
-
817
-
-
77955513770
-
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine
-
Gray G., Buchbinder S., Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010, 5:357-361.
-
(2010)
Curr Opin HIV AIDS
, vol.5
, pp. 357-361
-
-
Gray, G.1
Buchbinder, S.2
Duerr, A.3
-
818
-
-
75749141272
-
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)
-
Kibuuka H., Kimutai R., Maboko L., et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 2010, 201:600-607.
-
(2010)
J Infect Dis
, vol.201
, pp. 600-607
-
-
Kibuuka, H.1
Kimutai, R.2
Maboko, L.3
-
819
-
-
45749099294
-
Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration
-
Bansal A., Jackson B., West K., et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008, 82:6458-6469.
-
(2008)
J Virol
, vol.82
, pp. 6458-6469
-
-
Bansal, A.1
Jackson, B.2
West, K.3
-
820
-
-
38749132973
-
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
-
Harari A., Bart P.A., Stohr W., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008, 205:63-77.
-
(2008)
J Exp Med
, vol.205
, pp. 63-77
-
-
Harari, A.1
Bart, P.A.2
Stohr, W.3
-
821
-
-
79751487021
-
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
-
Goepfert P.A., Elizaga M.L., Sato A., et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011, 203:610-619.
-
(2011)
J Infect Dis
, vol.203
, pp. 610-619
-
-
Goepfert, P.A.1
Elizaga, M.L.2
Sato, A.3
-
822
-
-
85158966553
-
Human immunodeficiency virus
-
Saunders/Elsevier, Philadelphia, PA, S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.)
-
Girard M., Koff W. Human immunodeficiency virus. Vaccines 2008, 1213-1251. Saunders/Elsevier, Philadelphia, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
-
(2008)
Vaccines
, pp. 1213-1251
-
-
Girard, M.1
Koff, W.2
-
823
-
-
24644479045
-
HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine
-
Gilbert P.B., Ackers M.L., Berman P.W., et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005, 192:974-983.
-
(2005)
J Infect Dis
, vol.192
, pp. 974-983
-
-
Gilbert, P.B.1
Ackers, M.L.2
Berman, P.W.3
-
824
-
-
37349036786
-
Lessons from the AIDSVAX B/B′ Vaccine Efficacy Trial
-
Horizon Press, Norkfolk, UK, W. Koff, P. Kahn, I. Gust (Eds.)
-
Buchbinder S.P., Fuchs J.D. Lessons from the AIDSVAX B/B′ Vaccine Efficacy Trial. AIDS Vaccine Development: Challenges and Opportunities 2007, 105-110. Horizon Press, Norkfolk, UK. W. Koff, P. Kahn, I. Gust (Eds.).
-
(2007)
AIDS Vaccine Development: Challenges and Opportunities
, pp. 105-110
-
-
Buchbinder, S.P.1
Fuchs, J.D.2
-
825
-
-
77954722964
-
Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine
-
Gilbert P., Wang M., Wrin T., et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010, 202:595-605.
-
(2010)
J Infect Dis
, vol.202
, pp. 595-605
-
-
Gilbert, P.1
Wang, M.2
Wrin, T.3
-
826
-
-
69749121344
-
Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors
-
Sep 25
-
Santra S., Sun Y., Korioth-Schmitz B., et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 2009 Sep 25, 27(42):5837-5845.
-
(2009)
Vaccine
, vol.27
, Issue.42
, pp. 5837-5845
-
-
Santra, S.1
Sun, Y.2
Korioth-Schmitz, B.3
-
827
-
-
84856880087
-
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
-
O'Hara G.A., Duncan C.J.A., Ewer K.J., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205:772-781.
-
(2012)
J Infect Dis
, vol.205
, pp. 772-781
-
-
O'Hara, G.A.1
Duncan, C.J.A.2
Ewer, K.J.3
-
828
-
-
84902046259
-
The Thai VaxGen Trial: What have we learned?
-
Horizon Press, Norkfolk, UK, W. Koff, P. Kahn, I. Gust (Eds.)
-
Beyrer C. The Thai VaxGen Trial: What have we learned?. AIDS Vaccine Development: Challenges and Opportunities 2007, 111-116. Horizon Press, Norkfolk, UK. W. Koff, P. Kahn, I. Gust (Eds.).
-
(2007)
AIDS Vaccine Development: Challenges and Opportunities
, pp. 111-116
-
-
Beyrer, C.1
-
829
-
-
43949099690
-
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
-
Priddy F.H., Brown D., Kublin J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46:1769-1781.
-
(2008)
Clin Infect Dis
, vol.46
, pp. 1769-1781
-
-
Priddy, F.H.1
Brown, D.2
Kublin, J.3
-
830
-
-
44949100369
-
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans
-
Watkins D.I., Burton D.R., Kallas E.G., et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008, 14:617-621.
-
(2008)
Nat Med
, vol.14
, pp. 617-621
-
-
Watkins, D.I.1
Burton, D.R.2
Kallas, E.G.3
-
831
-
-
79952445068
-
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial
-
Rolland M., Tovanabutra S., Decamp A.C., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011, 17:366-371.
-
(2011)
Nat Med
, vol.17
, pp. 366-371
-
-
Rolland, M.1
Tovanabutra, S.2
Decamp, A.C.3
-
832
-
-
68349130410
-
Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells
-
Hutnick N.A., Carnathan D.G., Dubey S.A., et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 2009, 15:876-878.
-
(2009)
Nat Med
, vol.15
, pp. 876-878
-
-
Hutnick, N.A.1
Carnathan, D.G.2
Dubey, S.A.3
-
833
-
-
68349135329
-
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans
-
O'Brien K.L., Liu J., King S.L., et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009, 15:873-875.
-
(2009)
Nat Med
, vol.15
, pp. 873-875
-
-
O'Brien, K.L.1
Liu, J.2
King, S.L.3
-
835
-
-
79953019952
-
Statistical interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: a case study for statistical issues in efficacy trials
-
Gilbert P.B., Berger J.O., Stablein D., et al. Statistical interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011, 203:969-975.
-
(2011)
J Infect Dis
, vol.203
, pp. 969-975
-
-
Gilbert, P.B.1
Berger, J.O.2
Stablein, D.3
-
836
-
-
84859393693
-
Immune-correlates analysis of an HIV-1 vaccine efficacy trial
-
Apr 5
-
Haynes B.F., Gilbert P.B., McElrath M.J., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012 Apr 5, 366(14):1275-1286.
-
(2012)
N Engl J Med
, vol.366
, Issue.14
, pp. 1275-1286
-
-
Haynes, B.F.1
Gilbert, P.B.2
McElrath, M.J.3
-
837
-
-
69749111528
-
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults
-
Harro C., Sun X., Stek J.E., et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine Immunol 2009, 16:1285-1292.
-
(2009)
Clin Vaccine Immunol
, vol.16
, pp. 1285-1292
-
-
Harro, C.1
Sun, X.2
Stek, J.E.3
-
838
-
-
77949263061
-
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
-
Barouch D.H., O'Brien K.L., Simmons N.L., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323.
-
(2010)
Nat Med
, vol.16
, pp. 319-323
-
-
Barouch, D.H.1
O'Brien, K.L.2
Simmons, N.L.3
-
839
-
-
54949106244
-
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara
-
Sandstrom E., Nilsson C., Hejdeman B., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198:1482-1490.
-
(2008)
J Infect Dis
, vol.198
, pp. 1482-1490
-
-
Sandstrom, E.1
Nilsson, C.2
Hejdeman, B.3
-
840
-
-
78649733251
-
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate
-
Currier J.R., Ngauy V., de Souza M.S., et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010, 5:e13983.
-
(2010)
PLoS One
, vol.5
-
-
Currier, J.R.1
Ngauy, V.2
de Souza, M.S.3
-
841
-
-
67649338409
-
Recombinant modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
-
Gudmundsdotter L., Nilsson C., Brave A., et al. Recombinant modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27:4468-4474.
-
(2009)
Vaccine
, vol.27
, pp. 4468-4474
-
-
Gudmundsdotter, L.1
Nilsson, C.2
Brave, A.3
-
842
-
-
44749088148
-
EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone
-
McCormack S., Stohr W., Barber T., et al. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26:3162-3174.
-
(2008)
Vaccine
, vol.26
, pp. 3162-3174
-
-
McCormack, S.1
Stohr, W.2
Barber, T.3
-
843
-
-
77957871228
-
The safety and immunogenicity of the replicative Tiantan Vaccinia HIV vaccine in phase I clinical trial. Presented as a poster at AIDS
-
Cape Town, South Africa; Oct 13-16, 2008. Poster pp., 1
-
Shao Y., Li T., Shen X., et al. the safety and immunogenicity of the replicative Tiantan Vaccinia HIV vaccine in phase I clinical trial. Presented as a poster at AIDS. Vaccine 2008, 13-18. Cape Town, South Africa; Oct 13-16, 2008. Poster pp., 1.
-
(2008)
Vaccine
, pp. 13-18
-
-
Shao, Y.1
Li, T.2
Shen, X.3
-
844
-
-
48449105674
-
The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers
-
Kennedy J.S., Co M., Green S., et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008, 26:4420-4424.
-
(2008)
Vaccine
, vol.26
, pp. 4420-4424
-
-
Kennedy, J.S.1
Co, M.2
Green, S.3
-
845
-
-
0030896310
-
Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity
-
Tubiana R., Gomard E., Fleury H., et al. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity. AIDS 1997, 11:819-820.
-
(1997)
AIDS
, vol.11
, pp. 819-820
-
-
Tubiana, R.1
Gomard, E.2
Fleury, H.3
-
846
-
-
10544220020
-
Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection
-
Eron J.J., Ashby M.A., Giordano M.F., et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996, 348:1547-1551.
-
(1996)
Lancet
, vol.348
, pp. 1547-1551
-
-
Eron, J.J.1
Ashby, M.A.2
Giordano, M.F.3
-
847
-
-
77958464026
-
A tonsillar polyICLC/At-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation
-
Vagenas P., Aravantinou M., Williams V.G., et al. A tonsillar polyICLC/At-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One 2010, 5:1-13.
-
(2010)
PLoS One
, vol.5
, pp. 1-13
-
-
Vagenas, P.1
Aravantinou, M.2
Williams, V.G.3
-
848
-
-
50849140177
-
+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization
-
+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization. Vaccine 2008, 26:5107-5110.
-
(2008)
Vaccine
, vol.26
, pp. 5107-5110
-
-
Gudmundsdotter, L.1
Boström, A.C.2
Burton, C.3
-
849
-
-
73349096659
-
Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate
-
Bellino S., Francavilla V., Longo O., et al. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 2009, 4:195-204.
-
(2009)
Rev Recent Clin Trials
, vol.4
, pp. 195-204
-
-
Bellino, S.1
Francavilla, V.2
Longo, O.3
-
850
-
-
67349268940
-
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up
-
Longo O., Tripiciano A., Fiorelli V., et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009, 27:3306-3312.
-
(2009)
Vaccine
, vol.27
, pp. 3306-3312
-
-
Longo, O.1
Tripiciano, A.2
Fiorelli, V.3
-
851
-
-
79952706286
-
Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a phase I safety study
-
Kityo C., Bousheri S., Akao J., et al. Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a phase I safety study. Vaccine 2011, 29:1617-1623.
-
(2011)
Vaccine
, vol.29
, pp. 1617-1623
-
-
Kityo, C.1
Bousheri, S.2
Akao, J.3
-
852
-
-
77954962865
-
Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection
-
Jones T. Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection. Curr Opin Invest Drugs 2010, 11:964-970.
-
(2010)
Curr Opin Invest Drugs
, vol.11
, pp. 964-970
-
-
Jones, T.1
-
853
-
-
78349309046
-
Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides
-
Kran A.M., Jonassen T.O., Sommerfelt M.A., et al. Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides. AIDS 2010, 24:2609-2618.
-
(2010)
AIDS
, vol.24
, pp. 2609-2618
-
-
Kran, A.M.1
Jonassen, T.O.2
Sommerfelt, M.A.3
-
854
-
-
70449713593
-
Development of a therapeutic HIV vaccine comprised of autologous dendritic cells loaded with a mixture of lipopeptide HIV antigens
-
Cobb A.J., Mead H., Montes M., et al. Development of a therapeutic HIV vaccine comprised of autologous dendritic cells loaded with a mixture of lipopeptide HIV antigens. Retrovirology 2009, 6(suppl. 3):19-45.
-
(2009)
Retrovirology
, vol.6
, Issue.SUPPL.. 3
, pp. 19-45
-
-
Cobb, A.J.1
Mead, H.2
Montes, M.3
-
855
-
-
40449119721
-
Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals
-
Connolly N.C., Whiteside T.L., Wilson C., et al. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008, 15:284-292.
-
(2008)
Clin Vaccine Immunol
, vol.15
, pp. 284-292
-
-
Connolly, N.C.1
Whiteside, T.L.2
Wilson, C.3
-
856
-
-
70349299844
-
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy
-
Gandhi R.T., O'Neill D., Bosch R.J., et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27:6088-6094.
-
(2009)
Vaccine
, vol.27
, pp. 6088-6094
-
-
Gandhi, R.T.1
O'Neill, D.2
Bosch, R.J.3
-
857
-
-
77954990423
-
Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART
-
Macatangay B.J., Szajnik M.E., Whiteside T.L., et al. Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One 2010, 5:e9852.
-
(2010)
PLoS One
, vol.5
-
-
Macatangay, B.J.1
Szajnik, M.E.2
Whiteside, T.L.3
-
858
-
-
70349784438
-
Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine
-
Lopez A., van der Lubbe N., Sanchez-Palomino S., et al. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. Vaccine 2009, 27:6166-6178.
-
(2009)
Vaccine
, vol.27
, pp. 6166-6178
-
-
Lopez, A.1
van der Lubbe, N.2
Sanchez-Palomino, S.3
-
859
-
-
73549125003
-
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy
-
Routy J.P., Boulassel M.R., Yassine-Diab B., et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010, 134:140-147.
-
(2010)
Clin Immunol
, vol.134
, pp. 140-147
-
-
Routy, J.P.1
Boulassel, M.R.2
Yassine-Diab, B.3
-
860
-
-
77954973455
-
Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection
-
Routy J.P., Nicolette C. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. Immunotherapy 2010, 2:467-476.
-
(2010)
Immunotherapy
, vol.2
, pp. 467-476
-
-
Routy, J.P.1
Nicolette, C.2
-
861
-
-
77955671541
-
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein
-
Schooley R.T., Spritzler J., Wang H., et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010, 202:705-716.
-
(2010)
J Infect Dis
, vol.202
, pp. 705-716
-
-
Schooley, R.T.1
Spritzler, J.2
Wang, H.3
-
862
-
-
56649097350
-
Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy
-
Greenough T.C., Cunningham C.K., Muresan P., et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 2008, 26:6883-6893.
-
(2008)
Vaccine
, vol.26
, pp. 6883-6893
-
-
Greenough, T.C.1
Cunningham, C.K.2
Muresan, P.3
-
863
-
-
38949098104
-
Therapeutic vaccination reduces HIV sequence variability
-
Hoffmann D., Seebach J., Cosma A., et al. Therapeutic vaccination reduces HIV sequence variability. FASEB J 2008, 22:437-444.
-
(2008)
FASEB J
, vol.22
, pp. 437-444
-
-
Hoffmann, D.1
Seebach, J.2
Cosma, A.3
-
864
-
-
78650311033
-
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine
-
Papagno L., Alter G., Assoumou L., et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011, 25:27-36.
-
(2011)
AIDS
, vol.25
, pp. 27-36
-
-
Papagno, L.1
Alter, G.2
Assoumou, L.3
-
865
-
-
79955523128
-
The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children
-
Palma P., Romiti M.L., Li Pira G., et al. The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children. Vaccine 2011, 29:6810-6816.
-
(2011)
Vaccine
, vol.29
, pp. 6810-6816
-
-
Palma, P.1
Romiti, M.L.2
Li Pira, G.3
-
866
-
-
77954637904
-
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection
-
Rosenberg E.S., Graham B.S., Chan E.S., et al. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One 2010, 5:e10555.
-
(2010)
PLoS One
, vol.5
-
-
Rosenberg, E.S.1
Graham, B.S.2
Chan, E.S.3
-
867
-
-
77955067596
-
The renaissance in HIV vaccine development: future directions
-
Koff W.C., Berkley S.F. The renaissance in HIV vaccine development: future directions. N Engl J Med 2010, 363:e7.
-
(2010)
N Engl J Med
, vol.363
-
-
Koff, W.C.1
Berkley, S.F.2
|